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I 
Abstract 
 
 
 
Malignant catarrhal fever (MCF) is caused by two closely associated 
gamma herpes viruses namely alcelaphine herpesvirus 1 (AlHV-1) 
and ovine herpesvirus 2 (OvHV-2) and characterised with 
lymphocyte infiltration in non-lymphoid tissues, vasculitis and 
epithelial damage. The mechanism by which the viruses cause the 
disease is not fully understood. The hypothesis of this project was 
that MCF is initiated by aberrant gene expression in endothelium, 
epithelium and infected T cells of susceptible animals, because they 
are not the natural hosts for the viruses and the viruses will not 
have evolved in them. The first goal was to examine whether rabbit 
epithelium and bovine endothelium can be infected in vitro and in 
vivo with AlHV-1 using q PCR and, if infected whether viral 
transcripts could be identified in these tissue cells using q PCR and 
in situ hybridisation (ISH). The results revealed that endothelium 
and epithelium can be infected and latent infection can be 
established in them. This suggests the likelihood of establishing a 
similar type of infection in vivo. Secondly, the trial to identify 
latency-associated transcripts using 5-azacitidine treatment on 
bovine turbinate fibroblast (BT) cells and rabbit large granular 
lymphocytes (LGLs) was only partially successful. However, pan T 
antigen was expressed in 5-azacitidine treated but not untreated 
LGLs cells. This may indicate a function of the drug either directly or 
II 
through the latency state. Transcriptome analysis in the infected 
and treated LGLs and BT cells showed that several pathways were 
affected by 5-aza although a possible latency (low transcript levels) 
was only seen in the BTs. Transcriptome analysis revealed similar 
pathways to those described for MCF in the tissues in vivo, and an 
effect of 5-aza on these. Viral transcripts analysis showed that 
genes related to productive/lytic cycles were higher than latent ones 
on day 17 of the in vivo experiment demonstrating that the virus 
may replicate at this stage of the disease. The attempt to localize 
the viral transcripts on the rabbit infected tissues using ISH was 
unsuccessful due to a lack of time.   
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 Chapter 1 
Introduction 
Osama Kumati                                                          Introduction 
1 
1.1 Malignant catarrhal fever (MCF) 
1.1.1 General comments: 
Malignant catarrhal fever (MCF) is acute, systemic, lethal 
lymphoproliferative disease of cattle and even-toed ungulates 
including pigs, deer, and bison (Buxton, 1984; Plowright, 1960; 
Schultheiss, 2000). The disease is caused by group of viruses 
belonging to the Herpesviridae family, subfamily 
Gammaherpesvirinae, genus Macavirus (Li et al., 2005). Two 
viruses of this group that are known to cause MCF, alcelaphine 
herpes virus 1 (AlHV-1) and ovine herpes virus 2 (OvHV-2), are 
widely distributed and extensively studied (Russell et al., 2009). 
Wildebeest (Connochaetes taurinus) is the reservoir host for AlHV-1 
in the sub-Saharan area, hence the name wildebeest-associated 
MCF (WA-MCF) for disease susceptible-animals that contract MCF 
from wildebeest. Sheep (Ovis aries) are the reservoir host for OvHV-
2 worldwide; hence the name sheep associated MCF (SA-MCF) 
(Dewals et al., 2008, Russell et al., 2009). There are no clinical 
signs of MCF in the reservoir hosts, however, often-fatal MCF is seen 
when virus is transmitted to the disease-susceptible species (cattle, 
deer, bison, pigs and water buffalo) (Russell et al., 2009). The 
clinical signs of MCF range from per-acute to mild form and the 
outcome are usually fatal although recovery has been recorded. The 
most common symptoms recorded are high fever; salivation, nasal 
and ocular discharge, diarrhoea, and enlarged lymph nodes. 
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Pathologically, the disease is characterised with erosions and 
haemorrhages in the intestinal tract, vasculitis, and infiltration of 
lymphoid cells in non-lymphoid organs (kidney, lung, and liver) 
(CFSP, 2012, OIE, 2013). The importance of MCF lies in the fact that 
the disease is a major cause of death in many disease-susceptible 
animals worldwide that come into contact with reservoir hosts. It is 
also a serious welfare issue (Lankester et al., 2015a, Li et al., 
2014). MCF occurs worldwide wherever reservoir and disease-
susceptible animals are close to each other, and can affect a wide 
range of naturally-susceptible species within the Artiodactyl families 
Cervidae, Suidae, Bovidae, and Geravidae. Most of the well-adapted 
carrying hosts are within the subfamilies Hippotraginae, 
Alcellaphinae, and Caprinae, containing roan antelope, wildebeest, 
sheep, and goats (Li et al., 2005, Russell et al., 2009). Based on 
their susceptibility to MCF, animals can be classified as relatively 
resistant (such as European cattle to OvHV-2 MCF) intermediate 
susceptibility (e.g. water buffalo and most deer) to the highly 
susceptible ones like Pere David’s deer, bison and Bali cattle (CFSP, 
2012). Transmission of MCF is brought about by wildebeest calves 
and lambs between two to nine months through aerosol and close 
contacts (Li et al., 2011a, Mushi et al., 1981).  MCF is associated 
with a high mortality rate (often 100% in outbreaks where clinical 
signs are observed) and low morbidity rate (sporadic) (Schultheiss 
et al., 1998). Rabbits and hamsters are good animal models for the 
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disease as they show similar clinical signs and pathological changes 
to those exhibited in the susceptible animals (Anderson et al., 2007, 
Buxton and Reid, 1980, Buxton et al., 1984).  
Gross diagnosis of MCF can be achieved through noting the 
characteristic clinical signs and pathological changes. Nevertheless, 
an accurate (specific) diagnosis is necessary as well. Molecular tools 
such as the polymerase chain reaction (PCR) and serological tests 
like the enzyme-linked immunosorbent assay (ELISA) have become 
bench standards for detecting MCF viral DNA and antigen/antibody 
respectively (Fraser et al., 2006, Li et al., 2001). To date, there is 
no effective treatment for MCF (Li et al., 2014, Russell et al., 2009). 
However, there have been vaccine trials by several researchers 
most without success (Mirangi, 1991, Rossiter et al., 1977) until 
recently (Haig et al., 2008). Despite the fact that the disease is 
generally sporadic (affecting small numbers of animals) the 
incidence of MCF fluctuates year on year and continues to be a 
problem (Anderson et al., 2007). In some outbreaks MCF can affect 
up to 40 % of a herd (Russell et al., 2009). The details of the virus 
life cycle and the pathogenesis (the mechanism by which the 
disease happens) of MCF is still not well understood (Russell et al., 
2009).  
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1.2 Aetiology of MCF  
1.2.1 Herpes viruses 
Herpes viruses comprise a large family of DNA viruses that induce 
disease in both animals and humans (Mettenleiter et al., 2009). The 
herpesvirion, an infectious virus particle, comprises an icosahedral 
capsid (Figure 1) consisting of 162 capsomeres (Mettenleiter et al., 
2009) which contain a large double stranded linear DNA genome 
(125 to 240 kilo base pair Kbp), and encircled with an envelope 
holding glycoprotein spikes on its surface. The structure between 
the capsid and the envelope is called the tegument which is made 
up of proteins that are related to the capsid proteins (Pellett and 
Roziman, 2007). The aim of the productive/lytic infection is to 
produce progeny virions that are able to spread and infect new cells. 
In this type of infection, there are regulated viral genes expressions, 
and genome replication, virion assembly, egress and transmission.  
Early in this cycle, successive sets of genes are transcribed including 
α immediate early (IE) that are involved in initiation of virus DNA 
replication, β early (E) genes that act to DNA replication and control 
cellular activities such as RNA polymerase II (Estes et al., 2007). 
After that, the transcription program switches to γ late genes 
expressing γ proteins. The newly replicated viral DNA is integrated 
into immature capsids and tegument proteins in the nucleus 
(Mettenleiter & Minson, 2006).  The virus also gets its primary 
envelope in the nucleus, nuclear membranes play role in virus 
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capsid nuclear egress (Peng et al., 2010). The virus gains its 
secondary membrane when buds through Golgi apparatus derived 
vesicles (Mettenleiter et al., 2006). Eventually, mature virion fuse 
with the cell membrane and buds to the extracellular spaces 
(Mettenleiter, 2006).     
 
 
Figure 1  schematic figure illustrates the simple structure of the herpes virus 
virion (stdgen.northwestern.edu/stdgen/bacteria/hhv2/herpes.html).  
 
The viruses of the family Herpesviridae have common biological 
features, i.e. they contain groups of enzymes that are implicated in 
metabolizing nucleic acid, DNA synthesis, and processing of proteins 
as well as the ability to establish latent infection in their natural 
hosts (Pellett and Roziman, 2007). The family Herpesviridae is 
classified into three subfamilies (Alphaherpesvirinae, 
Betaherpesvirinae, and Gamaherpesvirinae) according to their 
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biological properties and the viruses within these subfamilies further 
categorised to genera on the basis of resemblances in the DNA 
sequence (Pellett and Roziman, 2007). 
Herpesviridae are well distributed in nature in a way that most 
animals have at least one herpesvirus and some viruses have more 
than one definitive host. To date more than 200 herpesviruses have 
been recognized, nine of which are human viruses (Pellett & 
Roizman, 2013). Viruses of veterinary importance are found in 
mammals, birds and fish. The range of diseases caused by 
herpesvirus infections is quite large. Moreover, the same virus can 
provoke different diseases, depending on the viral strain, the age of 
the animal or the route of infection. Bovine herpesvirus 1 (BHV-1) 
and Suid herpesvirus 1 (SHV-1) are good examples: BHV-1 infection 
of cattle causes rhinotracheitis, vulvovaginitis, conjunctivitis, 
abortion in pregnant cows, encephalitis in young calves, metritis; 
BHV-1 is also associated with enteritis and mastitis (Pastoret et al., 
1982). SHV-1 infection of pigs is followed by abortion in pregnant 
sows, by septicaemia in neonates, by encephalomyelitis in piglets or 
by respiratory diseases in young pigs and adults. In domestic 
animals, clinical disease is usually produced following a primary 
infection; recrudescent disease, i.e. caused by a reactivated virus, 
seems to be rare. The situation differs in humans: labial and genital 
recrudescent lesions are commonly observed in humans infected 
with herpes simplex virus type 1 and 2 (HSV 1 and 2), even in the 
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presence of a high level of specific immunity (Nahmias et al., 1981). 
Shingles is a painful expression of reactivation of varicella-zoster 
virus, another human herpesvirus. 
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1.3 Malignant catarrhal fever viruses (MCFV) 
Malignant catarrhal fever viruses (MCFV) belong to the genus 
Macavirus in the subfamily Gammaherpesvirinae within the family 
Herpesviridae (Davison et al., 2009, Gasper et al., 2012). The 
classification of these viruses within the genus Macavirus came after 
being categorised previously under the genus Rhadinovirus, and is 
based on the existence of the 15A antigenic epitope and also due to 
the resemblance in in the conserved regions of the DNA polymerase 
gene among MCFV (Li et al., 2003, Russell et al., 2009). At least 
two of these viruses within the MCFV can give rise to the disease in 
naturally susceptible species and have been studied in detail- AlHV-
1 and OvHV-2 (Davison et al., 2009). The MCFV group comprises 
ten viruses (Table 1). Six of these viruses have been recognised as 
pathogenic (capable of inducing disease in the susceptible host) (Li 
et al., 2003). The pathogenic ones consist of alcelaphine herpes 
virus 1 (AlHV-1), ovine herpes virus 2 (OvHV-2), alcelaphine herpes 
virus 2 (AlHV-2), ibex-MCFV, caprine herpes virus 2 (CpHV-2), and 
MCF- white tailed deer (WTD) (Gasper et al., 2012, Li et al., 2003). 
Wildebeest associated MCF (WA-MCF) caused by AlHV-1 poses an 
important problem in cattle in Eastern and Southern Africa and zoos 
where natural and susceptible species are kept together in the same 
vicinity. Sheep associated MCF (SA-MCF) is considered as a major 
problem in many parts of the world, in particular, to the highly 
vulnerable animals, like Bali cattle, Pere David’s deer, and bison as 
Osama Kumati                                                          Introduction 
9 
well as in zoological collections where sheep and susceptible animals 
co-mingle (Heuschele, 1988, Plowright et al., 1960, Schultheiss et 
al., 1998).  
Table 1 shows malignant catarrhal fever viruses and their resevoir and susceptible 
species (Li et al., 2014). 
 
The virus Disease 
documented 
natural 
host 
Susceptible host 
AlHV-1 √ Wildebeest cattle 
AlHV-2 √ Hartebeest  Deer and bison 
OvHV-2 √ Sheep Cattle, deer, bison, pigs, and 
giraffe 
CpHV-2  √ Goat Sika deer and white tailed deer 
Ibex-MCF √ Ibex Bongo and anoa  
MCF-WTD √ Unknown White tailed deer 
HiHV-1  X Roan 
antelope 
Unknown  
Oryx-MCF X Oryx Unknown  
Muskox-
MCF 
X Muskox Unknown  
Aoudad-
MCF 
X Aoudad Unknown  
 
Abbreviations: AlHV-1, alcelaphine herpes virus 1. AlHV-2; 
alcelaphine herpes virus 2. OvHV-2; ovine herpes virus 2, CpHV-2; 
caprine herpes virus 2, Ibex-MCF; ibex9-malignant catarrhal fever, 
MCF-WTD; MCF-white tailed deer, HiHV-1; hippotrogine herpes virus 
1, Oryx-MCF; Oryx-malignant catarrhal fever, Muskox-MCF; 
Muskox-malignant catarrhal fever, Aoudad-MCF; Aoudad-malignant 
catarrhal fever. √: Yes, X: NO.    
  
The reservoir host for MCFV-WTD is still unidentified. However, the 
virus can infect and give rise to MCF in white tailed deer in North 
America and the virus was found to be genetically closely related to 
AlHV-1 and OvHV-2 (Li et al., 2000). Domestic and wild goats are 
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the reservoir hosts for CpHV-2 and the virus is endemic in them. In 
addition, it has been reported that the virus can cause MCF in a 
wide range of species including pronghorn antelope, white tailed 
deer, and sika deer. The most common symptoms associated with 
the CpHV-2 MCF are emaciation, alopecia, and dermatitis (Keel et 
al., 2003, Li et al., 2011b). AlHV-2, initially, was classified as 
apathogenic under natural circumstances. Nevertheless, the virus 
was isolated from Jackson’s hartebeest which induced MCF in 
Barbary red deer leading to the observation that the virus can be 
pathogenic (Klieforth et al., 2002, Li et al., 2003, Li et al., 2005). 
Ibex MCF virus found in ibex is capable of inducing MCF in bongo, 
an American forest antelope and in anoa (midget buffalo) (Li et al., 
2011b). The non-pathogenic MCFV are Hippotragine herpes virus 1 
(HiHV-1) and Oryx-MCFV in roan antelope and Oryx respectively 
with no recognisable susceptible hosts as well as Muskox and 
Aoudad MCFV in Muskox and Aoudad also with no susceptible hosts 
recognised to date (Li et al., 2005).    
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1.4 Genomic structure of AlHV-1 and gene function 
AlHV-1 can easily be grown in cell culture. In contrast, it has been 
difficult to propagate OvHV-2 in vitro. This has hindered the study of 
OvHV-2 virology, infection, and pathogenesis. However, the use of 
T-lympho-blastoid cell lines with the morphology of large granular 
lymphocytes (LGL) derived from organs from MCF-affected animals 
has enabled researchers to study the host-virus communication 
(Hart et al., 2007a). These large granular lymphocytes are large 
lymphoblasts that can grow in the absence of exogenous cytokines 
and are indiscriminately cytotoxic, killing various target cells in a 
non-MHC-dependent manner (swa et al., 2001). The two viruses 
have had their genomes sequenced (Figure 2) (Ensser et al., 1997a, 
Hart et al., 2007a). The OvHV-2 genome is very similar to that of 
AlHV-1 and herpesvirus saimiri (HVS), a gamaherpesvirus 
categorised under the genus Rhadinovirus. Both viruses have a 
unique sequence of around 131 kbp and these are flanked by 
terminal repeats of 4.2 kbp and 1.1 kbp for OvHV-2 and AlHV-1 
respectively. OvHV-2 has 73 open reading frames (ORFs), 62 of 
which have homologues in other gammaherpesviruses whereas 
AlHV-1 contains 70 ORFs, 61 of which are conserved among other 
gammaherpesviruses. Eight out of the 10 unique genes, designated 
A1 to A10 in AlHV-1, have homologues in OvHV-2 while OvHV-2 
includes 3 completely unique ORFs, i.e. Ov2.5, Ov3.5, and Ov8.5 
(Ensser et al., 1997a, Hart et al., 2007a). All ORFs of the two 
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viruses were named after those within the other 
gamaherpesviruses. As such, ORFs with similarity in herpesvirus 
saimiri were given the number of the related herpesvirus saimiri 
gene. Those which are unique to each virus were designated 
prefixes with A and Ov for AlHV-1 and OvHV-1 respectively followed 
by numbers one to ten. The unique genes of OvHV-2 assigned a 
nomenclature showing the relative position of the adjacent genes, 
for example, Ov2.5 locates between OV2 and Ov3 and so on and so 
forth for the other genes (Hart et al., 2007a, Russell et al., 2009). 
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Figure 2 demonstrates the genome structure of AlHV-1 and OvHV-2. 
Genes are shown as block arrows representing their orientation and position of open reading frames. Gene designations are written below 
according to the numbering system adopted in Herpes virus saimiri. The unique genes in both viruses are shaded grey and named 
beneath each gene with a prefix A for AlHV-1 virus and Ov for OvHV-2 whereas conserved genes are shown as white arrows. The terminal 
repeats (TR) are given grey shaded blocks. (Russell et al., 2009). 
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1.5 AlHV-1 genome sequence classification 
Following the complete AlHV-1 DNA genome characterized by Ensser 
and co-researchers in 1997, Coulter et al. (2001) arranged the 
Herpesvirus genome sequences in five blocks, designated the roman 
numbers, based on the gene similarity among the viruses within this 
family. Blocks I, II, IV include ORFs that are conserved within all 
herpesviruses subfamilies while blocks III and V comprise ORFs that 
are conserved between the subfamily Gamaherpesvirus only. Block I 
contains ORFs 6 to 9. Block II contains ORFs 17 to 47. Block III 
contains ORFs 48 to 50. Block IV contains ORFs 52 to 69. Block V 
contains ORF75. 
There are changeable areas which can be assigned A-F disseminated 
between these conserved blocks of genes throughout the family of 
Herpesviruses. In AlHV-1 area A comprises A1 to A4 and ORF3. Area 
B comprises A5 and ORFs 10 and 11. Area D/E comprises A6, A7, 
A8, ORFs 73, 75, A9, and A10 (Coulter et al., 2001).        
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1.6 AlHV-1 genome sequence 
As in Herpesvirus saimiri, the low guanine-cytosine (GC) content (L-
DNA) (46.17%) in AlHV-1, which contains the coding ORFs is 
surrounded by high GC content area of nucleotide repeats (H-DNA) 
(71.83%) which is considered as predominately a non-coding region 
(Ensser et al., 1997a). The L-DNA region of around 131,000 Kbp 
nucleotide sequence comprises (Figure 2) 70 ORFs as previously 
found by Ensser et al. (1997a). However, Mills et al. (2003) and 
Russell et al. (2013) discovered two new ORFs in AlHV-1 virus 
located in the inter-genic spaces between ORF 6 and ORF3 
(designated ORF A4.5) and between ORF A9 and ORF A10 which is 
assigned ORF A9.5. This brings the number of open reading frames 
in the L-DNA region to 72 ORFs instead of 70 as previously stated. 
Consequently, the number of the unique genes (shared by AlHV-1 
and OvHV-2 plus unique to AlHV-1) in AlHV-1 virus is twelve to 
date. Ten of these have homologues in OvHV-2 and two are unique 
to AlHV-1. Ovine herpes virus genes Ov2 and Ov3 which have 
homologues in AlHV-1 lie in the left end of the unique region 
whereas Ov2.5 and Ov3.5 locate in the same area but with no 
homology with AlHV-1 genes (Hart et al., 2007a, Russell et al., 
2009).   
The ORFs A1 to A4 are located at the left end of L-DNA genome and 
at the right end of the H-DNA region whereas ORF A4.5 and Ov4.5 
lie between ORF3 and ORF6 (Coulter et al., 2001, Hart et al., 2007a, 
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Russell et al., 2009). ORF A5 and Ov5 locate between ORFs 9 and 
10 (Coulter et al., 2001, Hart et al., 2007a). ORFs A6, A7, A8 and 
Ov6, Ov7, and Ov8 locate amongst ORF50 and ORF52. Ovine herpes 
virus Ov8.5 with no homology in AlHV-1 locates between ORF73 and 
ORF69 (Hart et al., 2007a, Russell et al., 2009). ORF A9 and Ov9 
locate after ORF75 towards the right H-DNA genome while A10 and 
Ov10 locate adjacent to and to the left of the right H-DNA repeat 
(Coulter et al., 2001, Hart et al., 2007a, Russell et al., 2009). ORF 
A9.5 and its homologues Ov9.5 lie between A9 and A10, and Ov9 
and Ov10 respectively (Russell et al., 2014, Russell et al., 2013). 
Figure 2 shows the location of the unique genes on both AlHV-1 and 
OVHV-2 genomes.  
 
1.7 Spliced genes in AlHV-1 virus 
Splicing is a process that happens in the nucleus after transcription 
to RNA in which the introns are removed and the exons are joined 
together to make mRNA which can then be translated to a protein 
within the ribosomes (House, 2008; Poulos, 2011). This process is 
important as it removes the introns (non-coding sequence) and 
joins exons (coding-sequence) to produce mature mRNA.  
In the two MCF viruses that have been sequenced (AlHV-1 and 
OvHV-2) splicing takes place in both conserved and unique ORFs 
(Ensser et al., 1997a, Hart et al., 2007a). ORF A2 encodes a spliced 
product and ORF50 the R-transactivator gene is expected to show 
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splicing due to the fact that herpesviruses equivalent genes exhibit 
splicing (Ensser et al., 1997a). 
 
1.8 Functions of non-conserved genes 
ORF A1 has no homology to other herpes virus ORFs and its 
putative protein product is not similar to any known proteins with no 
known function. It is therefore assumed to be non-functional or a 
pseudogene (Russell et al., 2009). Table 2 lists the known and 
predicted functions of the twelve unique genes of AlHV-1. ORF A2 
and ORF Ov2 are similar to ATF3 which is considered as stress-
induced transcription factor. A2 gene and its product is a member of 
the basic leucine zipper proteins implicated in altering host genes 
expressions. Therefore, they may play a role as transcription factor 
(Hart et al., 2007a, Parameswaran et al., 2014). Nevertheless, 
AlHV-1 ORFA2 is dispensable for the induction of MCF 
(Parameswaran et al., 2014). Semaphorins are huge family of 
glycoproteins that are found in all vertebrates and invertebrate’s 
species in addition to viruses (Jongbloets et al., 2013). It has been 
found that these proteins are involved in many biological activities 
like cancer, bone haemostasis, and immune system (Xu et al., 
1998). Semaphorin 7A (SEMA7A) is encoded by AlHV-1 ORF A3 and 
OvHV-2 ORF Ov3 homologue (Myster et al., 2015). However, AlHV-1 
ORF A3 has not been implicated in lymphocytes infiltration in MCF 
but is essential for avoiding immune evasion (Myster et al., 2015). 
Osama Kumati                                                          Introduction 
18 
Ovine herpes virus Ov3.5 is a unique gene with no similarity to any 
other viral genes encoding a putative signal peptide. Therefore, it 
thought to be secreted by the infected cells (Hart et al., 2007a, 
Thonur et al., 2006). ORF A4 has no obvious role with no homology 
to other herpes virus ORFs (Russell et al., 2009). ORF A4.5 is 
similar to OvHV-2 Ov4.5 which encodes a protein similar to Epstein-
Barr virus EBV BALF1 and cellular B-cell lymphoma genes of the Bcl-
2 family that regulate programmed cell death (apoptosis). It seems 
therefore that this gene may be involved in inhibiting/supporting cell 
death, hence encouraging cell survival and establishment of 
productive and / or latent infection cycles (Hart et al., 2007a, 
Russell et al., 2009). 
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Table 2 Function of unique genes in AlHV-1 and OvHV-2 (Russell et al., 2009).  
 
AlHV-1 
ORF 
OvHV-2 
ORF 
Function  
A1  Unknown  
A2 Ov2 Leucine zipper protein; transcription 
regulation 
 Ov2.5 Viral IL-10 
A3 Ov3 Semaphorin homologue; intracellular 
signalling 
 Ov3.5 Unknown, signal peptide 
A4  Unknown 
A4.5 Ov4.5 Bcl-2 homologue; cell death regulators 
A5 Ov5 GPCR (G-protein coupled receptor); 
intracellular signalling 
A6 Ov6 Similar to Epstein-Barr virus BZLF1; viral 
transactivator 
A7 Ov7 Virus glycoprotein 
A8 Ov8 Virus glycoprotein 
 Ov8.5 Unknown  
A9 Ov9 Bcl-2 homologue; cell death regulators 
A9.5 Ov9.5  Secreted glycoprotein with unknown function 
A10 Ov10 Unknown, glycoprotein  
 
ORF A5 is similar to OvHV-2 Ov5 encodes a G protein-coupled-
receptors orthologue (GPCRs), hence it may play a role in 
modulating the host immune defence or any of the other functions 
of this diverse family of molecules (Ensser et al., 1997a, Hart et al., 
2007a). However, the role of this ORF was investigated using the 
bacterial artificial chromosome AlHV-1BAC to produce a recombinant 
virus with a deleted A5 gene. Animals infected with this clone 
developed MCF-like syndrome indicating that A5 has no function in 
the development of MCF (Boudry et al., 2007). ORF A6 is similar to 
OV6 encodes a protein similar to EBV BZLF1 which encodes a 
protein considered as a transcriptional factor that is responsible for 
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the activation of early genes leading to latent / lytic cycle switch 
(Coulter et al., 2001, Hart et al., 2007a). ORF A7 and A8 and their 
homology Ov7 and Ov8 in OvHV-2 virus are viral glycoproteins and 
may have a role in cell attachment and entry to the host cell 
(Coulter et al., 2001, Hart et al., 2007a, Russell et al., 2009). ORF 
A9 and Ov9 has similar predicted function to ORF A4.5 as it has 
homology to bcl-2 anti-apoptosis family genes and therefore may 
inhibit/induce the host cell death (Coulter et al., 2001, Russell et al., 
2009) to enhance productive and /lytic infections. ORF A10 is 
putative (unknown gene function) glycoprotein and may be involved 
in cell attachment and entry to the host cell (Coulter et al., 2001).  
ORF A10, similar to Ov10, is putative (unknown gene function) 
glycoprotein and may be involved in cell attachment and entry to 
the host cell (Coulter et al., 2001, Hart et al., 2007a, Russell et al., 
2009).  Ovine herpes virus Ov8.5 with no similarity to any genes in 
AlHV-1 genome has no identified function (Hart et al., 2007a, 
Thonur et al., 2006). ORF A9.5 is similar to Ov9.5 encoding secreted 
glycoprotein that is similar to IL-4 (Lankester et al., 2015b, Russell 
et al., 2014, Russell et al., 2013). However, the role of this gene in 
inducing MCF is still unknown.                   
 
1.9 Gene similarities to other herpes viruses 
AlHV-1 ORF73, encodes latency associated nuclear antigen (LANA), 
is homologous to latency associated transcripts of other herpes 
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viruses including HHV-8- also known as Kaposi’s sarcoma-
associated herpesvirus (KSHV LANA) ORF73 (Palmeira et al., 2013, 
Taus et al., 2007), herpes saimiri ORF73 (Blake, 2010), And EBV 
Epstein Barr nuclear antigen (EBNA1) (Blake, 2010). These are 
important for the viral latency cycle (Hu et al., 2002). It looks likely 
therefore that AlHV-1 ORF73 has the same function (Dewals et al., 
2008, Palmeira et al., 2013). The R transactivator (RTA) ORF50 has 
a role in switching from latency to lytic replication responsible for 
the productive life cycle (Frame and Dalziel, 2008, Goodwin et al., 
2001, Staudt and Dittmer., 2007). ORF 25 homologue is conserved 
in all herpesviruses and encodes a major capsid protein (Ensser et 
al., 1997a). This ORF product is expressed during the lytic cycle 
demonstrating viral replication (Cunha et al., 2008, Dewals et al., 
2008). ORF63 is conserved among other herpes viruses and 
encodes a tegument structural protein (Boyle and Monie, 2012, 
Ensser et al., 1997a). The presence of these proteins is associated 
with the expression of ORF50/ORF25 responsible for productive/lytic 
cycle (Gailbreath et al., 2008, Meier-Trummer et al., 2009b). 
 
1.10 Gene expression of the MCF viral genome, 
latency and lytic cycles 
Based on the genome sequence of OvHV-2, Thonur et al. (2006) 
studied the transcription of OvHV-2 genes and its conformation in 
lymphocytes from both natural (wildebeest and sheep) and 
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susceptible hosts (cattle, bison, pigs, deer, water buffalo). OvHV-2 
viral genome from peripheral blood mononuclear cells derived from 
sheep (natural host reservoir species) was primarily circular as 
measured using Gardella gel analysis, indicating a latent 
conformation and mRNA for only Ov3.5 unique gene, encoding a 
putative signal peptide which thought to be secreted by the infected 
cells, was identified. In contrast, cultured large granular 
lymphocytes (LGL), have natural killer (NK)/T cells morphology, 
contain enriched-population of infected cells and are good source to 
study virus-host interaction, from the rabbit (a MCF-susceptible 
species following experimental infection) had mainly a linear viral 
genome indicating productive cycle whereas bovine (natural 
disease-susceptible host) LGL cultures contained mainly circular 
viral DNA indicating latency dominance. Both these susceptible 
species genomes expressed nearly all of the virus unique genes. 
Their expression in this experiment indicates that they may be 
involved some way in MCF pathogenesis. Treating the LGLs from the 
susceptible species with doxorubicin, a drug used for cancer 
treatment that drives the productive life cycle (AbuHammad and 
Zihlif, 2013, Feng et al., 2004, Rahman et al., 2001), stimulated 
predominantly linear genome from latent circular ones, while 
treatment with 5-azacytidine, a drug utilised to stimulate latency in 
EBV-infected tissues (Feng et al., 2004, Mossman et al., 1989, 
Schaefer et al., 1997), supported circular genome production in LGL 
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lines and a range of putative latency transcripts (Thonur et al., 
2006). In spite of productive cycle gene expression, no virions were 
detected by electron microscopy (EM) in the cultures, indicating an 
incomplete virus life cycle (Thonur et al., 2006). These results are in 
agreement with the previous work of Rosbottom and co-researchers 
who made the same conclusion (Rosbottom et al., 2002).  
In particular, OvHV-2 and AlHV-1 gene expression in the tissues of 
infected cattle or rabbits indicated that the latency transcript ORF 73 
could be detected, leading to a belief that MCF is a disease of 
latency (Meier-Trummer et al., 2009a, Palmeira et al., 2013). In 
contrast, other researchers have shown evidence of viral replication 
and productive virus associated with this (Cunha et al., 2012, Cunha 
et al., 2013, Li et al., 2008a, Nelson et al., 2013). The structural 
viral proteins (as mRNA transcripts) were identified in organs within 
SA-MCF virus-infected rabbits indicating viral replication was 
occurring (Gailbreath et al., 2008). In addition, it was found that 
there was low expression of ORF50 in lymphoid tissues extracted 
from WA-MCF-affected rabbits, which might indicate productive 
infection (Dewals et al., 2008). 
 
1.11 Virulent and attenuated forms of AlHV-1 
AlHV-1 C500 strain derived from a cow (Plowright et al., 1960, 
Plowright et al., 1975) that developed MCF can be cultured in bovine 
turbinate (BT) cells (Handley et al., 1995). After several passages 
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(up to 5 times) the virus exists as free virus that is virulent and can 
cause disease when injected into MCF-susceptible animals (Dewals 
et al., 2011, Haig et al., 2008, Palmeira et al., 2013, Parameswaran 
et al., 2014) but as culture passages proceed, the proportion of 
virus that is attenuated (i.e. cannot induce disease when injected 
into MCF-susceptible animals) increases. Virus can exist as free in 
culture or as a proportion that is cell-associated and not excreted 
into the cultures (Wright et al., 2003). Handley et al. (1995) 
conducted the first study of these changes. They found out that an 
area in the middle of AlHV-1 DNA was deleted that results in virus 
attenuation. This region contains the distal part of ORF 50b, 
proximal part of A6 and distal part of A10.  
The AlHV-1 C500 strain was completely sequenced by Ensser et al,. 
(1997a), allowing more detailed study. Wright et al. (2003) 
discovered that after multiple passages in vitro there was evidence 
of gene deletion, translocation, and duplication that could be 
involved in attenuation process. Candidate ORFs included ORF50 
and ORF A6 that were truncated and translocated (distal part of ORF 
50b, proximal part of A6 and distal part of A10). ORF48 and ORF A7 
might have been affected which locate to either side of the 
translocated fragments (Figure 3) (Wright et al., 2003). 
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Figure 3 schematic map shows the changes in genes due to passage resulting in 
attenuation (Wright et al., 2003). 
 
A further proteomic study identified differences in protein expression 
between the virulent and attenuated forms of AlHV-1 (Dry et al., 
2008). This revealed that 23 virus proteins were expressed in both 
virus forms. This means that there was no change in the structural 
composition of the virulent and attenuated viruses detectable by 
this method. It was concluded therefore that the attenuation of the 
virus was not due to the virus particle structure, but perhaps a 
result of altered viral gene expression in the infected cell (Dry et al., 
2008). 
 
1.12 Virus life cycle 
The life cycle (Figure 4) of viruses of the herpesvirus family is 
initiated when the virus engages with the host cell surface, binding 
to specific receptors, for example, it was shown that gD of herpes 
simplex virus-1 (HSV-1) bound to the herpes virus entry mediator A 
(HveA receptor) whereas gp42 of Epstein-Barr virus (EBV) bound to 
HLA-DR (Flint et al., 2009). The receptors used by MCF-related 
viruses to enter the host cell are still not known (Russell et al., 
2009). After binding of viral envelope glycoproteins to cell 
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membrane receptors, entry is brought about by membrane fusion 
proteins. By contrast, a study carried out to identify the different 
stages of Gammaherpesvirus life cycle using murine 
gammaherpesvirus 68 (MHV 68) and utilizing dual-axis electron 
tomography (ET) revealed that the entry occurs by endocytosis 
(Peng et al., 2010). Once the virion is internalised, un-coating or 
disassembling occurs and the DNA genome is released and then 
transported via transit Golgi network (TGN) to the nucleus where 
the linear double stranded DNA genome is circularised by covalent 
bonds before replication. After that, viral DNA is transcribed into 
early mRNAs which are then transported to the cytoplasm for early 
protein synthesis. These early proteins are imported into the 
nucleus and promote viral DNA replication. The viral DNA is then 
transcribed into the late mRNAs which are responsible for late viral 
protein synthesis (capsid and envelope proteins). The viral envelope 
proteins are processed in the endoplasmic reticulum (ER) and Golgi 
complex. The capsid proteins are imported into the nucleus and 
then encapsidate the newly replicated genomes. The assembly of 
the progeny virions partially occurs in the nucleus and in the 
cytoplasm by the Golgi membranes. The release of the enveloped 
virus from the host cell occurs by budding (Flint et al., 2009). 
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Figure 4 illustrates the herpesvirus life cycle steps from entry to egress. The entry happens when virus glycoprotein attaches to specific 
cell receptors. Un-coating of the virus takes place in the cytoplasm and linear DNA transferred to the nucleus where the replication and 
transcription occur. The virus is transported to the cytoplasm through inter-nuclear pore (INP) from the nucleus where complete 
assembly of the progeny virus takes place. The release of the Herpes virion occurs by budding. 
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There have been studies carried out on MCF viruses’ replication, in 
particular, OvHV-2. These studies were able to identify the stages 
through which OvHV-2 replicate in both reservoir and susceptible 
host (Li et al., 2008a, Rosbottom et al., 2002, Taus et al., 2010). In 
sheep, the reservoir host for SA-MCF, the virus initially replicates in 
particular in the alveolar epithelium of the lung. This takes place in 
the early stage of the disease course. Afterwards, the virus 
disseminates into the blood (tropism) favouring the lymphocytes 
where it can establish latent infection (Li et al., 2008a, Taus et al., 
2010). Ultimately, the virus targets the respiratory system, 
especially the lung and nasal sinuses where it departs the host in a 
cell-free form (Cunha et al., 2012). In susceptible species such as 
rabbits and bison that have been experimentally infected, the 
pattern of infection, initially, is similar to the reservoir host where 
the virus replicates in the lung tissue and then disseminates into the 
blood. However, the pattern here varies from the one in the 
reservoir host. The expression of ORF50, ORF25, and ORF73 is 
marked in most of the tissues (Cunha et al., 2012). The expression 
of ORF63 and ORF43 genes encoding structural proteins in the 
tissues of the susceptible species supports the incidence of viral 
replication (Meier-Trummer et al., 2009b). With regard to AlHV-1 
virus, the details of virus life cycle are still unknown. Nonetheless, 
recent work has shown that the virus replicates in the lung of the 
susceptible species in very early clinical stage and then disseminate 
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into the blood where it establishes latency in T lymphocytes (mainly 
CD8+ T lymphocyte) (Myster et al., 2015, Palmeira et al., 2013).  
 
1.13 Latency 
MCF-associated viruses (AIHV-1 and OvHV-2) are assumed similar 
to the viruses of the family Herpesviridae in terms of their ability to 
become latent. The herpes viruses are able to establish latency in 
natural host tissues and sometimes in tissue culture (Flint et al., 
2009). The hallmark of this stage is that the viral genome is 
preserved as a circular episome inside the nucleus, few viral genes 
are expressed (Virgin et al., 1999), and no virions produced. 
Moreover, the cytopathic effects (cell lysis due to the lytic virus 
cycle) are inhibited and the virus can avoid the host immune control 
(Blake, 2010). Reactivation occurs when the host immune system is 
stressed or compromised (Russell et al., 2009).  Different 
herpesviruses have the ability to establish latency in certain cells. 
For example, Herpes simplex virus (HSV) remains latent in 
peripheral sensory ganglia (Flint et al., 2009) whereas the Epstein-
Barr virus undergoes latency in B lymphocytes and epithelial cells 
(Mesri et al., 1996). In regard to the MCF-associated viruses AlHV-1 
or OvHV-2, the site in which the viruses establish latency it is still 
unknown (Russell et al., 2009).  
The mechanism by which Herpes viruses establish latency is 
complex and not completely known (Flint et al., 2009, Nicoll et al., 
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2012). In herpes simplex virus 1 (HSV 1), supporting of latency 
goes through two important steps. In the first one the virus 
suppresses the expression of lytic cycle genes and secondly prevent 
programed cell death (apoptosis) (Nicoll et al., 2012). The 
expression of latency associated transcripts (LAT) is important in 
establishing latency in HSV1 and HSV 2 (Nicoll et al., 2012). LAT is 
a set of RNAs encoded from the virus genome resulting in the 
construction of minor LAT transcripts. These transcripts inhibit the 
immediate early genes (IE), such as ICP0 (transcriptional activator) 
and ICP4 (transcriptional regulator), required to initiate 
lytic/productive cycle in the host cell (Nicoll et al., 2012). In 
addition, LATs are involved in repression of proteins production such 
as glycoprotein gD and gJ, ICP27 (transcriptional factor), ICP10 
(apoptotic regulator), which is responsible for the promotion of cell 
survival (Nicoll et al., 2012). 
The role of micro-RNA (miRNA) in regulating viral latency has been 
highlighted. Micro-RNA is non-coding sequence belongs to the RNA 
family and found in plants, animals, algae and viruses (Griffiths-
Jones, 2008). EBV and KSHV which belong to gammaherpes virus 
subfamily, have been found to encode miRNAs (Pfeffer, 2005) that 
are associated with immune response (Grundhoff, 2011) and also 
have anti-apoptotic role (Seto, 2010).  
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1.14 Symptoms and pathology of MCF 
1.14.1 Clinical signs 
Animals affected include cattle deer, bison, and pigs. The signs are 
similar for AlHV-1 and OvHV-2 MCF. The clinical signs of MCF are 
diverse as the disease can affect many systems of the infected 
animals including the digestive system, respiratory system, head 
and eye, nervous system, and uro-genital system (Liggitt and 
DeMartini, 1980a, Liggitt and DeMartini, 1980b, Russell et al., 
2009). MCF has many forms ranging from peracute to mild stages. 
The symptoms are few in the peracute phase, which is characterised 
by sudden death. However, depression, weakness, dysentery may 
develop 12 to 24 hours before the onset of death. This is mostly 
seen in the highly susceptible species (CSFH, 2012; OIE, 2013).  In 
the acute form, the clinical signs are more obvious and are 
associated with the emergence of high fever, inappetence, 
lachrymation, nasal discharge which progresses to mucopurulent, 
corneal opacity, decrease in milk production, and skin lesions in the 
form of ulceration and exudation that are mainly found in perineum, 
udder and teats. Salivation, erosions of the tongue and the buccal 
papillae are detected. Superficial lymph nodes are enlarged and limb 
joints may be swollen. Head pressing, hyperesthesia, tremors and 
nystagmus are the most obvious nervous signs of the MCF (Russell 
et al., 2009, Zemljic et al., 2012). The severity of the disease 
depends on the causative agent, species infected and the course of 
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disease (Russell et al., 2009). Although the clinical signs are similar 
in other species to those found in cattle, there is some variance in 
some aspects. For instance, in bison, the animals usually die in the 
acute stage without developing the head and eye form, diarrhoea, 
neurological signs as well as lymph nodes only slightly enlarged. 
Acute MCF is predominant; however, chronic disease and recovery 
of some cases have also been documented (Milne and Reid, 1990, 
O'Toole et al., 1997). 
 
1.14.2 Pathology of MCF 
The macroscopic pathological changes are commonly diffuse and 
mirror the intensity of the clinical signs, and may include most body 
systems (OIE, 2013). Erosions and petechial haemorrhages are 
seen in the gastrointestinal tract and echymotic haemorrhages (a 
haemorrhagic spots forming rounded and irregular patch) of the gall 
bladder epithelium. In the respiratory tract the development of a 
diphtheric membrane and erosions are often recognized. Lymph 
nodes are enlarged, in particular in cattle and can be solid, and 
white when cut. Kidneys’ surfaces are, generally, characterised by 
the presence of white foci (OIE, 2013; CSFH, 2012; Russell et al, 
2009).  
Epithelial degeneration, vasculitis, hyperplasia and necrosis of 
lymphoid organs, and the accumulation of lymphoid cells in 
nonlymphoid organs are the main obvious microscopic appearances 
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in MCF (OIE, 2013). Vascular lesions exist and are obvious in the 
arterioles, venules, arteries and veins of tissues including the brain. 
They are identified by the infiltration of the lymphoid cells in the 
tunica adventia and media of the blood vessels. The accumulation of 
the lymphoid cells is pronounced, especially, in the renal cortex, 
periportal regions of the liver, and extremely large in the kidney 
(OIE, 2013). 
 The infiltration of lymphoid cells in both SA-MCF and WA-MCF are 
mostly T cells, the majority of which are CD8+ T cells along with 
very small numbers of CD4+ T cell (Anderson et al., 2007, Dewals et 
al., 2008).  
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1.15 Epidemiology of MCF 
1.15.1 MCF Transmission 
Although MCF viruses (AlHV-1 and OvHV-2) show no clinical signs in 
the reservoir host, they can induce the disease in susceptible 
species. Both viruses can be propagated horizontally from reservoir 
to susceptible host by either direct contact or respiratory route, 
mostly from lambs and wildebeest calves under 12 months old (Li et 
al., 1998, Mushi and Rurangirwa, 1981, Mushi et al., 1980). The 
horizontal transmission between the susceptible hosts does not 
occur and they are considered as dead end hosts (Ackermann 
2006). Nonetheless, some cases of transmission among infected 
deer were documented (Reid et al., 1986). Also, it has been shown 
that the inability of animals to transmit the disease horizontally is 
owing to the cell-associated trait of the viruses as well as the failure 
to shed cell-free viruses by the animals (Li et al., 2014). However, 
vertical transmission has been documented in susceptible host 
animals. In study carried out by Plowright et al, (1972) a cow was 
inoculated with AlHV-1. After 84 months the cow was killed and the 
virus was grown in a culture from its organs. It was found that four 
out of the six calves that the cow yielded throughout its life were 
infected with the virus after parturition. In addition, OvHV-2 
genome was identified in specimens of digestive tract, respiratory 
and urogenital tract of a sheep as well as semen of rams (Hussy et 
al, 2001; CFSPH, 2012). These observations have defined a possible 
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role for vertical transmission for passing the infection to the progeny 
after birth. Although the presence of both reservoir and susceptible 
hosts within the same vicinity is fundamentally required to transmit 
MCF, some cases of infection have been recorded when both types 
of hosts were at some distance up to five Km (CFSPH, 2012).  The 
role of external parasites (Plowright, 1965) and urine (Michel, 1993) 
in transmitting MCF is ruled out. 
 
1.15.2 Geographical distribution 
Malignant catarrhal fever is distributed all over the globe; however, 
the incidence of the disease is dependent on both the causative 
agent and the susceptible host (CFSPH, 2012). WA-MCF is found in 
the sub-Saharan region in Africa when cattle and wildebeest are 
reared together in the same proximity. In addition, many cases of 
WA-MCF have been reported from wild parks and zoological 
gatherings (Russell et al., 2009). Sheep associated malignant 
catarrhal fever is found mainly in Europe and North America (Russell 
et al., 2009). However, the disease has been reported from various 
areas of the world in the Middle East (Abu Elzein et al., 2003) in 
New Zealand (Russell et al., 2009). Moreover, the disease is 
considered as a serious problem in Bali cattle in Indonesia (Wiyono 
et al., 1994).  
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1.15.3 Susceptible species  
Malignant catarrhal fever viruses can infect a wide range of animals 
worldwide and exhibit clinical signs in these species. These animals 
belong to subfamily Bovinae including, cattle, bison, and water 
buffalo as well as family Cervidae containing, deer and moose. It 
has also been found that MCF viruses can induce the disease in 
animals belong to other species such as pigs and giraffes (Russell et 
al, 2009; CSFH, 2012). Some species are more sensitive to the 
infection of certain type of MCF virus than other species. For 
example, European cattle are more easily infected with OvHV-2 and 
are somewhat more resistant to AlHV-1. In contrast, animals such 
as Pere David’s deer, wild-tailed deer, and bison are extremely 
susceptible to OvHV-2 infection (CFSPH, 2012). 
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1.16 Disease Impact 
The lack of an effective reporting approach along with misdiagnosis 
of the clinical MCF has almost certainly led to the under-diagnosis of 
MCF (O'Toole et al., 1997). The significance of MCF lies in the fact 
that the disease is considered as a major cause of death in farmed 
bison in North America (Li et al., 2006), farmed deer and Bali cattle 
as well as a cause of death wherever the reservoir and host species 
for the virus cohabit. In the USA, an outbreak of MCF in 2003 led to 
the death of about 800 bison resulting in a loss of millions of dollars 
to the owners (Li et al., 2006). This has led the United States 
department of agriculture (USDA) placing MCF research in its 
priority programme. MCF is also reported as a serious problem in 
farmed deer in variety of locations and Bali cattle in Indonesia 
(Wiyono et al., 1994). The disease is mainly sporadic in Europe and 
the UK. However, outbreaks range (60-300) occurs annually in the 
UK. In addition, MCF may contribute to Bovine respiratory disease 
(Parameswaran et al., 2014). This has led organisations such as 
Animal and Plant Health Agency (APHA), Department for 
Environment, Food and Rural Affairs (DEFRA), and Global Alliance 
for Livestock Veterinary Medicines (GALVMED) to support research 
on MCF control (personal comment, David Haig). In Africa, it has 
been estimated that about 7% of the cattle exposed to wildebeest 
calves during migration perish due to MCF (Cleaveland et al., 2001). 
Consequently, MCF has been placed as one of the most significant 
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cattle diseases in certain parts of eastern and southern Africa 
(Cleaveland et al., 2001). MCF is a major cause of death in 
zoological gatherings where susceptible and reservoir hosts cohabit, 
hence loss of some expensive animals (Russell et al., 2009). The 
significance of MCF does not only lie on the fact that the disease can 
cause death in many animals around the world but also due to 
serious welfare issues that this brings and also socio-economic 
problems for farmers and pastoralists (Li et al., 2014, Palmeira et 
al., 2013). Eventually, the research on MCF and studying the virus 
life cycle and how it reacts with the host may contribute 
scientifically towards opening opportunities for researchers studying 
herpes viruses to gain more knowledge about the virus behaviour. 
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1.17 Diagnosis of MCF 
Diagnosis of MCF depends, initially, on the clinical signs and the 
pathology of the disease (Li et al., 2011b). The existence of the 
susceptible species close to the reservoir hosts in the same vicinity 
could be a valuable approach for diagnosing MCF (CFSP, 2012). 
Tissues such as liver, kidney, intestines, lung, spleen, and lymph 
nodes should be collected from animals developing MCF clinical 
signs for diagnostics (Anderson et al., 2007, Parameswaran et al., 
2014). Histologically, lesions such as vasculitis and accumulation of 
lymphocytes in the lymphoid tissues are suggestive of MCF 
incidence (Anderson et al., 2007, Cunha et al., 2012, Palmeira et 
al., 2013). MCF should be differentiated from other viral diseases 
such as mucosal disease, bovine viral diarrhoea virus, and infectious 
bovine rhinotracheitis (OIE, 2013; CFSP, 2012). One of the effective 
methods for diagnosing MCF with regard to AlHV-1 virus infection is 
to infect bovine turbinate fibroblast (BT) cells with the isolated virus 
and monitor any cytopathic effect (CPE) development. This is 
characterized by the absence of monolayer and the accumulation of 
cell debris (Wright et al., 2003). However, the advent of molecular 
based techniques like the polymerase chain reaction (PCR) assays 
has considerably enhanced MCF laboratory diagnostics (Li et al., 
2011a, Russell et al., 2009). Especially, real time quantitative PCR 
(RT q-PCR) and nested PCR which are considered powerful and 
reliable tools for detecting viral DNA in the samples of MCF infected 
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animals (Hussy et al., 2001, Traul et al., 2005). This is due the fact 
that MCF affected animals have detectable levels of Viral DNA in 
their blood (at certain stages of the disease) and organs at post-
mortem (Dewals et al., 2008). There are serological approaches to 
detecting MCF virus antibodies including the virus neutralisation test 
(VN), enzyme-linked immunosorbent assay (ELISA), 
immunoperoxidase test (IPT), immunofluorescence assay (IFA) and 
immunoblotting introduced for the diagnosis of MCF (OIE, 2013). 
These techniques depend upon identifying antibodies for specific 
MCF virus antigens (CSFH, 2012). Neutralisation test (VN) could be 
effective for detecting antibodies from animals infected with AlHV-1 
virus or viruses associated with AlHV-1 such as AlHV-2 and HiHV-1 
whereas it is non-specific for detecting antibodies in animals 
infected with OvHV-2 or other related viruses (CSFH, 2012). The 
use of competitive enzyme-linked immunosorbent assay (cELISA), 
monoclonal antibody based technique utilizing 15A antibody 
targeting a conserved epitope among all MCF viruses or an indirect 
ELISA using virus extract are the methods of choice for identifying 
antibodies in MCF affected animals (Fraser et al., 2006, Li et al., 
1994). 
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1.18 Treatment and prevention 
There is currently no effective remedy or licensed vaccination for 
treating or preventing MCF (Russell et al., 2012b, Russell et al., 
2009). The only current approach to control the disease is to 
separate the reservoir host from the susceptible species (CSFH, 
2012; OIE, 2013). The efficiency of this method depends upon the 
reservoir host, susceptible species, separation distance as well as 
the age of the carrying host (CSFH, 2012; OIE, 2013). With regard 
to WA-MCF, separation of cattle from wildebeest is crucially 
important in preventing MCF transmission especially around the 
calving season whereas in SA-MCF this approach is of less 
significance in particular in the European cattle, the relatively 
resistant species (CSFH, 2012; OIE, 2013). However, isolation of 
highly susceptible animals to SA-MCF such as bison, Pere David’s 
deer, and Bali cattle is highly recommended (CSFH, 2012; OIE, 
2013). The MCF viruses can be transmitted over several km (Li et 
al., 2008b), with one report of disease in bison located 5km from 
the nearest sheep farm (CFSH, 2012). The age of wildebeest calves 
and lambs should be avoided ranges from two to nine months as 
these animals have higher cell-free virus titrations in their nasal 
secretions (CSFH, 2012; OIE, 2013). Avoiding stress factors such as 
starvation, high stock density, travelling could be effective in 
controlling MCF as such factors can induce virus reactivation (CSFH, 
2012; OIE, 2013). Equine herpesvirus 1 (EHV-1) latently infected 
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horses can reactivate if the appropriate conditions such as stress, 
immunosuppression, transportation, sale barns and competitions 
appear (Dunowska., 2014).     
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1.19 Prospective vaccine development 
The lack of effective treatment for MCF has encouraged scientists to 
develop a strategic vaccination approaches to protect susceptible 
species against the disease. Therefore, many studies (Plowright et 
al., 1975, Ferris et al., 1976, Edington and Plowright, 1980, Haig et 
al., 2008, Russell et al., 2012a) have been carried out in order to 
fulfil this target.  The first trial to protect cattle utilising live or 
attenuated WC11 strain of AlHV-1 was not effective (Plowright et 
al., 1975). Similarly, study using inactivated cell free virulent C500 
AlHV-1 virus in rabbits challenged parentally to generate immunity 
against cell free virus did not provide complete protection (Russell, 
1980). However, another study using rabbits inoculated systemically 
with cell-associated virus and vaccinated with live cell-associated 
virus produced protection against the virus while inactivated cell-
associated vaccination did not generate immunity (Edington and 
Plowright, 1980).  
In order to examine whether cattle immunised with AlHV-1 C500 
strain naturally and challenged with the attenuated virus could 
develop protective immunity Haig et al. (2008) conducted a study to 
address this hypothesis. In this trial cattle challenged with virulent 
cell-free virus naturally (intranasal inoculation) and immunised with 
attenuated AlHV-1 C500 strain in Freund’s adjuvant (intramuscular 
route).  The data obtained revealed that nine out of ten of the cattle 
systemically administrated developed a high level of neutralizing 
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antibodies in their nasal discharges as well as generating protective 
immunity. Moreover, animals challenged systemically did not 
develop protection against the virus (Haig et al., 2008). 
The role of licensed adjuvant (Emulsigen, MVP Technologies) in 
helping protective immunity in cattle challenged with AlHV-1 
(intranasal route) has been examined. The results indicated that 
considerable number of cattle were protected from the virulent virus 
at around three months post immunisation, however, the disease is 
developed when cattle further challenged at later time from 26 to 39 
weeks post primary immunisation (Russell et al., 2012a). In 
addition, the high level of neutralising antibodies in the nasal 
secretions and blood from vaccinated and survived animals 
highlighted their role as a mucosal barrier for blocking the virus 
entry (Russell et al., 2012a).  
The bulk of the vaccine development work has been done on AlHV-1 
rather than OvHV-2. This is due to the absence of an effective 
propagating system for OvHV-2 in culture (Hart et al., 2007b).  
However, there are many factors such as the high similarity 
between AlHV-1 and OvHV-2 (Hart et al., 2007b, Ensser et al., 
1997b), the existence of good reliable experimental animals 
(Anderson et al., 2007), and the use of large granular lymphocytes 
(LGLs) generated from the tissues of infected animals (Thonur et 
al., 2006), which can pave the way for researchers to develop a 
promising vaccine for MCF protection. 
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1.20 Chemicals for the experiments 
1.20.1 5-azacitidine 
5-azacitidine is a chemical analogue of cytidine, a nucleotide in DNA 
and RNA. The drug is a chemotherapeutic agent and used in the 
treatment of cancer (Brodovsky et al., 2013). The drug works 
through two mechanisms- at low doses, by inhibiting of DNA 
methyltransferases leading to hypo methylation of DNA, and high 
doses through its incorporation to the nucleic acids causing cell 
death (Kaur et al., 2014). The drug has wide spectrum of side 
effects ranging from anaemia, renal failure, foetal damage, fever, 
vomiting, and diarrhoea. Due to its hypo methylation activity, it has 
been found that 5-azacitidine can reduce the stability of silencing 
signals (stabilized by methylation) and hence affecting gene 
expression (Navada et al., 2014). 
 
1.20.2 Cyclosporine A 
Cyclosporine A is an immunosuppressant agent used in organ 
transplantation to prevent tissue rejection (Mott, Zhang et al. 
2004). The drug decreases the activity of the immune system by 
interfering with the development and activity of T cells. Beside its 
use in tissue transplantation, it has been used for the treatment of 
rheumatoid arthritis, acute ulcerative colitis, and dry eyes. The 
adverse effects of cyclosporine A include fever, diarrhoea, vomiting, 
convulsions, hypertension, thrombosis in renal vasculature and 
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weakening the immune response through lowering the growth of T 
cells (Henry et al., 1995, Robert et al., 2010). The mechanism of 
action of cyclosporine A is not well known but it is thought that 
cyclosporine binds to cyclophilin of T cells. This cyclosporine and 
cyclophilin complex inhibits calcineurin required for the transcription 
of IL-2 (Youn et al., 2002). 
1.21 Pathogenesis  
Malignant catarrhal fever is a lymphoproliferative disease 
characterised by the proliferation of lymphocytes in lymphoid 
tissues (lymph nodes, spleen, and appendix) and interstitial 
infiltration of lymphoid cells in non-lymphoid organs (Liver, kidney, 
and lung) and this is often connected with tissue necrosis (Buxton et 
al., 1984). Many hypotheses have been suggested and many 
studies have been conducted in order to interpret the pathogenesis 
(mechanism by which the disease occurs) of MCF (Dewals et al., 
2008, Anderson et al., 2007, Buxton et al., 1984).  However, it is 
yet unknown. 
 
1.21.1 Direct versus indirect mechanism of MCF 
Buxton et al. (1984) infected rabbits with sheep-associated 
malignant catarrhal fever virus (SA-MCF) in lymphoid cells 
intravenously; it was found that the systemic pathological changes 
were analogous to those found in rabbits similarly infected with WA-
MCF virus. It was also discovered that there was augmentation in T-
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lymphocytes which was due to hyperplasia instead of neoplasia. 
Moreover, after treating the infected rabbits with cyclosporine 
(lymphocyte proliferation suppressor), the T cell proliferation ceased 
but areas of necrosis and disease were unaffected suggesting to the 
authors that tissue necrosis was due to autoimmunity induced by 
cytotoxic activity of uninfected cells under the control of a small 
number of infected cells.  This indicated that the development of 
MCF was not associated with cell infiltration as such but to the 
tissue necrotic lesions. This hypothesis was strengthened by the 
paucity of virus or viral antigen in infected tissues, supporting this 
indirect mechanism (Bridgen et al., 1992). However, further studies 
have shown that both viruses induce lymphoid cell accumulations 
comprised mainly of T-lymphocytes, of which CD8+ T-cells 
predominate (Anderson et al., 2007, Simon et al., 2003). Using in 
situ PCR, Simon et al. (2003) confirmed that larger numbers of the 
CD8+ T-cells were infected with OvHV-2 in the brain of a cow and 
bison than previously thought indicating that the pathogenesis of 
MCF may not be by bystander cell activity after all. 
Dewals and Vanderplasshen continued examining the pathogenesis 
of WA-MCF (AlHV-1) in rabbits using multi-colour flow cytometry 
staining to phenotype mononuclear leucocytes in both lymphoid 
(during the infection and at time of euthanasia) and lymphoid 
tissues (at time of euthanasia). They found that the prevalent T cell 
subsets were CD3+ CD8+ CD4- and the majority of these cells 
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produced gamma interferon (IFN-γ) and perforin (Dewals and 
Vanderplasschen, 2011). In addition, the identification of CD8 
perforin+ γδ- T cells has been reported (Nelson et al., 2010) in the 
perivascular spaces throughout experimental SA-MCF (OvHV-2) in 
bison. These outcomes show that MCF is associated with the 
extension and infiltration of infected activated and cytotoxic CD8+ T 
cells expressing high levels of IFN-γ and perforin. 
 
1.21.2 Experimental MCF 
The use of rabbits as experimental animals has facilitated the study 
of the pathogenesis of MCF as they develop the same symptoms 
and systemic changes that occur in the naturally-susceptible hosts 
(Anderson et al., 2007, Buxton et al., 1984, Cunha et al., 2013, 
Gailbreath et al., 2008). These studies have demonstrated certain 
variations between MCF caused by AlHV-1 and OvHV-2.  AIHV-1-
related lesions were more abundant in the peripheral lymph nodes, 
while lesions associated with OvHV-2 were more obvious in visceral 
lymph nodes such as mesenteric lymph nodes. Moreover, AIHV-1-
associated lesions showed less necrotic regions than those seen in 
OvHV-2 (Anderson et al., 2007, Buxton et al., 1984).  
In an experiment carried out by Gailbreath et al. (2008) cell-free 
OvHV-2 removed from nasal secretions of virus-shedding sheep was 
inoculated by intranasal nebulisation into eight rabbits. Five of 
these, developed clinical signs and systemic pathological changes 
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which were similar to those changes in rabbits infected 
intravenously by cell-associated OvHV-2 in earlier studies. 
 
1.21.3 Large granular lymphocytes in MCF and their 
phenotype 
Large granular lymphocytes (LGL) are the T/NK cells that grow in 
culture from the tissues (usually lymphoid tissue) of MCF-affected 
animals. They are enriched for virus-infected cells that are difficult 
to detect in vivo. They possess cytotoxic activity and seem to 
express either natural killer or T cell phenotypes (Burrells and Reid, 
1991). The phenotype of LGLs has been studied in cells from various 
species infected with either OvHV-2 or AIHV-1 (Burrells and Reid, 
1991, Schock et al., 1998, Schock and Reid, 1996). Schock et al. 
(1998) examined the phenotype of LGLs in five different cell lines 
derived from some cattle infected with OvHV-2. It was shown that 
surface antigen CD2 and CD5 expressed on greater than 97.5 % of 
cells in all cell lines. CD4 was expressed on the majority of cells in 
three cell lines while CD8+ was expressed on one cell line. However, 
CD8+ T cell was the predominant cell type accumulated in the brain 
of a cow and bison infected with OvHV-2 (Simon et al., 2003). It 
was also demonstrated that CD25, the interleukin-2 (IL-2) alpha 
chain receptor, was expressed on all the cell lines. The growth of 
LGLs infected with OvHV-2 is enhanced in the presence of IL-2 and 
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high cell density (Schock et al., 1998). However, these cells can 
develop in IL-2-free culture (Swa et al., 2001).  
Greater than 90% of LGL cell lines are virus infected as identified by 
immunocytochemistry or by in situ hybridisation for viral DNA or 
mRNA, despite the scarcity of cells containing virus in MCF affected 
organs in vivo. LGL cell lines are able to induce MCF when 
transferred to rabbits (Russell et al., 2009). LGLs are able to 
destroy tissue cells in an MHC-unrestricted manner and do not grow 
after stimulation with mitogens, while control T cells do (Schock et 
al., 1998, Swa et al., 2001). The interpretation of the activated 
cytotoxic phenotype of infected LGLs, in IL-2 free culture, includes 
constitutively activated Lck and Fyn kinases. These kinases are 
normally significant for the primary stimulation of T cells via the T 
cell receptor and co-receptors on the cell surface (Swa et al., 2001). 
LGLs produce various cytokines including TNF-alpha, IFN-gamma 
but are usually deficient in IL-2 either before or after stimulation by 
mitogen (Schock et al., 1998). LGLs have been used intensively to 
study the pathogenesis of MCF in vitro (Hart et al., 2007a, Thonur 
et al., 2006). 
 
1.21.4 The role of cytokines in MCF pathogenesis 
The role of cytokines, in particular, interleukin 15 (IL-15) and 
interleukin 2 (IL-2) in the pathogeneses of MCF has been examined 
(Anderson et al., 2008, Meier-Trummer et al., 2009a) IL-15 is a 
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cytokine which has a structural resemblance with IL-2. It is secreted 
by a wide range of cells and tissues containing, monocytes, 
macrophages, dendritic cells (DC), epithelium, and endothelium 
(Grabstein et al., 1994). Its function is to recruit, activate the 
proliferation of, and regulate cytotoxic cells including CD8+ cytotoxic 
T lymphocytes, natural killer cells (NK), NK T cells, and CD4+ 
cytotoxic lymphocytes. Therefore, it plays a significant role in both 
innate and adaptive immunity. Also, it has an anti-apoptotic function 
(Anderson et al., 2008, Lodolce et al., 2002). Moreover, the 
involvement of IL-15 in the pathogenesis of various autoimmune 
diseases has been documented. It has been found that, in mouse 
paradigms of autoimmunity, inhibiting IL-15 abolished the intensity 
of the diseases (Smith et al., 2000).  
It was discovered; utilizing in situ hybridisation, after infecting 
rabbits with either AlHV-1 or OvHV-2 that IL-15 was abundant in 
the lymphoid tissues. The abundance of IL-15 is associated with 
tissue lesions indicating that the cytokine may be implicated in the 
pathogenesis of MCF (Anderson et al., 2008). In addition, it was 
found in the same experiment that the intensity of BLT esterase, 
(that detects tryptase) measuring cytotoxicity, was preserved in 
LGLs when stimulated with IL-15 in comparison with IL-2. These 
observations demonstrate that IL-15 may play a role in the 
regulation of the active cytotoxic cells in MCF (Anderson et al., 
2008).  
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IL-2 is a cytokine which plays a significant role in the growth of T 
cells as well as the development of T regulatory cells (Tregs). It is 
expressed by T cells, mainly CD4+ T lymphocytes during immune 
responses (Boyman and Sprent, 2012, Meier-Trummer et al., 
2009a). IL-2 transcript abundance was low in lymphoid tissues 
derived from cows infected with OvHV-2 using microarray RNAseq 
assay. Although, the abundance of CD28 and T cell receptor (TCR), 
co-stimulatory enhancer for IL-2 production, was very high. It was 
also demonstrated that the ratio of CD4+ was less than CD8+ 
lymphocytes. These observations indicate that IL-2 deficiency may 
have a significant role in the pathogenesis origin of MCF (Meier-
Trummer et al., 2009a).  
 
1.21.5 The site of infection and MCF pathogenesis 
A reverse-transcription PCR was used as the technique to detect 
OvHV-2 in organs in which OvHV-2 replication takes place in-vivo. 
Samples (turbinate, lungs, and trachea) were collected from 
naturally-infected sheep (reservoir species) and samples including 
kidney, bladder, brain, and intestine were obtained from cattle and 
bison infected with OvHV-2. OvHV-2 major capsid protein gene 
(ORF25) was utilised as a marker of viral replication. The data 
obtained revealed that the ORF25 transcript was present in 30% of 
the respiratory tract-related samples, 66% of which were turbinate, 
in sheep, indicating that this is the site of virus production in the 
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reservoir host. In contrast, most of the bovine and bison samples 
contained ORF25 transcripts indicating that replication or at least 
partial productive cycle appears to takes place in most tissues 
(Cunha et al., 2008). Of course in the MCF-susceptible animals this 
productive cycle is incomplete as discussed above. In situ 
hybridisation and immuno-histochemistry using antibodies for 
capsid and tegument structural proteins (ORF43and ORF63) of 
OvHV-2 were used to identify regions of viral replication in six 
OvHV-2 infected rabbits. The results showed that all infected rabbits 
developed pathological lesions in the samples. However, virus 
structural proteins were identified solely in the appendix, in 
particular, in the epithelial cells and M-cells, while ORF63 mRNA was 
only found in the epithelial cells but not in the M-cells suggesting 
that these cells may have a role in the pathogenesis of MCF and 
may represent an entry site for the virus (Meier-Trummer et al., 
2009b).  
It may be worth mentioning that the researchers in both 
experiments have used different techniques, different virus 
administration approaches (intravenous and aerosol), and different 
viral strains.  This may have an impact on the data obtained as, for 
example, the OvHV-2 virus used was from European and American 
strains (Meier-Trummer et al., 2009b). Although it has been found 
in earlier work that the two strains are highly similar 94-100% (Hart 
et al., 2007b, Taus et al., 2007), variations in the genomic 
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sequences between the two strains may interpret their biological 
diversity (Meier-Trummer et al., 2009b). 
 
1.21.6 Recombinant AlHV-1  
 In order to study the role of virus genes in pathogenesis, 
Researchers have exploited the availability of virulent AIHV-1 virus 
in low passage tissue culture to construct a stable virus genome as 
a bacterial artificial chromosome (BAC), for this, a modified loxP-
flanked BAC cassette was integrated in one of the two large non-
coding sites of AlHV-1 DNA. The integration led to the generation of 
an AlHV-1 BAC clone in bacteria and capable of producing infectious 
particles when transfected into permissive cells. AlHV-1 virions 
originated from BAC were able to replicate and generate MCF in 
rabbits that were similar to that of the AlHV-1 virulent parental 
strain. This discovery will greatly assist our understanding of MCF 
pathogenesis by allowing gene knockout and reinsertion 
recombinant viruses to be made (Dewals et al., 2006a).  
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1.22 Hypothesis 
Malignant catarrhal fever is initiated by aberrant gene expression in 
infected T cells, epithelium and endothelium. 
 
1.23 Objectives 
1. Objective 1: To determine whether bovine endothelium and 
rabbit epithelium can be infected with AlHV-1 C500 strain in 
vitro (cell lines, rabbit and cattle) and in vivo (in rabbits 
detected by in situ hybridisation). Also to determine the life 
cycle stage of the virus in the infected cells (by RT-qPCR and 
in situ hybridisation) using known latent and lytic transcript 
analysis.  
2. Objective 2: to attempt to switch the virus life cycle from 
lytic to latent in large granular lymphocytes (LGLs, mixed 
latency and lytic cycle) and BT fibroblasts (lytic cycle only) 
infected with AlHV-1 C500 strain after treatment with 5-
azacitidine (a drug used to support latency). In addition, 
RNAseq will be used to map the host and viral gene 
transcripts in these cells to look for pathways associated with 
latency and the lytic cycle.  
3. Objective 3: To determine viral gene expression in the 
tissues of animals infected with AlHV-1 and treated with 
cyclosporine-A (CSA) to attempt removal of the infiltrating 
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infected T cells. The effect of this on disease outcome and 
virus gene expression will be monitored. 
  
 
Chapter 2 
General materials and 
methods
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2.1 Introduction 
This chapter describes the approaches which have been done in 
most of the work and common for all of the chapters while more 
specific methodology will be described in the results chapters. 
 
Virus:  The C500 strain (Plowright et al., 1960, Plowright et al., 
1975) was used. For preparation of virus stocks, see section (2.2.4) 
below. 
 
2.2 Tissue culture 
Three types of cultured plate adherent cells were grown for the 
study; bovine turbinate fibroblast (BT) cells were kindly donated by 
Dr George Russell of Moredun institute (Palmeira et al., 2013, 
Parameswaran et al., 2014), bovine aortic endothelium (BAE) cells 
(cat# 87022601, ECACC) the official name is BFA but BAE is used 
throughout the project, (Pollock et al., 1991), and statens 
seruminstitut rabbit cornea (SIRC) cells (Cat# 89090404, ECACC), 
(Parameswaran et al., 2014). The media used were Iscove’s 
Modified Dulbecco’s Medium (IMDM, Gibco® ThermoFisher 
Scientific, UK) for the growth of BT cells and Dulbecco’s Modified 
Eagle Media (DMEM, Gibco® ThermoFisher Scientific, UK) for the 
culture of BAE and SIRC. All the manipulations were undertaken 
under aseptic conditions in a laminar air flow tissue culture hood. 
The cells were split when they reached 80% confluence using 1% 
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trypsin in phosphate buffer saline (PBS) for up to 10 minutes (2ml 
for a 25 cm2 flask and 4ml for a 75cm2 flask) in 37˚ C, 5% CO2 in 
air incubator. Trypsin reaction was stopped by adding the same 
volume of warmed media containing 10% foetal calf serum (FCS). 
Supernatant was removed by centrifugation at the 1500 rpm for 5 
minutes at 21 ᵒC. The cell pellet was re-suspended by adding media 
(5ml for 25 cm2 and 14 ml for 75 cm2 flasks). Cells were incubated 
at 37 ᵒC, 5% CO2 in air and checked regularly (every 3 days) until 
cells become confluent. 
 
2.2.1 Large granular lymphocytes 
Large granular lymphocytes (LGLs) derived from rabbit mesenteric 
or popliteal lymph nodes are used in the study. Briefly, lymph node 
tissues were teased apart using sterile forceps and scissors. To give 
a single cell suspension the tissues were then passed through a 70 
µm filter using PBS (using back of 2ml syringe and 50ml centrifuge 
tube). The cells were washed twice with IMDM medium (containing 
Glutamax, 10% FCS, 100µg/ml penicillin, 50µg/ streptomycin). All 
manipulations were undertaken using sterile solutions, equipment 
and aseptic technique under the laminar flow hood. Cells were 
culture in upright 25cm2 flasks at 37ᵒC, in 5% CO2 in air. For 
maintaining the cultures, the cells were fed with fresh IMDM media 
(contain 10% special FCS and 50 µl interleukin-2 (IL-2) 50ng/ml 
media (Cat# 202-IL, Recombinant Human IL-2, R&D Systems)) 
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added up to 10 ml total volume of media by remixing the top ~one 
third of culture medium where most of the cells are at the bottom 
region of the flasks)) when the medium colour changes to 
yellow/orange or once every seven days. After that, cells are 
checked under the microscope for growth and stored back in the 
incubator in the upright position.        
 
2.2.2 Counting cells 
A haemocytometer was used to count cells and trypan blue 
exclusion used as a measure of cell viability. 
 
2.2.3 Cryopreservation of cells 
Adherent cells (BT, BAE and SIRC) were cryopreserved at 5x106- 
1x107 cells per ml medium containing 50% FCS in 10% v/v dimethyl 
sulfoxide (DMSO) (Cat# 472301, Sigma-Aldrich) and the LGLs and 
lymphoid cells at 1x107- 1x108 cells per ml. Adherent cells were 
detached from cultured plates by adding 1% trypsin in 1xPBS, 
centrifuged at 1200 rpm for 5 min. The cell pellet was re-suspended 
in freezing medium consists of 90% IMDM or DMEM media 
(containing 10% FCS, 1% penicillin/streptomycin) and 10% filtered 
(DMSO) according to the type of the cells. The cell suspension was 
then transferred to labelled cryo-tubes, placed in Mr frosty (freezing 
container, ThermoFisher Scientific, UK) in -80 ᵒC freezer overnight 
and then in liquid nitrogen. 
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2.2.4 AlHV-1 virus stocks 
Low culture pass (virulent) AlHV-1 C500 strain (Plowright et al., 
1975) virus stock was obtained from infected rabbit lymphoid cells 
incubated with BT cells where a mixture of cell-associated virulent 
and cell-free virulent viruses obtained from up to five passages in 
BT cells were harvested and frozen away as stock virus. The AlHV-1 
C500 strain used to infect BT cells to make the virus stock was 
obtained from AlHV-1 infected rabbit’s mesenteric lymph node 
(MLN) cells. The approach applied was as follows: All the 
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manipulations undertaken were under aseptic conditions in the 
laminar flow hood. BT cells were washed twice with PBS. Vials of 
infected rabbits MLN cells were taken out of the liquid Nitrogen 
storage and placed on dry ice. The vials were thawed and the MLN 
cells were added to a centrifuge tube containing 15 ml IMDM media 
and centrifuged then re-suspended two and half millilitres of the 
medium were added to each flask of BT cells (4 flasks in total) and 
one left as a BT only control. The flasks were incubated at 37 ᵒC, in 
5% CO2 in air incubator overnight.  
The following day, the media were discarded and the cells were 
washed with 1xPBS twice. Fifteen millilitres of IMDM media were 
added to each flask and then kept at 37 ᵒC, in a 5% CO2 air 
incubator. The cells were monitored daily for any cytopathic effect 
(CPE) which is characterised by the accumulation of cell debris and 
the absence of monolayer. 
The supernatant from the cultures were collected when the BT cells 
showed approximately 50% CPE, centrifuged and the pellet re-
suspended in 4 ml medium. The supernatant collected in 75 cm2 
flask and placed on Ice. Four ml 1xPBS was added to the attached 
cells which were mechanically detached from all the flasks, 
centrifuged and the pellet mixed with the previously obtained pellet. 
The mixture was then freeze-thaw three times in liquid nitrogen and 
spun down. The supernatant carefully collected and finally mixed 
with the supernatant initially collected in 75 cm2 flask. The 
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supernatant was aliquot in labelled cryo-tubes (1ml each), placed in 
-80 ᵒC freezer overnight and then stored in liquid nitrogen. Applying 
the same technique P1, P2, P3, and P4 were finally made. With regard 
to high pass attenuated AlHV-1 virus stock was made by passaging 
the virus in BT cells more than 5 times up to thirty passages.                       
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2.2.5 Virus titration : 50% tissue culture infective dose 
(TCID50) 
TCID50 is the approach used to measure virus titration. This 
measure the infective dose of the virus required to kill 50 % of 
infected BT cells measured as a cytopathic effect (CPE).  
The procedure was undertaken under aseptic conditions in the 
laminar flow hood. Seven Eppendorf tubes were labelled 101 to 107 
for the virus to be titrated. A volume of 100 µl of BT cell suspension 
(2x105 cells/ml in IMDM medium containing 10% FCS) was added to 
wells of a 96-well plate designated A1-4 to H1-4 (Figure 5). The 
plate was kept at 37 ᵒC, in 5% CO2 in air in an incubator overnight. 
The following day the media were discarded and the cells were 
washed twice with 1xPBS. A volume of 900 µl serum-free IMDM 
medium was loaded into each labelled Eppendorf tubes. AlHV-1 
C500 virus for titration was thawed from frozen storage. A volume 
of 100 µl of neat AlHV-1 virus was added to the tube labelled 101, 
and mixed thoroughly. A volume of 100 µl of 101 dilutions was then 
transferred to 102 Eppendorf tube and so on up to the 107 tube 
giving a number of serially diluted samples. A volume of 100 µl of 
dilution 101 was added to the wells B1-4 and dilution 102 to wells 
C1-4 and so on to H1-4. A volume of 100 µl of serum free medium 
was added to the wells A1-4 used as control (Figure 5).  
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Figure 5  Virus titration: 50% tissue culture infective dose (TCID50). 
The figure shows the steps were taken to carry out TCID50 for virus titration.  
 
The plate was finally placed in the 37 ᵒC, 5% CO2 incubator for two 
hours. After two hours, all the wells including the control were 
topped up with 100 µl IMDM medium containing 10% FCS. The plate 
was then placed in the 37 ᵒC, 5% CO2 incubator and read for % CPE 
after 4-5 days.  
Wells were positive if CPE was present. The virus titre is calculated 
by Spearman/Karber (http://www.cureffi.org/2015/09/20/the-
math-behind-spearman-karber-analysis/) Calculation as follows: Log 
TCID50-L-d (S-0.5) where 
L      = negative log of lowest dilution  
D     = difference between log dilution steps 
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S     = sum of proportion of positive tests (wells showing CPE from 
virus infection) 
Example of virus titration 
 
Table 3 example of virus titration 
 
Virus dilution Positive wells Proportion of infected culture 
10-1 + + + + 4/4 =  1 
10-2 + + + + 4/4 =  1 
10-3 + + + + 4/4 =  1 
10-4 + + - -   2/4 =  0.5 
10-5 - - + -    1/4 =  0.25 
10-6 - - - -            0/4 =  0 
            
3.75 
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2.3 Molecular techniques 
2.3.1 DNA extraction 
The total cellular and viral DNA was extracted using DNeasy blood 
and tissue kit (cat# 69506, Qiagen) according to manufacturer’s 
instructions. DNA was extracted from different tissues, blood and 
cultured cells. 
Cultured cells: appropriate number of cells was centrifuged 
(maximum 5x106) for 5 min at 300 g. The pellet was re-suspended 
in 200 µl phosphate buffered saline (PBS) and 20 µl proteinase K 
was added. A volume of 200 µl of buffer AL was added, mixed 
thoroughly by vortexing, and then incubated at 56 ᵒC for 10 min. 
After that, 200 µl of absolute ethanol was added to the sample and 
mixed thoroughly by vortexing. The mixture was then pipetted into 
DNeasy Mini spin column placed in a 2 ml collection tube, 
centrifuged at 6000g for 1 min, and the flow-through and the 
collection tube were completely discarded. The DNeasy Mini spin 
column was placed in a new 2 ml collection tube, 500 µl of buffer 
AW1 was added and centrifuged at 6000 g for 1 min. The flow-
through and the collection tube were discarded. The DNeasy Mini 
spin column was placed in a new 2 ml collection tube, 500 µl of 
buffer AW2 was added and centrifuged at 20,000 g for 3 min. The 
flow-through and the collection tube were discarded.  The DNeasy 
Mini spin column was placed in a clean 1.5 ml, 100 µl of buffer AE 
was directly loaded onto DNeasy membrane, incubated at room 
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temperature for 1 min, and then centrifuged for 1 min at 6000 g to 
elute. 
From blood: A volume of 20 µl of proteinase K was loaded into a 1.5 
ml Eppendorf tube. A volume of 50-100 µl anti-coagulated blood 
was added and the volume was adjusted to 220 µl with PBS.  A 
volume of 200 µl of buffer AL was added, mixed thoroughly by 
vortexing, and then incubated at 56 ᵒC for 10 min. After that, the 
steps were exactly similar to the ones done for cultured cells. 
Animal tissues: A piece of 25mg tissue was cut into small pieces, 
and then placed in a 2 ml micro-centrifuge tube. A volume of 200 µl 
of buffer ATL was then added. A stainless steel bead was added to 
the tube and the tube was placed in a tissue lyser (TissueLyser II 
Qiagen, Uk) to help disrupting the tissue.  A volume of 20 µl of 
proteinase K was added, mixed thoroughly by vortexing, and 
incubated at 56 ᵒC until the tissue is completely lysed. The next 
steps are similar to the ones done for cultured tissues.         
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2.3.2 RNA extraction 
Total RNA was extracted using RNeasy Plus mini kit (cat# 74134, 
Qiagen). A maximum of 1x107 cells were harvested and appropriate 
volume (600 µl) of Buffer RLT Plus was added and mixed by 
vortexing for 30 s. The homogenised lysate was transferred to a 
gDNA Eliminator spin column placed in a 2 ml collection tube and 
centrifuged for 30 s at 8000 g. the column was discarded and the 
flow-through was saved. One volume (600 µl) of 70% ethanol was 
added to the flow-through and mixed well by pipetting. Up to 700 µl 
of the sample was transferred to an RNeasy spin column placed in a 
2 ml collection tube and centrifuged for 15 s at 8000 g. the flow-
through was discarded.   A volume of 350 Buffer RWT was added to 
the RNeasy spin column and was centrifuged for 15 s at 8000 g to 
wash the membrane. The flow-through was discarded. A volume of 
10 µl DNase I stock (cat# 79254, Qiagen) solution was added to 70 
µl Buffer RDD (cat# 79254, Qiagen), mixed gently by inverting the 
tube, and centrifuged briefly. The DNase incubation mix (80) was 
directly added to the RNeasy spin column membrane, and placed on 
the benchtop for 15 min. A volume of 350 Buffer RWT was added to 
the RNeasy spin column and was centrifuged for 15 s at 8000 g to 
wash the membrane. The flow-through was discarded. A volume of 
500 µl Buffer RPE was added to RNeasy spin column, and 
centrifuged for 15 s at 8000 g to wash the membrane. The flow-
through was discarded.  A volume of 500 µl Buffer RPE was added 
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to RNeasy spin column, and centrifuged for 2 min at 8000 g to wash 
the membrane. The RNeasy spin column was placed in a new 1.5 ml 
collection tube. A volume of 30 µl RNase-free water was directly 
added to the spin column membrane, centrifuged for 1 min at 8000 
g to elute the RNA. 
Animal tissues: a piece of an animal tissue (less than 50 mg) was 
excised and loaded into a 2 ml collection tube. 600 µl of Buffer RLT 
Plus were added and a stainless steel bead was added to the tube 
and the tube was placed in a tissue-Lyser (Tissue Lyser II, Qiagen, 
UK) to disrupt the tissue. The tube containing the lysate was placed 
on the benchtop at room temperature for 5 min. The next steps are 
similar to the ones done for extraction of the RNA from the cultured 
cells. 
 
2.4 Nucleic acid amplification and quantitation 
2.4.1 Complementary DNA (cDNA) synthesis 
Complementary DNA was synthesised using the Transcriptor First 
Strand cDNA Synthesis Kit (cat # 04897030001, Roche Applied 
Sciences, UK). The template-primer mixture for 20 µl reaction was 
prepared in a sterile, nuclease-free, thin-walled PCR tube on ice by 
adding the components in the following order; the equivalent of 1 
µg total RNA, 2 µl random hexamer primer, and up to 13 µl RNase 
free water. After that, the RT (reverse transcriptase) mix was 
prepared by adding the following reagents; 4µl Transcriptor Reverse 
Osama Kumati                                               Materials & Methods 
70 
Transcriptase Buffer, 0.5 µl Protector RNase Inhibitor, 2 µl 
Deoxynucleotide Mix, and 0.5 µl Transcriptor Reverse Transcriptase 
(storage buffer; 200 mM potassium phosphate, 2 mM dithiothreitol, 
0.2 % Triton X-100 (v/v), 50% glycerol (v/v), pH approx. 7.2). The 
RT mix was then added to the tube containing the template-primer 
mix. The mixture was mixed carefully by flicking the tube, 
centrifuged briefly, and finally placed in a thermal block cycler with 
a heated lid for 10 min at 25 ᵒC followed by 35 min at 55 ᵒC. The 
Transcriptor Reverse Transcriptase was inactivated by heating to 55 
ᵒC for 5 min using XP Thermal Cycler (Bioer, UK). The reaction was 
stopped by placing the tube on ice and sample was stored at -20 ᵒC.   
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2.4.2 Polymerase chain reaction (PCR) 
2.4.2.1 PCR condition 
The procedure was undertaken under aseptic conditions in the ultra 
violet cabinet. The equipment (pipettes, tips, and nuclease-free 
water) were exposed to ultra violet light for 15 min. All the reagents 
except the Taq polymerase were thawed and placed into the ice 
box. The master mix mixture for 24 µl reactions was prepared in a 
sterile, nuclease-free, thin-walled PCR tube on ice by adding the 
components in the following order; 17,875 µl nuclease free water, 
2.5 µl 10x buffer, 1 µl MgCl2 (25mM), 0.5 µl dNTPs (10mM), 1 µl 
forward primer (5pmol/ µl), 1 µl reverse primer (5pmol/ µl), and 
0.125 µl Taq polymerase (5 u/µl). A volume of 1 µl sample/s was 
added to the tube containing the master mix mixture outside the UV 
hood. The tube was centrifuged and placed in the PCR machine to 
run according to the following programme; 1 cycle (initializing) x 94 
ᵒC, 35 (denaturation) x 94 ᵒC for 1 min, 60 ᵒC (annealing) for 1 min, 
72 ᵒC (elongation) for 1 min, and 1x 4 ᵒC hold. 
 
2.4.2.2 Agarose gel electrophoresis 
The PCR products were resolved to agarose gel (Sigma-Aldrich, UK). 
Certain amount of agarose powder, according to the concentration 
required, was dissolved in 100 ml 1xTAE buffer in a beaker. The 
beaker was then heated in the microwave oven for sometimes until 
completely dissolved, cooled down, and 3.8 µl Nancy-520 (nucleic 
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acid stain) (Sigma-Aldrich, Uk) was added. The gel solution was 
slowly poured into the gel tray and the air bubbles were removed 
using disposable tips. The gel was left for sometimes to set. The gel 
tray was placed in the gel tank and 1xTAE buffer (Tris base, acetic 
acid and EDTA) was added to the gel tank until the wells were 
covered. A volume of 1 µl 6% loading dye (New England BioLabs) 
was thoroughly mixed with 5 µl sample and then loaded into the gel 
wells along with 6 µl DNA ladder (New England BioLabs). The 
voltage was adjusted to 110 V for 1 hour and the DNA was viewed 
by the UV illuminator (ImageQuant 300 imager, GE healthcare, UK).   
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2.4.3 Viral load measurement  
Viral load is used to quantify the viral copy number in specific cells 
and tissues. q PCR is the device by which the viral load is identified. 
AlHV-1 virus copy number is measured by comparing the CT value 
with standard curve by normalizing AlHV-1 ORF3 gene with 105 copy 
number of rabbit β globin used as a reference gene as described in 
(Boudry, 2007). The forward primer sequence for ORF3 used 5’-
GGGCTAATTTGTGCAGTTTGTGA-3’ and reverse primer 5’-
AGGTGTTTCTGAAAAGAGGGGAA-3’ and the probe used for the assay 
was FAMAlHV-1 6FAM ACAGGCTCCTCGTCCTCGTCGTGT TAMRA. The 
rabbit β globin forward primer used 5′-
GGTATCCTTTTTACAGCACAAC-3′ and the reverse primer 5′-
CAGGTCCCCAAAGGACTCG-3′, in the presence of the fluorescent 
probe 5′-FAM-CCTGGGCTGTTTTCATTTTCTCAGG-TAMRA-3′. 
AlHV-1 BAC plasmid was utilized as standard as described in 
(Dewals et al., 2006a). The data obtained analysed using the 
absolute quantitative approach utilizing Light Cycler 480 software 
analysis.  
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2.4.4 Quantitative real-time PCR (q RT-PCR) 
The quantitative PCR, using the Light Cycler 480 System (Roche 
Applied Science, UK), is the method used to measure the viral copy 
number and detection of the virus DNA in the infected cells and 
tissues as well as measuring the viral gene expression profiles 
throughout the project work. The technique is utilized to amplify 
and quantify a target DNA based on the sequence-specific probes 
tagged with florescence probe upon hybridisation with its 
complementary DNA sequence in the presence of flanked primers. 
The probes and primer sequences for q RT-PCR used in this study 
are shown in table 4. The probes and primers were designed using 
Universal Probe Library (UPL) System Assay Design 
 (https://lifescience.roche.com/shop/products/universal-
probelibrary-system-assay-design). Probes were labelled with 
fluorescent reporter dye 5 carboxyfluorescein (FAM) at the 5’ end 
and quencher N,N,N,N’-tetramethyl-6-carboxyrhodamine (TAMARA) 
at the 3’ end. The technique was carried out utilizing the Light 
Cycler 480 Probes Master Kit (Roche Applied Science, UK) with the 
universal cycle profile. The 96-well plates were used for q RT-PCR 
with 20 µl added per reaction (well). For the test sample, each q RT-
PCR mixture contained 1x light cycler probe master, 900 nM forward 
primer, 900 nM reverse primer, 100 nM probe, 2 µl (10-50) 
template DNA, made up to 20 µl with RNase free water. Each q RT-
PCR reaction was carried out in duplicate. In addition, each q RT-
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PCR trial comprises two no template controls (NTC), test samples, a 
control from non- infected cells along with a standard log10 dilution 
series. The standard log10 dilution series were used to produce 
standard curves. The efficiency of the standard curve was measured 
using the Light Cycler 480 (LC480) software. The PCR reaction 
efficiency, ideally, should be 100% meaning that the amount of 
product doubles each cycle (E=2) (Figure 5 & 6). The normalised 
values for the gene expression profile were measured using the 
advanced relative quantification method utilizing the Light Cycler 
480 (LC480) analysis software. The genes selected for viral 
transcripts analysis (Table 4) are known with their involvement in 
latent and productive/lytic cycle in other herpesviruses. ORF73 
encodes latency associated nuclear antigen (LANA), homologue to 
Epstein Barr virus nuclear antigen (EBVNA1) and and KSAH ORF73 
LANA protein involved in latent infection, ORF50 encodes RTA 
protein the transcriptional and replication activator responsible for 
the switch to lytic cycle, ORF25 encodes a major capsid protein 
highly expressed during viral replication, A4.5 similar to Bcl-2 family 
of apoptosis and virus cycle expression not known and A9.5 encodes 
a secreted glycoprotein that is similar to IL-4 and virus cycle 
expression not known.  
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Table 4 primers and probes used for target and reference genes throughout the 
study. 
 
Gene symbol Oligonucleotide sequence (5’-3’) 
ORF50 F 
ORF50 R 
ORF50 P 
GCCACAGCCTCAATCTGAAT 
TTCTGGACGAACCTGGCTAT 
UPL23 
ORF73 F 
ORF73 R 
ORF73 P 
TGGGCCTTCTCCTTCAGAT 
AAGTGGACCAGGTTCGTCTG 
UPL32 
ORF25 F 
ORF25 R 
ORF25 P 
TTCACCGTTATGCACAATAAGC 
CTTGTGCTTTGCCTGCACT 
UPL155 
ORF A4.5 F 
ORF A4.5 R 
ORF A4.5 P 
TTTGACCCGGGTAGTCAATC 
GCTAGAATACATTCTGTGACCGTTAG 
UPL92 
ORF A9.5 F 
ORF A9.5 R 
ORF A9.5 P 
CAACCAGTTTTGTTGTTATTCAATG 
AAGAGAGTTAAAGTTAAATTTGGAGCA 
UPL83 
ORF63 F 
ORF63 R 
ORF63 P 
GCTGTAATTGGCACTCTCAGG 
TCATGAGGCGGAAGTTGC 
UPL40 
Rabbit SDHA1 F 
Rabbit SDHA1 R 
Rabbit SDHA1 P 
ACCGTGAAGGGCTCTGAC 
TTTCTAGCTCGACCACAGAGG 
UPL158 
Bovine RPS9 F 
Bovine RPS9 R 
Bovine RPS9 P 
GCCTCGACCAAGAGCTGAAG 
GGGCAGCCTTTCGGATCT 
TGATCGGCGAGTATGGGCTCCG 
Bovine G actin F 
Bovine G actin R 
Bovine G actin P 
  
CACCTTCCAGCAGATGTGGA 
CTAGAAGCATTTGCGGTGGAC 
AGCAAGCAGGAGTACG 
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Figure 5 snapshot of q RT-PCR amplification curve.  
The figure illustrates the amplification curves generated using Light Cycler 480 for 
determination of AlHV-1 DNA load from infected rabbit tissues utilizing ORF3 gene 
as a standard.  
 
 
Figure 6 snapshot of q RT-PCR standard curve.  
The figure shows the standard curve generated using Light Cycler for 
determination of AlHV-1 DNA load from infected rabbit tissues utilizing ORF3 gene 
as a standard and seven log10 serial dilutions 10-3 to 10 -8 and PCR efficiency of 
1.95.  
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2.4.5 Quantification of DNA and RNA by spectrophotometer 
DNA and RNA concentrations were assessed by a NanoDropTM ND-
8000 spectrophotometer (ThermoScientific, UK) according to the 
manufacturer’s instructions using the software program NanoDrop 
ND-8000 version 2.2.0. To make the data as precise as possible, 1.5 
µl blank was used for reading. After that, 1.5 µl of samples were 
loaded onto each lower measurement pedestal and read. The ratio 
of absorbance at 260 was used to measure the purity of nucleic 
acids.  A ratio of ~1.8-2.0 showed pure nucleic acids and values 
outside this range were presumed to indicate the presence of 
proteins or phenols or other contaminants. 
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2.5 Flow cytometry 
Flow cytometry was used to phenotype rabbit LGL samples 
(recognise the cell type and cell subset). Ten Eppendorf tubes 
labelled as non-stained, CD4 FITC, CD4 isotype control, CD8, CD11B 
(monocyte), B cell (CD19), Pan T (T cell), secondary antibody only 
FITC, secondary antibody only APC, and double staining (CD4&CD8) 
were used in this experiment. Labelling also includes rabbit LGL IDs 
(IYDY, IYJJ, LFLK, and LFKJ) for both 5-azacitidine-treated and non-
treated LGL. After three weeks, RPMI (cat 61870-010 Gibco Life 
technologies) was used with 2% FCS supplement for cell labelling: 
The only direct conjugated antibodies used were the CD4 FITC and 
CD4 isotype control (primary antibodies/one step labelling) For 
indirect immunofluorescence, the secondary antibodies used were 
mouse IgG1 FITC (CD11B, B cell, Pan T, and secondary FITC only) 
and mouse IgG1 APC (CD8, CD4&CD8, and secondary APC only). 
Table 5 shows the antibodies and the dilution factors used in the 
experiment. 
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Table 5 Labelling steps 
 
Antibody 
specificity  
Primary antibody + dilution factor Secondary antibody + dilution factor 
CD4 mouse IgG2a anti-rabbit CD4 FITC (KEN-4, AbD 
Serotec) 
NO 
CD4 isotype 
control 
mouse IgG2a CD4 isotype control-FITC (MCA929F, AbD 
Serotec) 
NO 
Non-stained NO NO 
CD11b Anti-rabbit CD11b (1:10) (MCA802GA, AbD Serotec) Goat anti-mouse IgG1 FITC (1:20) 
B cell  Anti-rabbit B cells (1:10) Goat anti-mouse IgG1 FITC (1:20) 
Pan T cell Anti-rabbit Pan T cell (1:10) (RTH2A, 2BScientific)   Goat anti-mouse IgG1 FITC (1:20) 
CD8  Anti-rabbit CD8 (1 :10) (MRB107A, 2BScientific)   Goat anti-mouse IgG1 APC (1:20) (A10530, 
Invitrogen, UK)   
CD8&CD4 Anti-rabbit CD8 (1 :10) and mouse IgG2a anti-rabbit 
CD4 FITC (1:10) 
Goat anti-mouse IgG1 APC (1:20)  
APC NO anti-mouse IgG1 FITC (1:20) 
FITC NO anti-mouse IgG1 FITC (1:20) 
Ten tubes were labelled for each cell line and four cell lines (IYJJ, IYDY, LFLK, and LFKJ) were used in the experiment. 
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2.5.1 Direct Immunofluorescence labelling of cells 
For this purpose, cells were spun at 2000 rpm for 5 minutes and 
pelleted then RPMI culture medium was added. Cells were counted 
to 5 X 105 cells/45 µl and placed in Eppendorf tubes. Antibodies of 
5µl mouse IgG2a anti-rabbit CD4 FITC (KEN-4, AbD Serotec) to CD4 
and CD4 & CD8 tubes, and 5µl mouse IgG2a CD4 isotype control-
FITC (MCA929F, AbD Serotec) were added to CD4 iso tube. 5µl of 
anti-rabbit CD8 (ISC29E, WS0768U-100, USA) (1:10) to CD8 and 
CD4 & CD8 tubes, 5µl of anti-rabbit CD11B (MCA802GA, AbD 
Serotec) (1:10) to CD11B tubes, 5µl of anti-rabbit Pan T cells 
(RTH2A, 2BScientific) (1:10) to Pan T tube, and 5µl of anti-rabbit B 
cells (MRB107A, 2BScientific) (1:10) to B cell tubes. Labelled 
Eppendorf tubes incubated in the dark in the fridge for 30 minutes.  
 
2.5.2 Indirect Immunofluorescence labelling of cells 
After that, cells were centrifuged at 2000 rpm for 2 minutes and 
washed twice with RPMI then 5µl (1:20 diluted) of goat anti-mouse 
IgG1 FITC (secondary Ab) was added to CD11b, B cell, and Pan T 
tubes, 5µl (1:20) of anti-mouse IgG1 APC (A10530, Invitrogen, UK) 
to CD8 and CD4 & CD8 tubes, 5µl (1:20) of anti-mouse IgG1 FITC 
secondary only tubes, 5µl (1:20) of anti-mouse IgG1 APC to APC 
secondary only tubes. Labelled Eppendorf tubes were again 
incubated in the dark in the fridge for 30 minutes. Cells were 
washed twice by spinning at 2000 rpm for 2 minutes leaving 100 µl 
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supernatant. Cells were fixed with 2% PFA and finally suspended in 
0.5 ml of PBS.   
 
2.5.3 Flow cytometry analysis of labelled cells 
The cells were centrifuged and rinsed then directed to FACScan TM 
flow cytometer system (Becton Dickinson, Bioscience, USA). The 
Cells population were gated out to appropriate forward scatter 
(FSC), side scatter (SSC), 280 and 400, respectively. Cell’s samples 
were then acquired by CellQuest pro-software (BD Biosceince, USA). 
Finally, the fluorescence data analysis was performed by FACSDiva 
software (BD Biosceince, USA) and the quadrant sitting for labelled 
and unlabelled cells was based on antibody-isotype control 
fluorescence. 
 
2.6 Animals 
Ten three month old New Zealand white female rabbits were used 
(Purchased from Harlan UK). Animals were kept at the animal 
facility at Sutton Bonington, University of Nottingham. Animal 
experiments were under ASPA (UK) regulations with a project 
license held by David Haig at the University of Nottingham. Ethical 
review was obtained from the local SVMS ethics committee and the 
University of Nottingham AWERB committee. After infection (see 
section 2.6.1) animals were observed and temperature was 
recorded daily using a subcutaneous mini chip. Animals were 
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euthanized when high body temperature (40˚C) developed for two 
consecutive days or more along with an accumulation of clinical 
signs typical of MCF that would progress the disease to a higher 
severity limit than moderate (limited by ASPA project license held 
by D Haig).        
 
2.6.1 Inoculation 
Wildebeest-associated MCF virus (AlHV-1) contained in mesenteric 
lymph node cells isolated from a rabbit previously infected with 
AlHV-1 virus C500 strain was used to infect the rabbits injected 
intravenously (IV, ear vein) with 2 x 106 cells in 1 ml PBS.  
 
2.6.2 Experiment (1) design 
Ten rabbits were infected with AlHV-1 C500 strain on day 0 of the 
experiment as described above. Six of the ten rabbits were treated 
with cyclosporine A (Cat# 239835, CALBIOCHEM, Germany) every 
other day starting at day 0 at dose of 0.25-0.5ml IV (depending on 
the weight of the rabbit) to give a dose of 20mg/kg body weight. 
The CsA was dissolved in 1XPBS D-α-Tocopherol 25mg/ml per 
animal in 1XPBS (Cat# 57668-25G, Sigma) containing 2% v/v 
ethanol in PBS. The remaining four rabbits were given vehicle 
(tocopherol- ethanol-PBS) only every other day intravenously. 
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2.6.3 Experiment (2) design 
The second experiment was similar to the first one with the 
exception that the number of rabbit groups included an uninfected 
control group. Four were infected with the virus; four were infected 
and treated with cyclosporine A as before except that it was 
dissolved in PBS containing castor oil 25mg/ml per animal 
(Kolliphor® EL, cat# C5135-500G, Sigma) and two non-infected 
controls given vehicle only.  
Experiment # 1 Inoculation  Treatment  Observations 
10 rabbits  All animals 
infected with 
the virus from 
day 0 of the 
experiment IV 
6 rabbits 
treated with 
CsA (20 mg/kg 
body weight) 
IV every other 
day 
D-α-
Tocopherol 
25mg/ml per 
animal in 
1XPBS 
containing 2% 
ethanol IV 
used as  a 
vehicle  
Experiment # 2    
16 rabbits 12 rabbits 
infected with 
the virus from 
day 0 of the 
experiment IV 
 
4 rabbits were 
not infected 
used as a 
control  
6 rabbits 
treated with 
CsA (20mg/kg 
body weight) 
IV every other 
day 
6 rabbits no 
treatment   
Castor oil 
25mg/ml per 
animal IV 
used as a 
vehicle 
 
2.6.4 Sample collection 
Liver, kidney, lung, spleen, and appendix tissues about 1cm3 were 
collected (four pieces per tissue) and one piece each placed in 
Eppendorf tubes containing 500 µl RNA-later (Cat# AM7020, 
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ThermoFisher Scientific, UK), and placed immediately in -20 C° 
freezer until RNA extraction. A second piece of each tissue was 
placed in Eppendorf tubes without adding RNA-later and then placed 
in -20 C° freezer for subsequent DNA extraction. Mesenteric (MLN) 
and popliteal lymph nodes were placed in 60ml tubes containing 
40ml sterile 1XPBS. The lymph nodes were processed immediately 
after collection (see section 2.2.1). Blood samples ~ 1800µl were 
placed in Eppendorf tubes and then placed in -20 C° freezer.   The 
third piece of liver, kidney, lung spleen, and appendix were placed 
in 7ml bijou tubes containing 5ml 4% paraformaldehyde (Cat# 
P/0840/53, Fisher Scientific) in PBS for 48 hours prior to paraffin 
embedding (see section 2.7.1) for in situ hybridisation work.  
Finally, the fourth piece of each tissue (liver, kidney, lung, spleen, 
and appendix) was placed in 60ml tubes containing 40ml 10% 
neutral-buffer-formalin (Cat# 361387P, VWR International) for 24-
48 hours prior to paraffin embedding (see section 2.7.1) for H&E 
staining. 
 
2.7 Histology 
Histological approaches are used to investigate the structural 
organisation of tissue. 
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2.7.1 Paraffin embedding 
Following fixation (see above), tissues were placed in an embedding 
cassette and dehydrated by processing with an increasing gradient 
of absolute ethanol in a tissue processor (Leica TP 1020, Leica 
microsystem. UK) as the following protocol: 
 70% (v/v) Ethanol, 1 hour. 
 80% (v/v) Ethanol, 1 hour. 
 95% (v/v) Ethanol, 1 hour. 
 100% (v/v) Ethanol, four changes, 30 min each. 
 Histoclear, three changes, 1 hour. 
 Paraffin wax (56-58 C°), two changes, 1 hour and half each.  
 
Finally, the processed tissue samples were oriented and embedded 
into paraffin molds and kept on the cold plate for 30 minutes to set. 
Then the mold is removed and the excessive paraffin is trimmed off. 
 
2.7.2 Tissue sectioning and staining 
Sections, 6µm thickness, from kidney and appendix fixed in buffered 
formalin were cut, de waxed and then stained with haematoxylin 
and eosin stain (H&E) according to the standard histological 
approach (described below) to visualize the histological structure of 
the tissues. The slides of tissue sections were passed into histoclear 
(two changes for 5 min each), dabbed to remove excess fluid, then 
rehydrated in a series of alcohol concentrations (100%, 95%, and 
70%) for 2 minutes each and then rinsed in running water. Slides 
were immersed in a bath comprising haematoxylin (Cat# H9627, 
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Sigma-Aldrich) for 3 minutes and then washed in running tab water. 
After that, slides were placed in 1% acid alcohol (300ml ethanol+ 
3ml HCl) for few seconds, and then washed in water. 
Slides were immersed in Eosin (cat# 318906-500 ml, Sigma-
Aldrich) for 5 minutes and then briefly washed in water. Eventually, 
slides were dehydrated by passing through different concentrations 
of ethanol (Cat# E10650DF/17, Fisher Chemicals) (95% and 100% 
alcohol), dabbed to remove excess, and then cleared in xylene for 5 
minutes in a fume hood before being mounted with 1,3-diethyl-8-
phenlxanthine (DPX) (Fluka analytical, Sigma Aldrich, UK). Sections 
were visualized using upright microscopy Leica DM 5000B 
epifluoresence imaging system. 
For the third experiment, sample preparation and fixation was 
performed manually applying the same parameters with the 
exception that xylene (cat# x10200/17, Fisher Chemicals) was used 
as an alternative to histoclear. In addition, DEPC-treated water was 
used in 1XPBS to make up 4% paraformaldehyde.  
  
2.8.1 RNA in situ hybridisation 
In situ hybridisation is the technique by which gene transcripts 
(mRNA) can be located on tissue using a combination of molecular 
and histological approaches providing that the tissue components 
(RNA and morphological features) are maintained.    
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2.8.1.1 Preparation of riboprobes for virus gene transcripts 
RNA probe synthesis is one of the steps towards achieving 
comprehensive in situ hybridisation procedure. The other two main 
steps include tissue fixation and sectioning and hybridisation of 
probes. 
    
2.8.1.2 Primers design 
The PCR primers used in preparing the riboprobes for AlHV-1 ORF 
65 and ORF A9.5 were designed by professor James Stewart 
(ORF65) and Dr George Russell and colleagues (Russell et al., 
2013). Table 6 shows the primers sequence and their amplicon size. 
 
Table 6 shows AlHV-1 ORF65 and ORF A9.5 primer sequences and amplicon size 
 
AlHV-1 gene Oligonucleotides sequence   Amplicon size 
ORF 65 Forward 
ORF 65 Reverse  
GCACGCTAGGCCTAAACTTCC 
GCCTTTGCCTAGTTTTCCTCTGG 
730 bp 
ORF A9.5 Forward  
ORF A9.5 Reverse  
TGGTTGTGAGAATGAAACACTTG 
GCACAAACCGAGTTTGACAG 
525 bp  
    
2.8.1.3 Polymerase chain reaction (PCR) amplification 
PCR was used to amplify the genes of interest according to the 
protocol described in the materials and methods, section (2.4.2) 
using Taq polymerase enzyme (NEB). The benefit of using Taq 
polymerase enzyme is to add a single deoxyadenosine A to the 3’ 
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end of the PCR product. The PCR fragment of the gene of interest 
was then inserted into a linearized plasmid victor (TOPO-TA one 
shot cloning kit, Invitrogen) having single overhanging 3’ 
deoxythymidine T residues. This will provide efficient ligation of the 
PCR insert with the plasmid DNA victor. Complementary DNA 
(cDNA) from rabbit’s kidney infected with AlHV-1 C500 strain was 
used to amplify the gene of interest. The reason for using cDNA is to 
obtain coding sequence without any introns (non-coding sequence), 
hence avoiding any complication while synthesising the RNA probe. 
Figure 7 shows the amplicon size for both genes. 
 
Figure 7  AlHV-1 PCR products for ORF A9.5 and ORF65 genes. 
 
The figure illustrates the PCR products (cDNA) for two AlHV-1 genes 
used to generate RNA probes utilizing plasmid vector. Image (A) 
shows the product size (525 bp) of ORF A9.5 while image (B) shows 
the product size (730 bp) of ORF65. One kilo base pair ladder was 
used to analyse the genes product size. NC: negative control.   
   
Osama Kumati                                               Materials & Methods 
90 
 
2.8.1.4 Gel extraction for ORF65 product 
Gel extraction was performed on ORF65 PCR products as it did not 
give a clear single band using QIAquick Gel Extraction Kit (Cat# 
28704, Qiagen). The protocol used was according to the 
manufacturer’s instructions as the following. The DNA fragment was 
excised from the agarose gel with a clean, sharp scalpel, weighed in 
a colourless tube, and 3 volumes Buffer QG were added to 1 volume 
gel. The tube incubated at 50 ᵒC for 10 min and 10 µl 3 M sodium 
acetate was added. One volume isopropanol was added to the 
sampled and mixed. The sample was applied to a QIAquick spin 
column in 2 ml collection tube and centrifuged for 1 min. The flow-
through was discarded. A volume of 500 µl Buffer QG was added to 
the spin column and centrifuged for 1 min. The flow-through was 
discarded. A volume of 750 µl Buffer BE was added to QIAquick 
column and centrifuged for 1 min to wash the DNA. The flow-
through was discarded. The QIAquick column was placed in a clean 
1.5 ml micro-centrifuge tube. A volume of 30 µl Buffer EB (10 mM 
Tris-Cl, pH 8.5) was added to the centre of the QIAquick membrane, 
let stand for 1 min, and then centrifuged for 1 min to elute the DNA. 
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2.8.2 Plasmid cloning, transformation and bacterial 
culture 
The PCR products for the genes of interest were then cloned into 
TOPO vector (PCR II TOPO, Invitrogen) utilizing TOPO-TA one shot 
cloning kit (Invitrogen) according to the following steps: Two µl of 
fresh PCR product mixed with 1 µl salt solution (1.2 M NaCl, 0.06 M 
MgCl2) and 2 µl of RNase free water was added then 1 µl of plasmid 
(10 ng/µl linearized plasmid, 50 glycerol, 50 mM Tris, 1mM DTT, 
0,1% 100x triton, 100 µg/ml BSA, phenol red) was added to make a 
final mixture of 6 µl cloning mix. The mixture was incubated for 5 
minutes at room temperature. The mix then placed on ice. 
Two µl of the TOPO cloning reaction was added to the chemically 
competent E. coli in a vial (one shot, Invitrogen), mixed gently and 
then incubated on ice for 30 minutes. The cells were then heat-
shocked for 30 seconds at 42˚C in water bath without shaking and 
quickly transferred on ice. A 250µl of room temperature supplied 
SOC medium (Invitrogen) was added to the bacterial vial. The vial 
was caped tightly and placed horizontally (200 rpm) at 37˚C for 1 
hour in a shaker.  
Upon incubation, 40 µl of the transformed cells were spread on agar 
plate with 50 µg/ml kanamycin (Cat# 15160054, Thermo-fisher 
Scientific) and x gal (Cat# 15520-018, Thermo-fisher Scientific) for 
white or blue colony screening. The plates were incubated overnight 
at 37˚C. The following day six white colonies were chosen and 
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cultured in 5 ml nutrient broth containing 50 µg/ml kanamycin and 
then incubated for 24 hours at 37˚C in universal tubes in orbital 
shaker at 200 rpm.  
 
2.8.2.1 Plasmid purification 
2.8.2.1.1 Minimum isolation of plasmid DNA (Mini-prep) 
The plasmid DNA was isolated using resource plasmid mini kit (cat 
# SBS27104, Source Bio Science, UK). One to five ml bacterial 
overnight culture was pelleted by centrifugation at 6000 g for 3 min 
at room temperature. Pelleted bacterial cells were re-suspended in 
250 µl buffer 1 and then transferred to a micro-centrifuge tube. A 
volume of 250 µl Buffer 2 was added and mixed thoroughly by 
inverting the tube 4-6 times until the solution becomes clear. A 
volume of 350 µl Buffer 3 was added, mixed immediately and 
thoroughly by inverting the tube 4-6 times, and then centrifuged for 
10 min at 17,900 g in table-top micro-centrifuge. The supernatant 
was applied to spin column in a 2ml collection tube, washed by 
adding 0.5ml Buffer B and centrifuged for 1 min. The flow-through 
was discarded. The spin column was washed by adding 0.75ml 
Buffer E and centrifuged for 1 min. The flow-through was discarded. 
The spin column was further centrifuged for 1 min to remove 
residual wash buffer. The spin column was placed in a clean 1.5 ml 
micro-centrifuge tube and 50 µl Elution buffer was added to the 
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centre of the spin column, let stand for 1 min, and then centrifuged 
for 1 min to elute the DNA.  
 
2.8.2.1.2 Maximum isolation of plasmid DNA (maxi-prep) 
The maximum isolation of plasmid DNA was performed using 
plasmid maxi kit (Cat# 12362, Qiagen). The 150 ml overnight 
nutrient broth culture was harvested by centrifuging at 6000 g for 
15 min at 4 ᵒC and the bacterial pellet was completely re-suspended 
in 10 ml Buffer P1. A volume of 10 ml Buffer P2 was added mixed 
thoroughly by inverting 4-6 times, and incubated at room 
temperature for 5 min. During the incuation, the QIAfilter Cartridge 
cap was screwed onto the outlet nozzle of the QIAfilter Cartridge in 
a falcon tube. A volume of 10 ml chilled Buffer P3 was added and 
mixed thoroughly by inverting 4-6 times. The lysate was loaded into 
the barrel of the QIAfilter Cartridge, incubated at room temperature 
for 10 min. After removing the cap from the QIAfilter Cartridge 
outlet nozzle, a plunger was gently inserted into the QIAfilter 
Cartridge to filter the cell lysate into the falcon tube. A volume of 
2.5 ml Buffer ER was added to the filtered lysate, mixed by inverting 
the tube 10 times, and then incubated on ice for 30 min. A QIAGEN-
tip 500 was equilibrated by applying 10 ml Buffer QBT and allowed 
the column to empty by gravity flow into a falcon tube. The filtered 
lysate placed on ice was applied to the QIAGEN-tip and allowed to 
enter the tip. The QIAGEN-tip was washed twice with 30 ml Buffer 
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QC. The DNA was eluted with 15 ml Buffer QN into a 30 ml 
endotoxin free tube, precipitated by adding 10.5 ml room-
temperature isopropanol, mixed, and then centrifuged at 15,000 g 
for 30 min at 4 ᵒC. The supernatant was carefully discarded and the 
DNA pellet was washed with 5 ml of endotoxin-free room-
temperature 70% ethanol, and centrifuged at 15,000 g for 30 min 
at 4 ᵒC. the supernatant was carefully decanted without disturbing 
the pellet. The DNA pellet was air-dried for 5-10 min and re-
dissolved in a suitable volume (100 µl) of endotoxin-free Buffer TE. 
 
2.8.2.1.3 DNA sequencing  
The plasmid DNA containing the PCR product inserts of the genes of 
interest were sent for a sequence check to Source Bioscience 
(Rochdale, UK) utilizing universal primers (M13 reverse and M13 
forward) to sequence sense and anti-sense DNA strands. The data 
obtained from the sequence analysis were compared with the genes 
of interest sequence available at 
 (http://www.ncbi.nlm.nih.gov/nuccore/10140926/) using clustalW2 
software programme.  
 
2.8.2.1.4 Restriction digestion for plasmid DNA preparation 
In order to prepare DNA template, plasmids were linearized using 
suitable restriction enzymes generating correct DNA cut. A volume 
of 8 µg of DNA was mixed with 8 µl restriction enzyme and 8 µl 
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restriction enzyme buffers (10X). The volume was then completed 
to 100 µl RNase free water and then incubated for 2 hours at 37˚C. 
A volume of 2.5 µl of the digested DNA were run on 1% agarose gel 
as described in section (2.4.2.2) to compare the size of plasmid and 
gene of interest. The restriction enzymes used were Bam H l (Ref# 
10798975001, version 12, Roche) to prepare anti-sense probe and 
Xho l (Ref# 10899194001, version 22, Roche) to prepare sense 
probe. Digested DNA was purified utilizing Phenol:Chloroform: 
Isomyl (25:24:1) (P 3803-100, Sigma) Chloroform:Isomyl alcohol 
(24:1) (Cat# C0549-1QT, Sigma) and ethanol and  then suspended 
in 50 µl RNase free water and kept in -20˚C freezer.  
 
2.8.2.1.5 In vitro transcription of digoxygenin (dig)-labelled 
RNA probes  
In order to produce digoxigenin-labelled RNA probes, the linearized 
DNA template was used for in vitro riboprobe synthesis utilizing Dig 
RNA labelling kit (Cat # 11175025910, Roche, USA) in line with the 
manufacturer’s instructions. An amount of 1 µg of purified template 
DNA was added into Eppendorf tube and 2 µl of 10X NTP labelling 
mix, 2 µl of 10X transcription buffer, 1 µl of protector RNAse 
inhibitor, 2 µl RNA polymerase SP6 to generate sense probe or 2 µl 
RNA polymerase T7 to produce anti-sense probe and then the 
volume was made up to 13 µl with RNase free water. The mix was 
centrifuged briefly and then incubated for 2 hours at 37˚C. a 
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volume of 2 µl DNase I were added and incubated for 15 minutes at 
37˚C to degrade the template DNA. The reaction was then stopped 
by adding 2 µl of 0.2 M EDTA pH 8. A volume of 1 µl of 1 mg/ml 
carrier yeast tRNA was added to the DNase digested probes, 
precipitated by ethanol and then re-suspended in 50 µl RNase free 
water.  
 
2.8.2.1.6 Dot blot analysis of generated probes  
In order to check the excellence of the generated probes, serial 
dilutions of sense, antisense and T7 control were prepared in 10 
µg/ml yeast tRNA (cat # VYAM7119, Fisher Scientific, UK) and 
tested by dot blot hybridization. A volume of 5 µl of each dilution 
was spotted on Amersham’s nylon membrane (Amersham 
Pharmacia biotech, Hybond-N+, England) from 10-5 to 10-1 in a petri 
dish. Upon drying, the dish containing the membrane was placed in 
UV croslinker (stratalinker) to fix the probes. The membrane was 
then placed on a bigger dish on a shaker and washed in 100 ml 
washing buffer (0.1 M maleic acid, 0.15 M NaCl pH 7.5, 0.3 % v/v 
Tween 20) for 2 minutes. The membrane was soaked in 100 ml 
blocking solution (Dig-wash and block, cat # 11585762001, version 
10, Roche) (0.1 M maleic acid, 0.15 M NaCl, pH 7.5) on a shaker for 
30 minutes. After that, the membrane was incubated with 20 ml 
labelled anti-DIG antibody solution (anti-Digoxigenin-AP FAb 
fragments, cat# 11093274910, Roche) diluted 1:5000 in blocking 
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solution) for 30 minutes. The membrane was then washed twice 
with 100 ml washing buffer for 15 minutes and equilibrated in 
detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5) for 3 minutes. 
The colour substrate was prepared by dissolving one tablet Sigma 
fast BCIP/NBT (Cat# B5655-25TAB, Sigma) in 10 ml RNase free 
water. The dish was then placed in the dark until the dot blot 
coulure develop. The reaction was then stopped by adding 50 ml TE 
buffer for 5 minutes. 
 
Figure 8  dot blot analysis of AlHV-1 ORF A9.5 RNA probe 
The figure shows the log10 dilutions of sense, antisense, dig-labelled 
RNA and T7 control which were spotted on Amersham’s nylon 
membrane from 10-1 to 10-5 concentrations. The membrane was 
washed and blocked using dig-wash and block solutions to develop 
the dot blot colour. 
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2.8.3 Deparaffinisation, proteolysis, and acetylation 
of tissue sections 
Deparaffinisation was performed by placing tissue sections in xylene 
(Cat# X/0200/17, Fisher Scientific) twice in staining dishes for 5 
minutes. The sections were then rehydrated by dipping twice in 
100% ethanol for 5 minutes and 96% and 70% once for 5 minutes. 
The slides were dipped in DEPC treated water (diethyl 
pyrocarbonate, cat# E174-25G, Amresco) in staining dish for 5 
minutes. The slides were then transferred to coplin jar and washed 
with 1XPBS for 5 minutes.  
To achieve proteolysis, slides were incubated in 0.2 M HCl at room 
temperature for 30 minutes. Slides were then incubated twice 2X 
sodium saline citrate with 5 mM EDTA at 50ᵒC for 30 minutes, 
trailed by digestion in proteinase K solution ({proteinase K, 
recombinant PCR grade, cat# 03115836001, Roche}, with 1 M TRIS 
pH 8 and 0.1 M CaCl2 made up to 60 ml DEPC treated water) for 15 
minutes at 37ᵒC. Fixation steps were performed in room 
temperature through incubation in 0.2% glycine-PBS for 5 minutes, 
followed by washing in 4% paraformaldehyde for 4 minutes and 
then washing in 1XPBS for 2 minutes and 15 minutes in 5mM MgCl2 
in 1XPBS. 
Acetylation was done through incubation with 0.25% acetanhydrid 
(Cat# 45830-250ML-F, Sigma) with 0.1 M triethanolamine (Cat# 
1.08379.0250, VWR International Ltd) pH 7.5, followed by washing 
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in 1XPBS twice for one minute and once for 15 minutes in room 
temperature.  
 
2.8.4 Hybridisation of probes 
Pre-hybridisation, hybridisation, and post hybridisation wash: 
The slides were prepared for hybridisation by pre-warming in pre-
hybridisation buffer (0.1 mg/ml salmon sperm DNA [Sigma] and 
0.25 mg/ml yeast tRNA in a pre-hybridisation stock mix of 30% v/v 
20X SSC, 45% v/v 100% deionised formamide [cat# 11FORMD002, 
MP Biomedicals, LLC], 10% v/v 50x Denhardt’s solution [Invitrogen] 
with 14% DEPC-treated dH20) in coplin jar at 52ᵒC for 1 hour. 
To perform the hybridisation step, slides were transferred to metal 
tray and covered with 30-40 µl/ tissue section hybridisation buffer 
consisting of 250µg/ml tRNA, 10mg/ml salmon sperm DNA, 80 µl 
dextransulfate, 2-6 µl RNA probe (1:100) dilution added to 700 µl 
hybridisation mix 100% deionised formamide, 20X of 0.5 M EDTA 
pH 8, 0.5 M piperazin-N,N’bis 2-ethanesulfate-acid-PIPES pH 7.0 
(cat# P3768-25G, Sigma), 5 M NaCl, 50X Denhardt’s solution, 
heparin 20,000 U (Cat# H 3393-25 KU, Sigma), and 10% Triton X-
100. Slides were covered with hydrophobic surface of gel-bond film 
(Cat# LZ53734, Scientific Laboratory Supplies LTD, Uk), sealed with 
Fix-O-gum gel (Marabu, Tamm, Germany) and incubated at 52°C in 
a moist box overnight. 
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The following day gel bond was carefully removed and slides placed 
again in coplin jar for post hybridisation wash. Washes were 
performed twice in 6XSSC with 45% formamide (Cat# 
1.09684.1000, VWR International LTD) at 42ᵒC for 15 minutes, 
followed by two washes in 2XSSC for 5 minutes at room 
temperature and twice in 0.2XSSC at 50ᵒC for 15 minutes. 
 
2.8.5 Anti-DIG labelling for probe detection 
Tissue sections were washed with buffer 1 (TRIS 100mM, NaCl 
100mM, pH 7.5) for one minute at room temperature. Slides were 
then washed with blocking solution (sterile neutral sheep serum 
{NSS, cat# S2263-100ML, Signa}, 10% Triton X-100) for 30 
minutes at room temperature. Slides were then placed on metal 
tray, carefully dried, and circled by water repellent pen (PAP-PEN). 
Antibody solution 400 µl/slide (30 µl AP-conjugated {Anti-DIG-AK-
AP 1:200}, 42 µl NSS, 188 µl 10% Triton X-100, 6 ml buffer1) were 
added on top of the tissue sections for 2 hours at room 
temperature. Slides were then transferred to coplin jar and washed 
with buffer 1 twice for 15 minutes at room temperature. Tissue 
sections were further washed with buffer 3 (TRIS 100mM, NaCl 
100mM, pH 9.5, MgCl2+6H2O) for two minutes at room 
temperature. Ultimately, slides were incubated in the dark with 
staining solution (three tablets of BCIP/NBT, 30 mg levamisole 
(Cleaveland et al. L9756-5G, Sigma), 60 ml buffer 3) for long time 
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up to 1 week. Slides were periodically inspected under light 
microscope for signal development (dark blue colour in cell 
cytoplasm). The reaction was stopped by incubating slides with 
buffer 4 (TRIS 10mM and EDTA 1mM, pH 8) in the dark for 10 
minutes. Slides were kept in duple distilled water for 5 minutes. 
Counter staining was done by dipping slides in haematoxylin (Ref# 
HHS32-1L, Sigma Aldrich) for 10 seconds. After that, slides were 
blueing in tap water for 5 minutes. Slides were then dried and 
covered with cover slip using 1, 3-diethyl-8-phenlxanthine (DPX) 
(Fluka analytical, Sigma Aldrich, UK) and then stored in the dark. 
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2.9 RNA quality measurement using Agilent Bio-
analyser Nano 6000 kit 
Agilent Nano chips (Agilent Technologies, Stevens Creek Blvd, USA) 
comprise a set of micro channels used to separate nucleic acid 
fragments based on base sizes as they are driven through it 
electrophoretically. RNase ZAP (Cat# AM9780, ThermoFisher 
Scientific) which removes RNases and reduce nuclease 
contamination in RNA purification laboratories and RNase free water 
were used to decontaminate the electrodes by washing for 1 minute 
and 10 seconds respectively. All the reagents and samples used in 
the technique were equilibrated at room temperature for 30 
minutes. A volume of 550 µl of Agilent 6000 Nano gel matrix (red 
colour tube in the kit) was placed in a spin filter and centrifuged for 
10 minutes at 1500 g. A volume of 65 µl filtered gel was aliquoted 
in RNase free 0.5ml micro-centrifuge tubes. For single use, the gel 
dye mix was prepared by adding 1 µl of RNA 6000 Nano dye (blue 
colour) to 65 µl aliquot of pre-prepared filtered gel. The tube was 
mixed thoroughly by vortex and then centrifuged for 10 minutes at 
room temperature at 13000 g. The gel dye mix was loaded into the 
RNA Nano chip by pipetting 9 µl of the mix at the bottom of the 
wells marked  (Figure 9) after the chip was being placed on the 
chip priming station. The plunger was positioned at 1 ml position 
and the chip priming station was closed for 30 seconds. The plunger 
of the syringe was held down until it was held by the clip. After 30 
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seconds the plunger was released by a clip release mechanism. The 
chip priming station was opened and 9 µl of the gel dye mix was 
pipetted in the wells marked (Figure 9). 5 µl of RNA 6000 Nano 
marker (green colour) was pipetted into the 12 wells and the wells 
marked  (Figure 9).  The RNA samples and the ladder were heat 
denatured at 70ºC for 2 minutes to minimise secondary structure. 1 
µl of the ladder was pipetted to the wells marked  (Figure 9) and 1 
µl of each sample into each of the 12 sample wells. The chip was 
horizontally placed in the adapter of the available vortex mixer and 
vortexed for 1 minute at 2000 rpm. The chip was inserted in the 
Agilent 2100 Bioanalyzer and read. Figure 9 shows the Agilent 6000 
Nano chip shape and its various loading wells. 
 
Figure 9 shows the Agilent 6000 Nano chip appearance and its different loading 
wells 
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2.10 RNA sequencing (RNA-Seq) methods 
RNA-seq is also known as whole transcriptome shotgun sequencing 
(WTSS) and utilizes next-generation sequencing (NGS) to detect 
and quantify RNA molecule by way of DNA copies in a given 
biological sample (Morin et al., 2008, Wang et al., 2009). The use of 
this technique has enabled scientists to analyse cellular 
transcriptomes and simplified looking at alternative gene spliced 
transcripts, changes in gene expression, single nucleotide 
polymorphism (SNP), posttranscriptional modifications and the 
ability to look at RNA populations including mRNA, micro-RNA 
(miRNA), small RNA, total RNA, tRNA and ribosomal RNA (Ingolia et 
al., 2012, Maher et al., 2009). There are many approaches by which 
RNA sequencing can be achieved. 
 
2.10.1 RNA poly (A) library 
In this approach the polyadenylated (poly (A)) tail is targeted to 
guarantee that coding RNA is split from non-coding RNA. This can 
be done by using poly (T) magnetic beads (Wang et al., 2009). 
Because ribosomal RNA (rRNA) represent up to 80% of total RNA in 
a given cell resulting in dilution of mRNA species, tRNA is removed 
by either enzymatic degradation or hybridisation-based depletion 
approaches (Chen and Duan, 2011, Yi et al., 2011). Prior to cDNA 
synthesis, RNA samples are fragmented by either chemical 
hydrolysis or enzymatic digestion to approximately 200-250 
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nucleotide (nt) long (Mortazavi et al., 2008). After that, 
complementary DNA (cDNA) is synthesized by reverse transcriptase 
and oligonucleotides, used as adapters, are utilized to ligate to 
cDNA to assist amplification and allowing sequencing (Chu and 
Corey, 2012). 
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2.11 Illumina machine NextSeq500 sequencing 
platform work flow   
The work flow of the Illumina sequencing machine comprises four 
main steps; sample preparation, cluster generation, sequencing and 
data analysis. In the first step, the sample of interest (total RNA) is 
subjected to a series of stages to fragment the RNA molecule, 
converted into cDNA and then amplified to produce cDNA library. 
This library is then placed in an eight-lane flow cell in which the 
cDNA fragments are attached to oligonucleotide primers 
complementary through its adapters. The cDNA fragments then 
undergo a series of amplification by which clusters of double 
stranded DNA are produced. The flow cell is placed in the 
sequencing machine where each cluster is sequenced and at each 
cycle four-fluorescence labelled nucleotides are added and the 
emitted signals are recorded. The intensity of the fluorescence is 
translated into base-calls. The cycle numbers show the length of the 
reads whereas clusters numbers define the number of reads (Bullard 
et al., 2010). 
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2.12 Bioinformatics tools 
The activities that can be covered by bioinformatics include 
sequence alignment, prediction of gene expression, mapping and 
analysing DNA and protein sequencing and aligning DNA. All of 
these activities can be achieved by various bioinformatics tools 
(Luscombe et al., 2001). 
 
2.12.1 Blast like alignment tool (BLAT) 
BLAT is a sequence alignment tool introduced by Jim Kent in 2002 
to facilitate the assembly and annotation of the human genome. 
BLAT was ~500 times faster with performing mRNA/DNA alignment 
and ~50 times faster with protein/protein alignments than any other 
alignment tools. BLAT can be used for aligning multiple RNA 
sequences onto a DNA assembly to deduce their genomic matches, 
aligning of a protein or mRNA sequence from one species onto a 
sequence data base from another species and identification of gene 
family members of certain gene query. BLAT and BLAST have many 
things in common however they vary in some aspects. While BLAT 
scans the query sequence for matches, BLAST searches the data 
base for matches. BLAT is less sensitive than BLAST. BLAT involves 
query sequence in FASTA format, whereas BLAST requires the query 
in accession number and FASTA-formatted sequence. BLAT can be 
utilized as server-client programme or as stand-alone programme 
(Kent, 2002).  
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2.12.2 Scythe-a Bayesian adapter trimmer 
Scythe utilizes a Bayesian method categorising contaminant 
substrings in sequence reads. The software has the ability to 
remove the 3’ –end adapters which contain low quality bases. The 
process of a poor-quality trimmer is required before mapping, 
analysis and assemblies for the next generation sequencing run to 
pick out low quality bases.  The mechanism of scythe is based on 
two probabilities i.e. the likelihood of identifying the matches in a 
given contaminant or not given contaminant. Assuming that the 
read is contaminated, the likelihood of seeing the specific number of 
matches and mismatches is reliant on how good the quality of the 
sequence is. In the later model, the likelihood of seeing the specific 
number of matches and mismatches is an accidental. Scythe does 
not function on 5’-end contaminant or any other contaminants 
(Lindgreen, 2012).  
 
2.12.3 Sickle- a windowed adaptive trimming tool for FASTQ 
files using quality 
The majority of contemporary sequencing technologies generate 
reads that have relapsing quality towards the 3’-end and some 
towards the 5’-end which in turn can affect mapping, assembles, 
and data analysis. Sickle is a bioinformatics tool that utilizes sliding 
windows along with quality and length thresholds in order to define 
when quality is appropriately low to remove the 3’-end of reads and 
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also determine when the quality is adequately high to trim the 5’-
end of the reads. Sickle also rejects reads based upon the length 
threshold. Sickle slides a window across quality values whose length 
is 0.1 times the length of the reads. Sickle backs up three sorts of 
quality standards i.e. Illumina, Solexa and Sanger.  Sickle comprises 
two techniques to work with both paired-end reads and single-end 
reads sickle se and sickle pe (Joshi and Fass., 2011) 
. 
2.12.4 HISAT 
The first step in RNA-Seq downstream data analysis is to align the 
reads against a reference genome. The use of pre-existing and 
vastly utilised alignment programmes such as TopHat2 and GSNAP 
is time consuming. In order to overcome this deficit, HISAT, a 
spliced aligner tool, was produced with indexing approach based on 
the Burrows-Wheeler transform and the FM index. The programme 
algorithms occupy two various sorts of indexes: a global FM index 
that denotes the whole genome and several small FM indexes that 
collectively cover the entire genome. Each index exemplifies ~ 
64,000 bp and ~ 48,000 bp are required to cover the human 
genome. These small indexes (local indexes) are stored in small set 
of files and other optimisations are applied to reduce the memory 
requirements. This has allowed the human genome to be indexed in 
almost 4 GB of space. The advantage of using these small indexes 
in combination with numerous alignment approaches is in allowing 
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effective alignment of RNA-seq reads, especially, reads spanning 
multiple exons. HISAT is a fast, accurate and sensitive alignment 
programme for mapping RNA-seq reads (Kim et al., 2015).  
 
2.12.5 Sequence alignment map (SAM) tool 
The sequence alignment map is a TAB-delimited text format 
comprising a header section which is optional and an alignment 
section. The header line begins with’@’ whereas alignment lines do 
not. Each alignment line contains 11 compulsory fields for important 
alignment information like mapping location and changeable figure 
for optional fields. SAM is a universal format for saving sequence 
nucleotide alignments and easy to work with. SAM’s file size is 
compact and permits the file to be indexed by genomic location to 
professionally recover all reads aligning to a locus. SAM permits 
most of the processes on the alignment to function on a stream 
without loading the whole genome into a memory. SAM tools deliver 
different advantages for handling alignments in the SAM format 
comprising merging, sorting and generating alignments in pre-
located format (Li et al., 2009).  
 
2.12.6 String Tie assembler tool 
The approaches utilised to sequence the transcriptome such as RNA-
seq generate more than 200 million short sequences. Each of these 
short reads is 100-150 bp. Due to the fact that various transcripts 
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have highly variable sequence coverage and alternative transcripts 
from the same locus can share exons, this has made assembling the 
short reads a hard task. String Tie is a computational approach 
enforcing a network flow algorithm initially designed in optimisation 
theory along with optional de novo assembly to assemble a complex 
data into transcripts. In comparison with other superior transcript 
assembly packages such as Cufflings, Isolasso, scripture and Traph, 
String tie generates comprehensive and precise reconstructions of 
genes and better evaluates the expression level. The software is 
faster on all data sets than other assembly softwares (Pertea et al., 
2015).   
 
2.12.7 Ballgown 
Ballgown is a software package to assist the analysis of RNA-Seq 
data. It supplies assignments to organise, visualize and analyse the 
expression quantities for transcriptome assembly. There are a 
number of pre-processing stages required prior to the use of 
ballgown R package i.e. the RNA-Seq reads should be aligned to a 
reference genome, a transcriptome should be assembled and 
expression for the traits (transcript, intron and exon junctions) 
ought to be evaluated in ballgown readable format. There are two 
sample pipelines for pre-processing and they are pipeline one 
(tophat2 + stringtie) and pipeline two (tophat2 + cufflinks + table 
maker). Certain files should be produced by stringtie and 
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tablemaker for ballgown to load and some of these are e_data.ctab, 
i_data.ctab and t_data.ctab. Data is then loaded utilizing ballgown 
function. The soft contain six slots to access the assembly data: 
structure, expr, indexes, dirs, mergedDate, and meas. Ballgown 
delivers broad bundles of simple, fast statistical approaches such as 
limma and stattest for examining whether transcripts are 
differentially expressed between experimental conditions or across a 
continuous covariate (such as time) (Frazee et al., 2014). 
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2.13 Statistical analysis 
Deferential statistical analysis was performed by ball gown (Frazee 
et al., 2014) and the experiment replicate was in duplicate (N=2). 
The gene expression analysis was done with q PCR LightCycler 480 
software and Microsoft Office Excel 2010 applying Pfaffl method 
(Pfaffl., 2004). LGL viral load was calculated using LightCycler 480 
software the experiment replicate was done in duplicate (N=2) and 
two-way ANOVA used to analyse the data followed Sidak’s multiple 
comparisons test.  
 
 
  
Chapter 3 
AlHV-1 infection of epithelial 
and endothelial cell lines
Osama Kumati                                                                  Results 
114 
3.1 Abstract 
Malignant catarrhal fever is characterised by accumulation of 
lymphocytes in non-lymphoid tissues, vasculitis and epithelial 
damage. The pathogenesis of MCF is not well understood. It 
could be due to the cytotoxic activity of infiltrated T cells or 
direct infection and destruction of tissues (particularly 
epithelium or endothelium) or a mixture of both. It is also not 
clear whether infection of these cell types establishes latent or 
productive virus life cycle or both. To address this, rabbit 
epithelium and bovine endothelium cell lines were used to 
attempt infection and measure virus life cycle gene 
transcripts. Bovine turbinate fibroblasts were included as a 
positive control for productive virus infection. The cells were 
infected with low pass AlHV-1 (fully virulent virus) and high 
pass AlHV-1 C500 strain (attenuated with gene deletions and 
translocations, Handley et al., 1995, Wright et al., 2003). 
Polymerase chain reaction and q PCR were used to detect the 
viral DNA and measure the viral gene transcript profiles in the 
infected cells. It was found that the virus infected the 
epithelial and endothelial cells (as measured by viral DNA). 
There was, however, no CPE and very low level gene 
expression such that it can only be concluded that there was 
no or limited productive infection in the infected epithelium 
and endothelium in vitro compared to a productive transcript 
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profile seen in the control BT Cells, or alternatively, that the 
cells were latently-infected. Importantly though, when the 
virus extracted from the BAE and SIRC cells was used to infect 
BT cells, a productive infection (with CPE) was recorded. This 
indicated that virus from the BAE and SIRC cells was infective 
and intact (expressed genes).  
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3.2 Introduction 
Malignant catarrhal fever is characterized by infiltration of 
lymphocytes in non-lymphoid tissues, lymphoid hyperplasia 
vasculitis and epithelial and endothelial degeneration (Buxton et al., 
1984, Jacoby et al., 1988, Liggitt and DeMartini, 1980a, Liggitt and 
DeMartini, 1980b, Simon et al., 2003). The severity of the lesions in 
particular in the epithelium of the oral cavity, gastrointestinal tract, 
urinary bladder, liver, biliary ducts, and kidneys as well as damage 
to the endothelium of arteries and veins is associated with an 
increase in T lymphocyte (mainly CD8+ T cells) infiltration a 
proportion of which are infected with virus in these tissues (Dewals 
et al., 2008, Dewals et al., 2011, Palmeira et al., 2013). 
Furthermore, this damage becomes more pronounced towards the 
end of the disease course (Liggitt and DeMartini, 1980a, Liggitt and 
DeMartini, 1980b). In addition, the paucity of viral transcripts 
supporting productive virus cycle as well as for the latent cycle 
(where this is expected possibly) in the tissues of animals infected 
with AlHV-1 has been reported (Dewals et al., 2008, Dewals et al., 
2011) leading to the hypothesis that MCF is a disease of latency. 
However, there is evidence of productive virus cycle transcripts in 
infected cells and ex vivo LGLs as well as antibody responses to 
envelope and capsid proteins that would indicate productive virus 
infection. The mechanism of epithelium and endothelium damage is 
not proved. It could be due to the cytotoxic activity of the 
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accumulating infected T cells in the tissues or may be due to direct 
infection of these cells and destruction of them (cytopathic effect) or 
possibly a combination of both mechanisms. The aim of this study is 
to examine whether AlHV-1 (low culture passage, virulent C500 
AlHV-1 or high pass attenuated virus) can infect epithelial and 
endothelial cells and cause cell damage, and also to investigate 
whether the virus is able to establish a productive/lytic infection or 
latent one in the infected cells. BT cells were used as controls where 
productive virus infection occurs.  
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3.3 Materials and methods 
3.3.1 Virus  
Low culture pass (virulent) AlHV-1 C500 strain and high pass 
attenuated C500 AlHV-1 were obtained from inoculated bovine 
turbinate fibroblasts (BT cells) and titrated as described in M&M 
chapter 2 (section 2.2.5). Titres obtained were ~ 103 TCID50 per ml 
for low pass and ~106 TCID50 per ml for high pass virus. The cells 
were infected with the virus (see virus dose below) when they 
become 80% confluent (confluency is the percentage of the cells 
covering the vessel). This is carried out by discarding the old media, 
washing the cells with 1x PBS and then inoculating the virus directly 
onto the cell surface with serum free media until the surface is 
covered. 
    
3.3.2 Virus dose 
Statens seruminstitut rabbit cornea (SIRC) epithelial cells, BT 
fibroblasts and bovine aortic endothelium (BAE) cells were cultured 
as described in Chapter 2 (section 2.2). The cells were infected with 
high pass AlHV-1 virus C500 strain at a dose of 5x 104 TCID50 per 
50 µl inoculum for SIRC and BAE and 5x103 TCID50 per 5 µl for BT 
cells. For low pass virus 2x103 TCID50 per 2 ml inoculum was used 
to infect both SIRC and BAE cells and 1x103 TCID50 per 1 ml 
inoculum for BT cells.   
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3.4 In vitro infection 
3.4.1 Direct virus infection  
Bovine turbinate fibroblast (BT) cells, SIRC, and BAE were cultured 
in two types of media IMDM or DMEM as described in chapter two 
(2.2). The cells were infected as described (3.3.1) with either low 
pass or high pass AlHV-1 virus C500 strain with the doses described 
above and DNA was extracted from the cells on 2, 5, and 10 days 
after infection. This was to determine the presence or absence of 
the virus as viral DNA detected by PCR. BT cells at 50% CPE were 
harvested as a productive virus control (around day 5 post 
infection).  
In order to determine whether the BAE and SIRC cells infected as 
described above contained infective virus, the cells and supernatant 
were harvested 7 days after infection and cell sonicate (to release 
cell-associated virus) and the supernatant were then added to 
uninfected cultures of BAE, SIRC and BT cells, which were analysed 
at different time points afterwards for the presence of virus DNA. 
For the harvest of the indirect (or secondary) infected cells, medium 
was collected from centrifuged cells placed into falcon tubes on ice. 
The cell pellet was re-suspended in medium after being centrifuged 
at 300xg for 10 minutes. The supernatant was collected and added 
to the collected supernatant placed on ice. The cell pellets were re-
suspended in medium, freeze/thawed once in liquid nitrogen, 
sonicated in water bath sonicator and then spun down at 300xg for 
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10 minutes. This supernatant was added to the already collected 
medium and supernatant to make up viral product from the cells 
which was used to infect healthy SIRC and BAE cells at 80% 
confluence in 75cm3. The flasks were placed in a 37 Cᵒ 5% CO2 
incubator for seven days. During this time cells were monitored for 
CPE development under the microscope. Finally, (day 7), cells were 
harvested and DNA and RNA extracted for further analysis of viral 
DNA and viral gene transcripts (as shown in Table 7) by PCR and Q 
RT PCR (as described in chapter 2 sections 2.3.1 and 2.3.2). 
 
Table 7 Viral gene transcripts representing either productive or latent cycle or 
involved in the virus life cycle. 
 
AlHV-1 genes 
(ORF) 
Putative function/homology to productive or lytic cycle 
herpesvirus genes. 
ORF50 Encodes RTA the transcriptional and replication activator 
responsible for the switch to lytic cycle. 
ORF25 Major capsid protein expressed during lytic cycle. 
ORF63 Encodes structural protein during lytic cycle. 
ORF73 Encodes LANA protein involved in latent infection. 
A4.5 Similar to Bcl-2 family of apoptosis. Virus cycle expression 
not known. 
A9.5 Encodes a secreted glycoprotein that is similar to IL-4. 
Virus cycle expression not known. 
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3.5 Results 
3.5.1 Infection of the epithelial and endothelial cell lines  
Three cell lines, BAE bovine endothelium, SIRC rabbit epithelium, 
and control BT bovine fibroblasts were infected with low and high 
pass AlHV-1 C500 strains. Bovine turbinate (BT) fibroblast cells 
showed a cytopathic effect (CPE) when infected with either low or 
high pass AlHV-1 virus five to six days after inoculation, indicating 
that both virus preparations contained infective virus capable of 
replicating and generating a CPE as part of the productive/lytic virus 
life cycle (Figure 10). 
 
 
Figure 10 infection of bovine turbinate fibroblast (BT) cells 
A: healthy BT cells used as a control, image B: infected BT cells with low pass 
AlHV-1 C500 strain. The arrow indicates the absence of monolayer and the circle 
shows the accumulation of dying or dead cells and debris. The pictures represent 
scale bar of 500 µm. 
 
3.5.2 BAE endothelial cells  
Infection of BAE cells directly or after secondary transfer of infected 
cell sonicates and supernatants to uninfected BAE cells did not show 
any signs of CPE and the cells remained intact up to ten days post 
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infection (Figure 11). Conversely, BT cells infected with cell 
sonicates and supernatant from directly infected BAE cells displayed 
CPE around day 5 post infection (Figure 12). This indicates that BAE 
cells were successfully infected and generated virus able to induce 
CPE in BT reporter cells. 
 
  
Figure 11 Infection of bovine aortic endothelial (BAE) cells 
A: control uninfected BAE cells, B and C: BAE cells infected directly with low pass 
or high pass AlHV-1 C500 respectively (day 10 of culture), Serial infection, D and 
E: BAE infected with sonicate and supernatant material from directly-infected BAE 
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cells. No CPE seen in the cells up to ten days post infection but cells look 
unhealthy at this point. Picture A represents scale bar of 500 µm whereas pictures 
B, C, D and E represent scale bar of 200 µm. 
 
 
Figure 12 Infection of bovine turbinate BT cells with infected BAE 
Serial infection, A and B: BT infected with directly-infected BAE and secondary 
BAE infected with cell sonicate and supernatant materials from directly infected 
cells, showing CPE of the BT cells. Arrows indicate absence of monolayers 
whereas circles indicate accumulation of cell debris. Pictures represent scale bar 
of 200 µm.   
 
3.5.3 SIRC epithelial cells 
There was no evidence of CPE in SIRC cells infected either directly 
or in a serial/ secondary infection using cell sonicates and 
supernatant, up to 10 days after infection (Figure 13). However, BT 
cells infected with cell sonicates and supernatant from directly-
infected SIRC cells displayed CPE within a few days post inoculation 
(Figure 14), indicating that SIRC cells had supported infection and 
generated infective virus capable of inducing CPE in BT reporter 
cells. 
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Figure 13 Infection of SIRC epithelial cells 
A: SIRC uninfected control. B and C: SIRC cells infected directly with low or high 
culture pass AlHV-1 C500 strain respectively. D and E: Serial infection: SIRC cells 
infected with cell sonicates and supernatant derived from directly-infected SIRC 
cells. No CPE was seen in the cells up to ten days post infection but cells look 
unhealthy. Pictures represent scale bar of 200 µm.   
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Figure 14 Infection of bovine turbinate BT cells with infected SIRC 
A and B, BT cells show CPE after infection with cell sonicates and supernatant 
derived from directly-infected SIRC and with SIRC infected with cell sonicate and 
supernatant materials from directly infected cells. Arrows indicate absence of 
monolayers and circles show accumulation of dying/dead cell and debris. Pictures 
represent scale bar of 200 µm.  
 
3.5.4 Detection of viral DNA in the infected cells 
Viral DNA was detected in SIRC, BAE and BT cells infected with 
either low pass AlHV-1 or high pass AlHV-1 at different time points 
(Figure 15 and 16) after infection. Viral DNA was not identified in 
non- infected cells (Figure 17). 
 
Figure 15 qPCR products for low-pass AlHV-1 ORF3 gene visualised on agarose 
gel. 
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SC2; DNA extracted from SIRC cells 2 days post infection with AlHV-1 low pass 
virus, SC5; DNA extracted from SIRC cells 5 days post infection with AlHV-1 low 
pass virus, SC10; DNA extracted from SIRC cells 10 days post infection with 
AlHV-1 low pass virus, SSL; Serial infection: DNA extracted from SIRC cells 
infected with whole cell sonicate plus supernatant collected from directly-infected 
SIRC cells infected (AlHV-1 low pass virus), BT SSL; serial infection: DNA 
extracted from BT cells infected with whole cell sonicate plus supernatant 
collected from directly–infected SIRC cells (AlHV-1 low pass virus), BE2; DNA 
extracted from BAE cells 2 days after infection with AlHV-1 low pass virus, BE5; 
DNA extracted from BAE cells 5 days after infection with AlHV-1 low pass virus, 
BE 10; DNA extracted from BAE cells 10 days after infection with AlHV-1 low pass 
virus, BBL;  serial infection: DNA extracted from BAE cells infected with whole cell 
sonicate plus supernatant collected from directly–infected BAE cells (AlHV-1 low 
pass virus). BT BBL; DNA extracted from bovine turbinate cells infected with 
whole cell lysate collected from BAE cells infected with whole cell sonicate plus 
supernatant collected from directly–infected BAE cells (AlHV-1 low pass virus), 
0.1KB ladder; 100 base pair ladder, red arrows; indicates PCR product. 
 
 
Figure 16 qPCR products for high-pass AlHV-1 ORF3 gene visualised on agarose 
gel 
 
SC2; DNA extracted from SIRC cells 2 days post infection with AlHV-1 high pass 
virus, SC5; DNA extracted from SIRC cells 5 days post infection with AlHV-1 high 
pass virus, SC10; DNA extracted from SIRC cells 10 days post infection with 
AlHV-1 high pass virus, SSL; serial infection: DNA extracted from SIRC cells 
infected with whole cell sonicate plus supernatant collected from directly–infected 
SIRC cells (AlHV-1 high pass virus), BT SSL; serial infection: DNA extracted from 
BT cells infected with whole cell sonicate plus supernatant collected from directly–
infected SIRC cells (AlHV-1 high pass virus), BE2; DNA extracted from BAE cells 2 
days post infection with AlHV-1 high pass virus, BE5; DNA extracted from BAE 
cells 5 days post infection with AlHV-1 high pass virus, BE 10; DNA extracted 
from BAE cells 10 days post infection with AlHV-1 high pass virus, BBL;  serial 
infection: DNA extracted from BAE cells infected with whole cell sonicate and 
supernatant collected from directly-infected BAE cells (AlHV-1 high pass virus), BT 
BBL; serial infection: DNA extracted from BT cells infected with whole cell 
sonicate and supernatant collected from directly-infected BAE cells (AlHV-1 high 
pass virus), 0.1KB ladder; 100 base pair ladder, red arrows; indicate the PCR 
products. 
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Figure 17 qPCR products for low and high pass AlHV-1 ORF3 gene visualised on 
agarose gel. Infected BT cells and controls uninfected BT, SIRC and BAE cells 
 
BT LP; bovine turbinate cells infected with AlHV-1 low pass virus, BT HP; bovine 
turbinate cells infected with high pass virus, BT ctrl; non-infected bovine turbinate 
cells. BAE ctrl; non-infected bovine aortic endothelium cells, SIRC ctrl, non-
infected statens seruminstitut rabbit cornea cells; 0.1 KB ladder; 100 base pair 
ladder, red arrows; indicate PCR products corresponding to ORF3 DNA. 
 
3.5.5 Viral gene expression in the infected cells 
The transcripts of six AlHV-1 genes (A4.5, ORF50, ORF25, ORF73, 
ORF63, and A9.5) were measured using qPCR. In BT cells infected 
with low pass virus, ORF50 and ORF25 genes were highly expressed 
compared to the others that were present at very low level (Figure 
18A) indicating that these transcripts were associated with the 
productive/lytic cycle and as such they can be used as productive 
cycle positive control transcripts. The other transcripts were very 
poorly expressed (Figure 18A).  There was no detectable expression 
of the transcripts in BT cells infected with serial/secondary infection 
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from BAE endothelium and SIRC epithelium cell sonicates and 
supernatant after infection with low pass virus (Figure 18A). On the 
other hand, in BT cells infected with high pass AlHV-1, we detected 
ORF50 transcript and the A4.5 gene transcript in all BT cells 
infected, although levels were variable between different cultures 
(hence the large error bars) (Figure 18B). In BT cells infected with 
cell sonicates and supernatant from directly-infected SIRC or BAE 
cells, variable but low levels of A4.5 and ORF 50 were also detected. 
There was no virus gene expression in non-infected BT cells (Figure 
18 A and B). 
 
 
Figure 18 AlHV-1 transcripts in infected BT cells 
 
Viral transcripts of six AlHV-1 C500 strain genes (A4.5, ORF9.5, ORF25, ORF50, 
ORF63, and ORF73) in BT cells infected with low and high pass virus. BT INF; BT 
cells infected directly with low culture pass virus (A) and high pass virus (B), BT 
SSL (A) and BT SSH (B); BT cells infected with whole cell sonicate and 
supernatant derived from SIRC cells directly-infected with low and high pass virus 
respectively, BT BBL and BT BBH; BT cells infected with whole cell sonicate and 
supernatant derived from directly-infected BAE cells (low culture pass (A) and 
high pass virus (B)), BT Ctrl; non-infected BT cells. Q RT PCR was used to 
measure the viral transcripts by normalizing the target genes with bovine 
ribosomal protein S 9 (RPS9) reference gene (chapter 2, section 2.4.4). The error 
bars indicate SD of duplicate samples from infected BT cells.  
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The viral gene transcript profile of the six virus genes revealed that 
they were expressed at very low levels in both endothelium (Figure 
19) and epithelium (Figure 20) infected with either low culture 
passage AlHV-1 or high pass virus. There was no gene expression in 
endothelial and epithelial cells serially-infected with directly-infected 
endothelium and epithelium-derived virus. The use of different 
reference genes in the bovine cells (BT and BAE) make the gene 
expression comparison between the two cell lines difficult. This is 
because the expression rate varies between the two genes.   
  
Figure 19 AlHV-1 transcripts in infected endothelial cells 
 
Viral transcripts of six AlHV-1 C500 strain genes (ORF25, ORF50, ORf73, A4.5, 
ORF9.5, and ORF63) in bovine aortic endothelial (BAE) cells infected with low and 
high pass virus. BAE was infected directly on day 0 and transcripts were 
measured at different time point two, five, and ten days post infection for both 
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low and high pass virus. Error bar, represented by continuous black dashed line, 
represents the variation between samples. q PCR was used to measure the viral 
transcripts by normalizing the target genes with bovine G actin reference gene 
(chapter 2 section 2.4.4).   
 
Figure 20 AlHV-1 transcripts in infected epithelial cells 
 
Viral transcripts of six AlHV-1 C500 strain genes (ORF25, ORF50, ORf73, A4.5, 
ORF9.5, and ORF63) in statens seruminstitut rabbit cornea (SIRC) cells infected 
with low and high pass virus. SIRC was infected directly on day 0 and transcripts 
were measured at different time point two, five, and ten days post infection for 
both low and high pass virus. Error bar, represented by continuous black dashed 
line, represents the variation between samples. q PCR was used to measure the 
viral transcripts by normalizing the target genes with rabbit SDHA1 reference 
gene (chapter 2 section 2.4.4). 
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Table 8  Summary of results. 
 
Virus Cell type/ infection1 Viral DNA CPE Transcripts 
Low pass BT + + ORF50; ORF25 
AlHV-1 SIRC + - Low level ORF50, A9.5 
 BAE + - V low level ORF50 
 BT+SIRCv2 + + - 
 BT+BAEv2 + + - 
 SIRC+SIRCv2 + - - 
 BAE+BAEv2 + - - 
High pass BT + + Low level ORF50, A4.5 
AlHV-1 SIRC + - V low ORF50, A4.5, A9.5 
 BAE + - V low ORF50 
 BT+SIRCv2 + + V low ORF50, A4.5 
 BT+BAEv2 + + V low ORF50, A4.5 
 SIRC+SIRCv2 + - - 
 BAE+BAEv2 + - - 
1BT fibroblasts support productive virus infection; SIRC epithelial 
cells and BAE endothelial cells. 2Serial infection: uninfected cells 
were inoculated with cell sonicates and supernatant from directly-
infected SIRC (SIRCv) or BAE (BAEv) after ~10 days in culture. 
Transcripts analysed: ORF50; ORF25; ORF63; ORF73; A4.5 and 
A9.5. Inoculated cells analysed on days 2, 5 and 10 after 
inoculation. CPE occurred around day 5 In BT cells. Viral DNA scored 
positive and transcripts listed only if present at all-time points after 
inoculation. 
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3.6 Discussion 
In this series of experiments (summarised in table 8), rabbit 
epithelial corneal SIRC cells, bovine aortic endothelium (BAE) cells 
and bovine turbinate fibroblasts (BT) cells were infected with either 
low culture passage virus or high pass AlHV-1 C500 strain to 
determine whether the endothelial cells and /or the epithelial cells 
could be infected, and if so whether they could induce CPE in the 
cells or not. A selection of viral gene transcripts was analysed, 
representing either productive cycle (ORF50, ORF 25, ORF 63), 
latent cycle (ORF 73) or where their involvement in the virus life 
cycle was unknown (A4.5, A9.5).    
The results indicate that low pass and high pass virus were able to 
infect SIRC and BAE cells although there was no CPE. This might 
indicate establishment of the latent cycle, and this was supported by 
the results of the gene transcription profiles that were of low 
abundance in these cells in spite of good evidence of viral DNA, 
indicating the presence of virus (Table 8 summary). The virus was 
intact and infective as, when directly-infected SIRC and BAE cell 
sonicates and culture supernatant were used to infect BT cells that 
support the productive life cycle, the BT cells were infected and 
showed CPE, evidence of virus replication and the productive life 
cycle. However, there was little or no viral gene transcription, 
possibly indicating a low level of gene expression.  
.  
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To speculate, a consequence of the study could be that BAE and 
SIRC represent endothelium and epithelium in vivo but a lack of 
direct virus-induced CPE in vitro may reflect a similar lack of CPE in 
vivo and that the destruction of epithelium and endothelium is the 
result of infected T cell damage. The BAE and SIRC cells may be in a 
latent state (low gene expression and lack of CPE in spite of 
infective virus present in the cells). This requires further study.  
The lack of knowledge of latency transcripts in particular in MCF is 
hampered by difficult access to the natural reservoir species for 
AlHV-1 – the wildebeest. This is where the latent and lytic cycles will 
have evolved and not in the disease-susceptible species where the 
virus is less likely to persist. Recent work from the Stewart 
laboratory may be challenging this view though, where evidence of 
subclinical infections is seen in cattle (unpublished results).  
The high expression of ORF50 and ORF25 in BT cells infected with 
low pass virus indicates their involvement in productive cycle, which 
given what they code for is expected. Why ORF63 was not seen 
here is a mystery, but may reflect the low abundance of the viral 
transcripts and lack of sensitivity of the q PCR used. The low 
expression and absence of productive/lytic ORFs has also been 
reported in lymphoid and non-lymphoid tissues from animals 
infected with AlHV-1 C500 strain (Dewals et al., 2008, Palmeira et 
al., 2013).  
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In BT cells infected with high pass virus and epithelium and 
endothelium derived virus, there was an expression of ORF50 and 
ORF A4.5 but no expression of the other genes, indicating that A4.5 
is probably a productive virus life cycle gene. The absence of the 
expression of the other genes is probably due to the deletion, 
translocation, and rearrangement that the high pass virus 
undergoes where ORF50 and ORFA6 were truncated and 
translocated (distal part of ORF50b, proximal of A6 and distal part of 
A10) (Wright et al., 2003). ORF A4.5 may be involved in preventing 
cell death, hence supporting cell survival and the establishment of 
either productive and/or latent infection. This is because the gene 
encodes a protein similar to Epstein-Barr virus EBV BALF1 and 
cellular B-cell lymphoma genes of the BCl-2 family that controls 
apoptosis (Hart et al., 2007b, Russell et al., 2009). The respiratory 
system including turbinate cells are the primary site of infection in 
OvHV-2 MCF-affected animals (Cunha et al., 2008, Myster et al., 
2015) and this is likely to be the case with AlHV-1 MCF as well.  
Recent work has shown that AlHV-1 establishes latency in infected 
tissues and cells (Dewals et al., 2008, Dewals et al., 2011, Palmeira 
et al., 2013) and that MCF is therefore a disease of latency. The 
epithelial and endothelial cell lines infected with the virus did not 
show any CPE. It was possible though that the virus may support 
latent infection in these cells. However, the undetectable levels of 
ORF73, a latency-associated transcript make it difficult to be clear 
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on this point. It would be interesting to establish sensitive detection 
methods for the transcripts and co-culture cells with uninfected 
activated T cells to see if this forces a latency programme in the 
cultured epithelial and endothelial cells. These cells may play, in 
vivo, a role in enforcing the virus to establish latency in order to 
avoid detection by the immune system (Blake, 2010). In addition, 
the longevity of infection may be required for the virus to support 
latency. 
To conclude, Endothelial and epithelial cells were infected with AlHV-
1 but there was no evidence of productive infection and although 
there was some indication that there may be a latent state (lack of 
CPE). The low level of gene transcripts makes a definitive conclusion 
currently difficult.  
  
Chapter 4 
The effect of 5-azacitidine on 
AlHV-1 viral gene expression 
in large granular lymphocytes 
(LGLs) and infected bovine 
turbinate (BT) cells
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4.1 Abstract 
Malignant catarrhal fever is fatal lymphoproliferative disease of 
even-toed ungulates. Although the tissue damage leading to 
animals’ death is linked to lymphocytes accumulating within these 
tissues, the pathogenesis is still unknown. Culture of infected 
tissues cells can be achieved ex vivo to develop large granular 
lymphocytes (LGL) that represent the infected cells in vivo. These 
cells enrich for MCF virus-infected cells and are useful to study 
virus-host interactions. In this series of experiments, AlHV-1 virus 
genes, known for their involvement in productive/lytic and latent life 
cycles, were examined in LGLs in the presence and absence of 5-
azacitidne, a drug used to drive latency programming from a 
productive cycle one (Thonur et al, 2006). In addition, bovine 
turbinate fibroblast (BT) cells were studied as they support the 
productive virus life cycle and virus genes expressed in these 
represent important ones in the productive virus life cycle. Flow 
cytometry was used to phenotype the LGL, which were 
predominantly CD8+ T cells. The results showed that LGL show gene 
expression representative of a mixture of productive/lytic and latent 
life cycle and the effect of 5-azacitidine on gene expression was 
irregular and inconsistent with respect to identifying key latency 
genes. Interestingly, 5-azacitidine had an impact on LGL phenotype 
where it increased the percentage of pan T cells in the treated LGLs 
group. There was also a slight increase in CD8+ cells in 5-aza 
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treated group in comparison to non-treated group. In the BT cells 
infected with the virus, productive/lytic associated genes ORF50, 
ORF25, and ORF A4.5 were highly expressed. The expression of 
these genes was reduced when BT cells were treated with 5-
azacitidine but there was no elevation in ORF73 latency-associated 
transcript. Importantly, there was no CPE in the infected and 
treated cells.  
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4.2 Introduction 
The mechanism by which the MCF related viruses (AlHV-1 and 
OvHV-2) induce disease is not yet well known (Li et al., 2014, 
Russell et al., 2009). Nonetheless, the pathogenesis of MCF is 
attributed in vivo to T cells accumulating in the tissues, many of 
which are infected with MCF virus (Dewals et al., 2011, Palmeira et 
al., 2013). Infected cells (LGL) can be developed in culture and are 
useful to study host-pathogen interactions (Reid et al., 1989, Reid 
et al., 1983). LGL are found to be capable of transmitting MCF when 
inoculated into naive rabbits (Reid et al., 1989). The viral genes 
profile, especially those responsible for productive/lytic and latent 
infection, from LGL derived from tissues of both reservoir and 
susceptible species, has been studied and found to be variable 
(Rosbottom et al., 2002). The ability to manipulate the 
productive/latent virus cycle, using drugs such as doxorubicin, 
which was found to stimulate productive virus cycle in lymphocytes 
infected with Epstein Barr virus (EBV) and 5-azacitidine, which had 
been found to drive latency in gamma herpes viruses (Szyf et al., 
1985, Feng et al., 2004) has motivated researchers to study virus 
life cycle in OvHV-2 MCF-affected animals (Thonur et al., 2006). 
Here we study the effect of 5-azacitidine to drive the AlHV-1 latent 
virus cycle in rabbits LGL and in BT cells. 
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4.3 Materials and methods 
4.3.1 Samples collection 
Popliteal lymph nodes were obtained from rabbits infected with 
AlHV-1 C500 strain virus (see general materials and methods 
(2.6.4)). Samples were collected from rabbits IYDY, IYJJ, LFLK and 
LFKJ which were euthanized on day 17 of the experiment. The 
lymph node samples were placed in 1XPBS and processed 
immediately (see materials and methods section 2.2.1). 
 
4.3.2 Tissue culture and infection 
Large granular lymphocytes (LGL) were cultured and BT cells were 
cultured and infected as described in materials and methods chapter 
2 sections (2.2.1 and 2.2). Quantitative PCR and PCR were 
performed as described in materials and methods, sections (2.4.4 
and 2.4.2) to detect the virus and measure the viral DNA load.  
 
4.3.3 Drug treatments 
LGL derived from AlHV-1-infected rabbits were cultured as described 
in materials and methods chapter, section (2.2.1) and treated with 
25µM 5-azacitidine (CALBICHEM, cat# 189825, Germany) over a 
period of three weeks with culture medium removal and drug 
replacement. This dose of drug was determined to be the highest 
concentration that did not affect the viability and growth of the LGLs 
or BT cells. Cultured LGL were exposed to the above mentioned 
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concentration for three days after which the drug was diluted by 
changing two thirds of the medium with fresh IL-2 IMDM medium 
every three days and adding fresh 5-azacitidine. Infected BT cells 
were treated with 5-azacitidine exactly in the same manner as the 
LGLs with the exception that the medium was completely discarded 
and replaced with fresh containing 5-azacitidine.   
 
4.3.4 Flow cytometry 
The protocol is as described in the materials and methods 
(chapter2, section 2.5.3). 
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4.4 Results 
4.4.1 Viral DNA detection 
Quantitative PCR was used to detect AlHV-1 DNA in LGL and BT 
cells. AlHV-1 ORF3 gene was utilised to perform the procedure. This 
is due to the fact that AlHV-1 ORF3 is validated for AlHV-1 DNA 
detection and quantitation (Traul et al., 2005). The results showed 
that AlHV-1 DNA was identified in all samples (Figures 21, 22 and 
23) demonstrating that LGL were infected with the virus. The virus 
DNA was not identified in non-infected BT cells (Figure 23). 
 
 
Figure 21 Q PCR and PCR products for AlHV-1 ORF3 gene 
The figure shows qPCR and PCR products of AlHV-1 ORF3 in the rabbit LGL (110 
bp) visualised on agarose gel. PCR product was estimated by comparison with the 
standard DNA (0.1 kb) ladder. AlHV-1 ORF3 was detected in LGL samples treated 
with 5-azacitidine drug. IYDY, IYJJ, LFKJ, and LFLK; different rabbit IDs from 
different cell lines, 0.1 KB ladder, 100 bp ladder, red arrows; indicate to the PCR 
product of the corresponding cell line.  
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Figure 22 Q PCR and PCR products for AlHV-1 ORF3 gene 
The figure shows qPCR and PCR products of AlHV-1 ORF3 in the rabbit LGL (110 
bp) visualised on agarose gel. The size of the gene was estimated by comparison 
with the standard DNA (0.1 kb) ladder. AlHV-1 ORF3 was detected in non-treated 
LGL samples. IYDY, IYJJ, LFKJ, and LFLK; different rabbit IDs from different cell 
lines, 0.1 KB ladder, 100 bp ladder, red arrows; indicate to the PCR product of the 
corresponding cell line.  
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Figure 23  Q PCR and PCR products of AlHV-1 ORF A3 gene 
The figure shows q PCR and PCR products of AlHV-1 ORF3 (110 bp) visualised on 
agarose gel. The size of the gene was estimated by comparison with the standard 
DNA (0.1 kb) ladder. AlHV-1 ORF3 was detected in BT cells samples (infected only 
and infected and treated with 5-azacitidine) whereas the viral DNA was not 
detected in uninfected BT control. BT IF; bovine turbinate cells infected with AlHV-
1 virus, BT 5-aza; bovine turbinate cells infected with AlHV-1 virus and treated 
with 5-azacitidine drug, BT ctrl; bovine turbinate cells not infected with the virus 
and not treated with 5-azacitidine; 0.1 KB ladder; 100 base pair ladder; red 
arrows; indicate to the PCR products of the corresponding cells.  
 
  
4.4.2 Viral DNA load in LGLs 
To evaluate AlHV-1 copy number in LGL (treated and non-treated 
samples), q PCR assay was performed on LGL samples. The viral 
DNA copy number was estimated by normalising AlHV-1 ORF3 gene 
with 105 rabbit β globin reference gene as described in Dewals et al. 
(2008). The data obtained showed that the viral load is nearly 
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similar in both groups (Figure 24) with values between 1-1.6x 105 
AlHV-1 copy numbers per 105 rabbit β globin. 
  
Figure 24 AlHV-1 DNA copy number in rabbits' large granular lymphocytes. 
The figure illustrates the viral load (as copy numbers per 105 beta globin DNA 
copies) in large granular lymphocytes (LGL) from rabbits infected with AlHV-1 
C500 strain. Four lines (IYJJ, IYDY, LFKJ, and LFLK) were treated with 5-
azacitidine drug or kept without treatment as a control. The viral load was 
estimated by normalizing the viral DNA copy number per 105 rabbit β globin 
reference gene using qPCR. The primers and probe (FAMAlHV-1) for AlHV-1 ORF3 
were used inside the standard sequence and then analysed using Roche Light 
Cycler 480 system. Two-way ANOVA was performed to do the statistical analysis 
using Sidak’s multiple comparisons test. The primers and probe (FAM) for rabbit β 
globin reference gene was utilized within the standard sequence.    
 
 
4.4.3 The effect of 5-azacitidine on BT cells 
There was an obvious cytopathic effect (CPE) in BT cells infected 
with the virus. However, the development of CPE was not seen in BT 
cells infected and treated with 5-azacitidine. Figure 25 shows the 
difference between infected BT cells in the presence and absence of 
5-azacitidine. 
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Figure 25  BT cells infected with AlHV-1 C500 strain and infected and treated with 
5-azacitidine 
 
The figure depicts BT cells infected with AlHV-1 and treatment of 
one of the samples with 5-azacitidine. Image (A) shows BT cells 
infected with the virus and treated with the drug the following day 
and the drug was changed every three days up to day 17 post 
infection. No CPE was seen after treatment. Image (B) BT infected 
with the virus without treatment and there was CPE detected from 
around day 5 post infection. The red arrows indicate the absence of 
monolayer and the yellow arrow show the accumulation of cell 
debris.     
 
4.4.4 Measuring viral gene transcripts  
In order to examine the viral gene profiles in LGL and BT cells, cDNA 
was synthesised from RNA for q PCR as described in chapter two, 
section (2.4.1). The results showed that all viral gene transcripts 
examined were expressed at very low level in two of the LGL lines 
(LFLK and LFKJ) and were not detected in the other two lines (IYDY 
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and IYJJ) (Figure 26). AlHV-1 ORF73 was expressed at a higher 
level in the 5-azacitidine treated group than non-treated in LFLK cell 
line. However, ORF50 expression is also identified. The expression 
of ORF 25, ORF63 and ORF A4.5 varied in each cell line in both 
groups.  
In infected BT cells there was high expression of ORF50, ORF25, 
and ORF A4.5 in comparison with the other genes (Figure 27). In BT 
cells infected and treated with 5-azacitidine there was an obvious 
reduction in the genes supporting productive/lytic infection namely 
ORF50 and ORF25, but no increase in ORF73 transcripts (Figure 27) 
even though the cells did not show any CPE illustrating that the 
drug has had an effect on the expression of these genes. No virus 
gene expression was seen in non-infected and non-treated control 
BT cells (Figure 27).               
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Figure 26 viral gene transcripts of AlHV-1 C500 in rabbit LGLs 
The figure shows the viral gene profiles of AlHV-1 C500 strain genes (ORF25, 
ORF50, ORF73, ORF63, ORF A4.5, and ORF A9.5) in rabbit LGLs treated with 5-
azacitidine or not-treated. Rabbit mesenteric lymph node cells from a non-
infected rabbit were used as a negative control. Q PCR was used to measure the 
gene expression by normalizing the target genes with rabbit SDHA1 reference 
gene (chapter 2 section 2.4.4).   
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Figure 27  viral gene transcripts of AlHV-1 C500 strain in BT cells 
The figure shows the viral gene transcripts of five AlHV-1 C500 genes (ORF A4.5, 
ORF25, ORF50, ORF63, and ORF73) in BT cells. QPCR was used to measure the 
gene expression by normalizing the target genes with bovine ribosomal protein S9 
(RPS9) used as a reference gene (chapter 2, section 2.4.4). BT INF; infected BT 
without treatment, BT 5-aza; infected BT and treated with 5-azacitidine, BT Ctrl; 
non-infected and non-treated BT cells.  
 
 
4.4.5 Flow cytometry analysis of LGL  
Monoclonal antibodies directed against CD4, CD8, CD11b, B cell, 
and Pan T cells were used for flow cytometry analysis of the rabbit 
LGLs (material and methods (2.5.3)). The results revealed that the 
predominant cell type in the LGLs was CD8+ whereas CD4+ T cells 
were not detected. Figure 28 depicts the percentage of mononuclear 
cells in LGLs in the absence or presence of 5-azacitidine. In addition, 
the results showed that the percentage of Pan T cells is low in non-
treated LGL but the percentage was high in 5-azacitidine treated 
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cells. The cell lines in both groups were devoid of both CD11b cells 
(expressed on leukocytes, particularly most monocyte/macrophage 
series cells) and CD19+ B cells. There was a bias towards CD8+ in 
the double staining samples used for all cell lines (Figure 29). Figure 
29 shows the typical results in one cell line (IYDY) in both treated 
and non-treated groups.   
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Figure 28  flow cytometry analysis of mononuclear cells in LGL non-treated and 
treated with 5-azacitidine 
The figure illustrates the percentage of cell types within LGL upon analysis by flow 
cytometry. CD8 represents the majority of expressed T cell subset in both 5-
azacitidine treated group and non-treated group whereas Pan T cell was high in 5-
azacitidine treated group and low in non-treated group. CD4, CD11b and B cell 
were not detected in both groups. 
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Figure 29  flow cytometry analysis of LGL double stained with two fluorescence 
antibodies in 5-azacitidine treated and non-treated IYDY cell lines 
The figure shows the flow cytometry dot blot double staining of IYDY LGL lines 
with secondary antibody APC for CD8 and primary antibody conjugated with FITC 
CD4. High percentage of labelled cells lie in the quadrants 1-2 and 1 representing 
APC fluorescence for CD8 whereas no cells labelled with FITC for CD4 in 
quadrants 4-2 and 4 in both treated and non-treated IYDY cell lines. The figure 
also shows high percentage of CD8 when parameter of count used versus 
fluorescence in both groups. For the calculation of cell percentage, CD4 isotype 
control was used as a negative control for CD4 samples. Therefore, the figures of 
CD4 isotype control were subtracted from the values of CD4 for each sample. Due 
to the fact that the secondary antibodies have a role in the detection and do not 
bind directly to the cells; the figures for secondary APC and secondary FITC can 
be subtracted from the figures of each cell type to give percentage of cell count. 
For example, secondary FITC must be subtracted from CD11b, Pan T, B cell and 
FITC only. Secondary APC must be subtracted from CD8, double stained and APC 
only. 
4.5 Discussion 
In this study, Rabbit LGLs were shown to be infected as determined 
by viral DNA presence, but expressed only a low abundance of 
transcripts. In a few, a mixture of known productive cycle (ORF50, 
ORF25, ORF63) and latent cycle (ORF73) transcripts were detected, 
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but not in all the LGLs. ORF50 is the R transactivator (RTA) which 
plays a role in driving the productive viral programme from latency 
(Frame and Dalziel, 2008, Goodwin et al., 2001); ORF 25 encodes a 
major capsid protein that is expressed during lytic cycle indicating 
viral replication (Dewals et al., 2008); ORF 73 encoding the latency 
associated nuclear antigen (LANA) is important for driving latent 
infection (Dewals et al., 2011, Hu et al., 2002, Palmeira et al., 
2013). ORF63 encodes a tegument protein which is involved in 
preventing apoptosis (Boyle and Monie, 2012). This indicates that 
ORF63 may serve a function within the lytic life cycle. ORF A4.5 (a 
bcl-2 anti-apoptosis orthologue) (Mills et al., 2003) and A9.5 
(secreted cytokine orthologue) (Lankester et al., 2015a, Russell et 
al., 2013) were included in the study to see if they could be 
identified as either productive cycle or latent cycle expressed. 
ORF73, ORF50, ORF63 and ORF25 were expressed in two LGL lines, 
indicating possibly predominance of productive cycle, but with no 
indication of a latent cycle within some of the cells which remains a 
possibility. This is in consistent with the observation made by 
Thonur et al., (2006) in cattle and rabbits using LGL infected with 
OvHV-2. There was also expression of ORF A4.5 in two of the rabbit 
lines (LFLK and LFKJ). Thonur et al. (2006) found similar results 
with Ov4.5 in LGL cell lines infected with OvHV-2 virus. ORF A9.5 
was expressed in one of the lines (LFLK). However, the role of this 
gene in latent and productive/lytic life cycle remains unclear. 
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Upon treatment with 5-azacitidine, there was an increase in ORF73 
expression in one cell line (LFLK) in comparison to the non-treated 
control. This is consistent with 5-azacitidine driving latency and was 
also seen in LGL infected with OvHV-2 virus and treated with 5-
azacitidine (Thonur et al., 2006). It is worth mentioning that ORF73 
can be ‘leaky’ with respect to expression in the different virus life 
cycles such that absence of ORF73 in productive infection is not 
necessarily absent (Thonur et al., 2006). The expression also of 
ORF50 indicates that the cells support both latent and lytic infection. 
The expression of the other genes: ORF25, ORF63 and ORF A9.5 
were different in each cell line in 5-aza treated and non-treated 
groups. This may indicate that LGL support both productive/lytic 
and latent virus cycle. In addition, the viral gene expression may be 
irregular in these cells. ORF A4.5 was expressed to a much lower 
level in 5-aza treated LGLs than the untreated control cells, 
indicating a role in the productive virus life cycle. ORF A9.5 was not 
investigated because of the time limit and lab authorisation required 
to repeat the experiment.  
5-azacitidine is a DNA hypo-methylating agent that functions by 
inhibiting DNA methyltransferase. It has also been found that 5-
azacitidine has different effects on different virus gene expression 
patterns (Chang et al., 2014, Qiu et al., 2010). In herpes-virus 
saimiri, 5-azacitidine encourages productive cycle from latency 
(Mossman et al., 1989) while it appears that it changes the form of 
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EBV expression from type I latency to type III latency in lymphoma 
cell lines (Schaefer et al., 1997). It seems therefore that the effect 
of 5-azacitidine on gene expression is possibly virus and cell-type 
specific (Thonur et al., 2006). Thonur et al. (2006) also discovered 
differences in viral gene expression between cattle and rabbit LGLs 
samples. As defined by Gardella analysis (Gardella et al., 1984), 
bovine LGLs infected with OvHV-2 supports predominately latent 
infection (circular DNA) and only a weak band (smear) of linear 
DNA. OvHV-2 -infected rabbit LGLs showed productive infection 
(linear DNA) and only a small amount of circular DNA. 
Unfortunately, time ran out before Gardella gels could be performed 
on the samples in this study. However, the match between Gardella 
analysis and productive and latent gene expression was high 
(Thonur et al., 2006). 
The high level of expression of ORF50, A4.5 and ORF25 in infected 
BT cells confirms the support of the virus productive/lytic cycle in 
these cells, which undergo a CPE and release infectious virions into 
the culture medium. However, when treated with 5-azacitidine, 
there was a lack of CPE and a sharp decline in the expression of 
these genes (ORF50, A4.5 and ORF25) consistent with a latency 
programme. This confirms the latency-inducing activity of 5-aza in 
this study with AlHV-1. ORF73 expression however was not 
increased, but this in itself may not be diagnostic of the latent state 
(i.e. an increase in expression rather than just expression). 
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MCF viruses (OvHV-2 and AlHV-1), initially, replicate in the 
respiratory system, in particular in the nasal turbinate (Li et al., 
2008, Myster et al., 2015) where ORF25 is identified. Afterwards, 
the virus disseminates to the blood where, in the case of one set of 
studies with AlHV-1 infection, it establishes latency in lymphocytes 
(mainly CD8+ T cells) and ORF73 expression is detected (Dewals et 
al., 2008, Palmeira et al., 2013). ORF A4.5 may be involved in 
preventing cell death, hence supporting cell survival and the 
establishment of productive infection. This is because the gene 
encodes a protein similar to Epstein-Barr virus EBV BALF1 and 
cellular B-cell lymphoma genes of the BCl-2 family that controls 
apoptosis (Hart et al., 2007, Mills et al., 2003).  
Flow cytometry analysis of the rabbit LGLs showed that the 
predominant cell type was CD8+ in both 5-azacitidine-treated and 
non-treated cells. The results are in line with the observations made 
in other studies that also found that the main cell type in LGL and 
infected tissues in vivo was CD8+ cells (Dewals et al., 2008, Dewals 
et al., 2011). The results showed that the LGL were devoid of CD4+ 
cells. Dewals et al. (2008) discovered that the rise in CD8+ cells is 
correlated with a reduction in CD4+ cells. The observation that T 
cells proliferating in MCF affected tissues outnumbered CD4+ cells 
was also highlighted by other researchers (Anderson et al., 2007). 
LGL are indiscriminately cytotoxic and have the morphology of 
T/natural killer (NK) cells (Swa et al., 2001).  
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However, in this study there was a surprising result. Very few LGL 
cells reacting with the Pan-T marker were detected in the LGLs not 
treated with 5-aza, whereas in the treated cells, the pan T marker 
was present on the majority of the cells. The actual antigenic target 
of the Pan-T antibody used is not known (Parameswaran et al., 
2014). However, a recent study showed that MCF virus infection is 
associated with an effect on T cell phenotype of infected cells. The 
A2 gene (transcription regulator) had an effect on the regulation of 
LGL T cell phenotype where there was downregulation of үδ TCR 
receptors and upregulation of αβ TCR receptors in the absence of A2 
gene (Parameswaran et al., 2014). This may explain the reduction 
in pan T cells in the non-treated group if A2 is involved in latency 
versus productive cycle gene expression affecting this phenotype. 
The effect of 5-azacitidine on human T cells in particular CD4 and 
CD8 has been reported. It was established that 5-azacitidine 
treatment of Human T cells reduced CD8+ T cells while CD4+ T cells 
increased (Stübig et al., 2014). 
In conclusion, 5-azacitidine affected the latency programme as 
evidenced in BT cells, where it prevented CPE and inhibited 
markedly productive virus gene transcription. In LGLs the effect of 
5-aza was less clear due to the low level of viral transcripts although 
in some lines there appeared to be a small effect. The drug clearly 
affected the LGLs as there was a marked increase in the pan T cell 
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marker on T cells compared to infected untreated controls. At this 
stage it is not clear what this means.  
  
Chapter 5 
Cellular and viral gene 
expression analysis (RNA-
Seq) in rabbit LGLs and BT 
cells infected with AlHV-1 and 
treated with 5-azacitidine
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5.1 Abstract 
The goal of this study was to determine the molecular-biochemical 
pathways affected by treatment of AlHV-1 infected rabbit large 
granular lymphocytes (LGLs) and bovine turbinate (BT) cells 
infected with the virus, with 5-azacitidine (5-aza). The hypothesis is 
that 5-aza will suppress productive virus infection and aid 
identification of virus latency transcripts and the host transcriptome 
in latently-infected cells. In order to achieve this objective, RNA-Seq 
was performed on the cell RNA (as copy DNA) samples. The results 
showed differences in gene expression patterns between treated 
and untreated cells, both LGLs and BT cells. Pathways identified 
using David® and Ingenuity Pathway analysis software showed that 
cell death (apoptosis), T cell chemo-attraction, proliferation and 
immune response pathways affected in 5-aza-treated LGLs 
compared to non-treated ones. In addition, the analysis indicated 
that mRNA translation, gene expression, cell cycle, DNA replication 
and post transcriptional modification pathways were affected in 5-
aza treated BT cells in comparison to non-treated BT cells. In 
conclusion the pathway analysis showed that there were variations 
between rabbit LGLs and cattle BT cells. While LGLs have pathways 
that aid T cell proliferation and accumulation and immune 
responsiveness in 5-aza-treated groups compared to untreated 
ones, BT cells contain pathways that support gene expression and 
mRNA translation in treated groups compared to untreated. In 
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addition, it is unclear whether rabbit LGLs support productive or 
latent virus cycle. RNA-Seq was not sensitive enough to pick up any 
other than a few viral transcripts.    
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5.2 Introduction 
In the previous chapter, the issue of 5-azacytidine effect on the viral 
productive and latency programmes was studied. In this chapter, 
the global transcriptome of LGLs and BT cells was compared in 
treated versus untreated cells using RNAseq. Although Gamma 
herpes virus latency, generally, is not connected with disease 
development, latency in lymphocytes can produce malignant 
lymphocyte activation and proliferation dependent upon the viral 
species and the infected host (Barton et al., 2011, Ensser and 
Fleckenstein, 2005). Latency is regulated by the control of a viral 
gene expression programme in the infected cells enabling the virus 
to avoid the detection by the host immune system and persist in the 
infected cells. One of the approaches the virus adopts to induce 
latency is the control of the expression of transcriptomes including 
mRNA and non-coding RNAs such as micro-RNAs (miRNA) (Bartel, 
2009, Kincaid and Sullivan, 2012, Pfeffer et al., 2004). The advent 
of sequence-based approaches such as deep sequencing, in 
particular RNA-Seq have opened opportunities to researchers to look 
at post transcriptional modification, mutations and gene expression 
alterations (Kumar et al., 2012, Wang et al., 2009, Wilhelm and 
Landry, 2009). Here, RNA-Seq technique is used to map host (and 
viral) gene transcripts in LGLs derived from rabbits infected with 
AlHV-1 virus and bovine turbinate (BT) cells infected with AlHV-1 
virus to look for host pathways associated with latency and the lytic 
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cycle. LGLs represent the T cells naturally-infected in vivo and in the 
previous chapter, as with a previous study with OvHv-2 (Thonur et 
al., 2006) infected rabbit cells showed that the cells supported a 
mixture of latency and productive cycle genes, although in this 
study gene expression was low and the results not particularly clear 
cut. 5-aza could suppress the productive virus life cycle and reveal 
latency transcripts. Cattle BT cells support productive virus infection 
and they are a control for viral productive cycle transcripts. It was 
of interest to compare the host responses in 5-aza-treated and 
untreated cells for both species.          
               
  
Osama Kumati                                                                  Results 
162 
5.3 Materials and methods 
 
5.3.1 Tissue and infection 
Large granular lymphocytes (LGL) were obtained and cultured and 
BT cells were cultured and infected as described in materials and 
methods chapter 2 sections (2.2.1). Quantitative PCR was 
performed as described in materials and methods, sections (2.4.4) 
to measure the viral DNA load.  
   
5.3.2 RNA extraction 
Total (viral and cellular) RNA was extracted using RNeasy Plus 
Universal Mini Kit (cat # 73404, Qiagen) according to the 
manufacturer’s instructions as described in materials and methods 
chapter, section (2.3.2).  
 
5.3.3 RNA quality measurement using utilizing Agilent Bio-
analyser Nano 6000 kit 
The RNA quality measurement was as described in the materials 
and methods, section (2.9).  
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5.3.4 Complimentary (cDNA) DNA Library preparation and 
sequencing 
This was done by Deepseq (University of Nottingham). Total RNA 
was measured using Qubit RNA BR assay kit (Life technologies, 
Q10210). 1µg of Total RNA was used for enrichment of mRNA using 
NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB, E7490). 
Illumina stranded whole transcriptome sequencing libraries were 
prepared using NEBNext Ultra Directional RNA library prep kit for 
Illumina (NEB, E7420S). Library QC was performed using the 
bioanalyser HS kit (Agilent biotechnologies, 5067-4626). Libraries 
were quantified using qPCR (Kapa Biosystems, KK4824). Libraries 
were pooled at desired concentrations, denatured and loaded for 
sequencing according to the manufacturer’s instructions. 
Sequencing was performed on the Illumina NextSeq500 sequencing 
platform to generate 2 x 75bp reads. 
 
5.3.5 Sequence analysis, bioinformatics and statistics  
This was done by Deepseq (University of Nottingham) with 
bioinformatics by ADAC (UoN). Ingenuity pathway analysis (IPA, 
www.ingenuity.com/products/pathway) was performed to look at 
relationships between the differentially-expressed gene lists (5-aza 
treated versus untreated for both cell types). The data from both 
species (cattle and rabbits) were interpreted utilizing the core 
analysis function included in IPA system in the context of biological 
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processes, pathways and networks. The up and down regulators 
were described as value parameters for the analysis. The 
significance of predicted bio-functions and canonical pathways was 
examined by the Fisher Exact test p-value (McKinney et al., 1989). 
Bio-functions were categorised in diseases and disorders, molecular 
and cellular functions. In a similar manner, canonical pathways were 
clustered in metabolic and signalling pathways. The bovine and 
rabbit (Cattle=Bos-taurus UMD3.1, rabbit=Orycorolagus-cuniculus 
2.0 from ensemble genome version 82) as contained in BT cells and 
rabbit LGLs respectively were used to map transcript sequences. 
The viral genome annotation file was modified to include A9.5_ORF. 
BLAT (Kent, 2002) was used to identify the overlapping sequence 
regions. The viral genome sequence and their cosponsoring 
annotations were merged with the cow and rabbit files so that the 
viral genome sequence appeared to represent an additional contig 
within the host genome.  
The reads were trimmed with scythe (Lindgreen, 2012) to remove 
residual adaptor contamination and with sickle (Joshi and Fass., 
2011) to remove low quality bases. The trimmed Reads were 
aligned to the modified reference genomes using HISAT v2 (Kim et 
al., 2015). Technical replicates from different lanes were merged 
with SAM tools (Li et al., 2009). The merged alignments were 
assembled using string tie (Pertea et al., 2015) and differential 
expression analysis was performed using Ballgown (Frazee et al., 
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2014). Scripts used in this analysis pipeline can be found in 
appendices in the soft copy version section (8.10).  
5.4 Results  
5.4.1 Viral DNA load in LGLs  
To evaluate AlHV-1 copy number in LGL (5-azacitidine-treated and 
non-treated samples), q PCR assay was performed on LGL samples. 
The viral DNA copy number was estimated by normalising AlHV-1 
ORF3 gene with 105 rabbit β globin reference gene copies as 
described in Dewals et al. (2008). The data obtained showed that 
the viral load is similar in both groups (Figure 30). This is the same 
as the figure shown in Chapter 2, as the same cells were used and 
analysed just prior to sending samples off for RNA-seq and doing 
the viral transcript studies in chapter 2. This is repeated here to 
provide context for this chapter. 
 
5.4.2 RNA Integrity Number (RIN) measurement 
The RNA integrity number is measured by a set of bio-analytical 
devices, which is a combination of microfluidic chips, voltage-
induced size separation in gel filtered channels and laser-induced 
fluorescence detection and analysis of data using Agilent software 
tool (Schroeder et al., 2006). The RIN number ranges from 1 to 10. 
A RIN number of 1 show completely degraded RNA whereas a RIN 
number of 10 indicate totally intact RNA samples. Upon RNA 
extraction, the RNA integrity was estimated and samples with RIN 
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numbers 7 and more were used for further analysis. Figure 31 
shows the RIN number in the some of the RNA samples sent for 
RNA-Seq analysis. Table 9 shows sample number, sample name, 
RNA concentrations and RNA integrity numbers (RIN) for samples 
sent for RNA-Seq analysis. 
 
 
Table 9 sample number, sample name, RNA concentrations and RNA integrity 
numbers (RIN) for LGL and BT samples sent for RNA-Seq analysis. 
 
Sample 
number 
Sample name  Sample type Concentration 
ng/µl 
RIN # 
1 LGLLK5aza Total RNA 297 10 
3 LGLKJ5aza Total RNA 291 10 
4 LGLLKcon Total RNA 655 9.90 
5 LGLKJcon Total RNA 1217 9.90 
6a BTinfa Total RNA 1788 8.40 
6b BTinfb Total RNA 1341 8.40 
7a BT5AZa Total RNA 1335 9.60 
7b BT5AZb Total RNA 916 9.60 
LGLLK5aza and LGLKJ5aza: large granular lymphocytes derived from rabbit IDs 
LFLK and LKKJ and treated with 5 azacitidine, LGLLK con and LGLKJ con: Large 
granular lymphocytes derived from rabbits IDs LFLK and LFKJ without treatment, 
BTinfa and b: Bovine turbinate infected only with AlHV-1 virus, BT5Aza and b: BT 
treated only with 5-azacitidine.  
 
 
Osama Kumati                                                                  Results 
167 
 
Figure 30 AlHV-1 DNA copy number in rabbit large granular lymphocytes 
The figure illustrates the viral load (as DNA copy numbers per 105 beta globin 
DNA copies) in large granular lymphocytes (LGL) from rabbits infected with AlHV-
1 C500 strain. Four lines (IYJJ, IYDY, LFKJ, and LFLK) were treated with 5-
azacitidine drug or kept without treatment as a control. The viral load was 
estimated by normalizing the viral DNA copy number per 105 rabbit β globin 
reference gene using qPCR. The primers and probe (FAMAlHV-1) for AlHV-1 ORF3 
were used inside the standard sequence and then analysed using Roche Light 
Cycler 480 system. Two-way ANOVA was performed to do the statistical analysis 
using Sidak’s multiple comparisons test. The primers and probe (FAM) for rabbit β 
globin reference gene was utilized within the standard sequence. 
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Figure 31 RNA Integrity Number. 
Samples with different RIN numbers show various RNA qualities. A RIN of 1 shows 
a completely degraded RNA sample while a RIN of 10 demonstrates a fully intact 
RNA sample. The two peaks in the electropherogram represent the 18S and 28S 
areas of the ribosomal RNA (rRNA) molecule during the single RNA cleavage. The 
height of 28S peak reflects the status of the RNA degradation as it dissolves 
faster than 18S peak. The highest peaks for categories 9 and 10 and the lowest 
for 1-3. (A), RIN value for LGLLK5aza sample; (B), RIN value for LGLKJ5aza 
sample; (C), RIN value for BT5Aza sample; (D), RIN value for BTinfa sample.  
 
5.4.3 Mapping results 
The raw data containing reads with low sequencing score were 
filtered and aligned to adapter sequences. All filtered reads were 
mapped against the reference genome (AlHV-1, Bos-tourus 8 and 
Oryctolagus-cuniculus 2) in line with known gene exon coordinates 
using HISAT2 (Kim et al., 2015). The data revealed that the number 
of trimmed reads ranged from 85.86 million reads for sample 
(LGLLFLKctrl) to nearly 112 million reads for (LGLLFLK5-aza) (Figure 
32). In addition, the number of mapped reads ranged from 23 
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million reads for (LGL LFLK ctrl) with sample to 35 million reads for 
sample (BTinfb) with percentage of 98% (Figure 33). Of those 
mapped reads, the correctly mapped reads ranged from 22 million 
counts to 35 million counts for the same samples respectively 
(Figure 32). The percentage of mapped reads ranged from 92.93% 
for sample (LGL LFLK ctrl) to 98.5% for ample (BT5Aza) and those 
for correctly mapped reads ranged from 89.8% to 96.8% for sample 
(LGL LFKJ5-aza) and (BT5Aza) respectively (Figure 33).  
 
 
Figure 32 genome coverage for rabbits (Oryctolagus cuniculus2 ) and cattle (Bos 
tourus 8). 
The figure shows the mapping count of trimmed reads, mapped reads and 
uniquely and correctly mapped reads for rabbit and cattle transcripts. The highest 
counts for trimmed reads were nearly 112 million reads and the lowest was 85 
million reads. The highest counts for mapped reads were 35.9 million counts while 
the lowest was 28.9 million counts. The highest counts for uniquely and correctly 
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mapped reads were 35 million reads whereas the lowest was 22 million counts. 
Reads with low sequencing score and reads aligned to adapter sequences were 
filtered. These reads were mapped against the rabbit and cattle gene transcripts 
in the context of known gene exon coordinates by HISAT mapping tool. LK5-aza; 
LGLs LFLK treated with 5-azacitidine, KJ5-aza; LGLs LFKJ treated with 5-
azacitidine, LKctrl; non-treated LGL LFLK, KJ ctrl; non-treated LGLs LFKJ, BTinfa; 
BT infected with AlHV-1 sample a, BTinfb; BT infected with AlHV-1 sample b, 
BT5Aza; BT infected with AlHV-1 virus and treated with 5-azacitidine sample a, 
BT5AZb; BT infected with AlHV-1 virus and treated with 5-azacitidine sample b.  
 
 
Figure 33 mapping percentage for rabbits (Oryctolagus cuniculus2) and cattle 
(Bos tourus 8) genomes. 
The figure shows the mapping count of mapped reads and uniquely and correctly 
mapped reads for rabbit and cattle transcripts. The highest counts for trimmed 
reads were nearly 112 million reads and the lowest was 85 million reads. The 
highest percentage for mapped reads was 98.5 % while the lowest was 92.9 %. 
The highest percentage for uniquely and correctly mapped reads was 96.8 % 
whereas the lowest was 89.8 %. Reads with low sequencing score and reads 
aligned to adapter sequences were filtered. These reads were mapped against the 
rabbit and cattle reference transcripts in the context of known gene exon 
coordinates by HISAT mapping toll. LK5-aza; LGLs LFLK treated with 5-
azacitidine, KJ5-aza; LGLs LFKJ treated with 5-azacitidine, LKctrl; non-treated LGL 
LFLK, KJ ctrl; non-treated LGLs LFKJ, BTinfa; BT infected with AlHV-1 sample a, 
BTinfb; BT infected with AlHV-1 sample b, BT5Aza; BT infected with AlHV-1 virus 
and treated with 5-azacitidine sample a, BT5AZb; BT infected with AlHV-1 virus  
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5.4.4 Differentially expressed host genes 
The data obtained from RNA sequencing analysis were run in 
BioMart- ensemble www.enssembl.org/biomart to identify the 
transcript descriptions for both species. The excel look up function 
was used to annotate the differential transcript lists with the 
clusters identified by David analysis (see sections (8.6 and 8.8)). 
Five top clusters represented the most affected pathways based on 
their enrichment score (the highest values) and then the overlapped 
differentially-expressed genes were identified between the clusters 
for both species. Table 10 and 11 show the pathways most affected 
in both species and the differentially expressed host genes 
expressed in the presence of 5-azacitidine in comparison to infected 
control as well as the up-regulated and down regulated genes.  
The data also revealed that the pathways that had the majority of 
genes that were down regulated in rabbits are nuclear lumen (cell 
structural components), lipid biosynthesis, DNA repair, apoptosis 
and cell cycle in the presence of 5-azacitidine in comparison to the 
infected control (Table 12-16). The data also showed that the 
principle affected pathways that had down-regulated genes overall 
in cattle (BT) cells are those involved in mitochondrion integrity, 
endosome (structural cell components), organelle lumen (structural 
cell components), lysosome (structural cell components), and purine 
and pyrimidine biosynthesis in the presence of 5-azacitidine in 
comparison to infected control (Table 17-21).  
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Some of the genes belong to the Bcl-2 family of apoptosis such as 
BCL2-Associated X Protein (BAX) and BCL2/Adenovirus E1B 19kDa 
Interacting Protein 2 (BNIP2), which were up-regulated in 5-aza-
treated LGLs compared to untreated controls are considered as pro 
and anti-apoptotic genes respectively while BCL2/Adenovirus E1B 
19kDa Interacting Protein 1 (BNIP1) and BCL2/Adenovirus E1B 
19kDa Interacting Protein 3 (BNIP3), which were down regulated 
are thought to be cell death suppressor and cell death activator 
respectively. The upregulated genes known to inhibit apoptosis were 
Tumor Necrosis Factor Receptor Superfamily, Member 1B 
(TNFRSF1B) and X-Linked Inhibitor of Apoptosis, E3 Ubiquitin 
Protein Ligase (XIAP) (Table 12-16). 
There were overlapped genes between the different pathways that 
are known to act as anti-apoptotic such as Mitogen-Activated 
Protein Kinase 7 (MAPK 7) and Pim-1 Proto-Oncogene, 
Serine/Threonine Kinase (PIM1) and genes acting as cell death 
activator like STE20-Like Kinase (SLK), Receptor (TNFRSF)-
Interacting Serine-Threonine Kinase 1 (RIPK1) and Macrophage 
Erythroblast Attacher (MAEA) (Table 10). In addition, the 
overlapped genes involved in apoptosis with unknown function, 
either as pro or anti apoptotic, were Brain and Reproductive Organ-
Expressed (TNFRSF1A Modulator) (BRE), Tubulin, Beta Class I 
(TUBB), Coagulation Factor II (Thrombin) Receptor-Like 3 (PAR4) 
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and Nuclear Receptor Subfamily 2, Group C, Member 2 (NR2C2) 
(Table 12-16). 
The host differentially-expressed genes in BT cells that were down 
regulated in 5-aza treated BT cells compared to untreated controls 
included Polymerase (RNA) III (DNA Directed) Polypeptide F, 39 
KDa (POLR3F), Proliferating Cell Nuclear Antigen (PCNA), GATA 
Binding Protein 2 (GATA2), Polyglutamine Binding Protein 1 
(PQBP1), and Kruppel-Like Factor 4 (Gut) (KLF4) (Table 17-21). All 
of these genes are involved in transcription, translation, post-
translational activity and DNA replication.  
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Table 10 conserved gene matrix of rabbit LGLs differentially expressed genes in the presence of 5-azacitidine in 
comparison to infected only control. 
 
 Nuclear lumen Lipid biosynthesis DNA repair  Cell death and apoptosis Cell cycle 
Nuclear lumen                 22 
22 
X 14                   7 10                          6 9                 2 
Lipid biosynthesis  X                 2 
7 
1                     0 X X 
DNA repair 14             7  1               1                11 
9 
11                          8 6                 3 
Cell death and 
apoptosis 
10             4 X 11            3                 22 
12 
7                 4 
Cell cycle 9               7 X 6              3 7               3                10 
15 
  The table contains the most affected pathways in rabbits in the presence of 5-azacitidine in comparison to the 
infected control. The total of differentially expressed genes in 5-aza compared to untreated controls in each cluster 
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is in bold black font, the up regulated genes are in red font, the down regulated genes are in green font and no 
overlapping is represented by X. The total number of the genes in the same cluster is split to halves. The line was 
drawn to split the genes in each pathway to up-regulated and down regulated genes.         
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Table 11 conserved gene matrix of cattle's differentially expressed genes in the presence of 5-azacitidine in comparison to infected 
control. 
 
 Mitochondrion Endosome Organelle 
lumen 
Lysosome Purine and pyrimidine 
biosynthesis 
Mitochondrion                20                      
34 
4 2                                     12 5          9                     5                       6                         2                    
Endosome 4              2                                   8                                    
6 
X 7                      4                                    X
Organelle lumen 12            7                   X              18                                     
27 
X 2                                     1                      
Lysosome 9              4                     7              3                                     X                 5                                         
4 
1              1                      
Purine and 
pyrimidine 
biosynthesis 
6              4                      X 2             1                                  1       0                                        9               
8                     
 177 
O
s
a
m
a
 K
u
m
a
ti                                                                 R
e
s
u
lts
 
The table contains the most affected pathways in rabbits in the presence of 5-azacitidine in comparison to the 
infected control. The total of differentially expressed genes in 5-aza compared to untreated controls in each cluster 
is in bold black font, the up regulated genes are in red font, the down regulated genes are in green font and no 
overlapping is represented by X. The total number of the genes in the same cluster is split to halves. The line was 
drawn to split the genes in each pathway to up-regulated and down regulated ones.  
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 Table 12  up-regulated and down regulated of rabbit gene transcripts involved in lipid bio-synthesis  
 
Gene ID Gene name/description p-value Log FC 
Lipid biosynthesis 
ENSOCUG00000025649 TPI1 triosephosphate isomerase 1  0.003501 -2.1 
ENSOCUG00000005722 CERS6 Cyramide synthase 6 0.007421 1.2 
ENSOCUG00000015384 OXSM 3 Oxacyl-ACP-synthase, mitochondarial  0.018148 -1.2 
ENSOCUG00000014801 Uncharacterised protein  0.035263 -3.5 
ENSOCUG00000024832 Uncharacterised protein 0.02456 1.2 
ENSOCUG00000003499 FADS 2 fatty acid desaturase 2 0.011453 -3.5 
ENSOCUG00000022356 Uncharacterised protein 0.016451 -0.9 
ENSOCUG00000004549 CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 0.040602 -0.8 
ENSOCUG00000015843 MCAT  Malonyl CO:CAP acyltransferase (mitochondorial) 0.040358 -1.2 
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The table shows the rabbits’ genes name involved in the lipid bio-synthesis pathway along with their gene IDs. (-) 
values of log FC indicates gene down regulation where positive values indicate gene transcript up-regulation in 5-
aza treated compared to untreated controls. P values are significant ≤ 0.04.  
Table 13   up-regulated and down regulated LGL transcripts involved in the nuclear lumen pathway  
 
Gene ID Gene name/description p-value Log FC 
Nuclear lumen   
ENSOCUG00000011841 LIG1 ligase I, DNA, ATP-dependent  0.000739 -1.67635 
ENSOCUG00000006346 PSKH1 protein serine kinase H1 [Source:HGNC Symbol;Acc:HGNC:9529] 0.001056 0.527987 
ENSOCUG00000014274 MNAT1 MNAT CDK-activating kinase assembly factor 1  0.003235 0.0827 
ENSOCUG00000015063 URI1 URI1, prefoldin-like chaperone  0.008231 0.54297 
ENSOCUG00000029326 serine/arginine-rich splicing factor 10  0.010133 3.421816 
ENSOCUG00000007138 EXOSC2 exosome component 2  0.01081 -0.1158 
ENSOCUG00000003624 RFC3 replication factor C (activator 1) 3, 38kDa  0.015444 -0.24525 
ENSOCUG00000010418 SAP30 Sin3A-associated protein, 30kDa  0.015697 -1.5082 
ENSOCUG00000015154 MAPK7 mitogen-activated protein kinase 7  0.018904 0.796661 
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ENSOCUG00000005172 ZSCAN30 zinc finger and SCAN domain containing 30  0.019611 -0.59829 
ENSOCUG00000017150 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H)  0.022724 0.573093 
ENSOCUG00000009275 PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme  0.023446 -1.71405 
ENSOCUG00000006975 NR2C2 nuclear receptor subfamily 2, group C, member 2  0.023524 -0.35353 
ENSOCUG00000008735 MAK16 MAK16 homolog  0.034845 0.145717 
ENSOCUG00000005398 CCNE2 cyclin E2  0.040346 -0.85486 
ENSOCUG00000025072 Uncharacterized protein  0.041209 -0.08768 
ENSOCUG00000005276 NF2 neurofibromin 2 (merlin)  0.04231 0.231713 
ENSOCUG00000002802 FANCD2 Fanconi anemia, complementation group D2  0.042852 -0.59767 
ENSOCUG00000027381 Uncharacterized protein  0.04345 -0.44872 
ENSOCUG00000000322 PARN poly(A)-specific ribonuclease  0.043932 -0.19677 
ENSOCUG00000007979 TBP TATA box binding protein  0.045047 0.407046 
ENSOCUG00000024051 IDH3B isocitrate dehydrogenase 3 (NAD+) beta  0.045702 0.159479 
ENSOCUG00000003848 TCOF1 Treacher Collins-Franceschetti syndrome 1  0.04798 0.278411 
ENSOCUG00000014124 SENP5 SUMO1/sentrin specific peptidase 5  0.048374 -0.53382 
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ENSOCUG00000002541 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3  0.010643 -2.36666 
ENSOCUG00000011703 PQBP1 polyglutamine binding protein 1  0.02809 1.548224 
ENSOCUG00000004604 EME1 essential meiotic structure-specific endonuclease 1  0.009054 0.278554 
ENSOCUG00000000408 Uncharacterized protein  0.018583 -1.83834 
ENSOCUG00000003879 CTDP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
phosphatase, subunit 1  0.013843 0.268011 
ENSOCUG00000010012 AK4 adenylate kinase 4  0.01612 -3.43355 
ENSOCUG00000006610 MAEA macrophage erythroblast attacher  0.02166 -0.85255 
ENSOCUG00000012396 ZMYM3 zinc finger, MYM-type 3  0.049674 0.179336 
ENSOCUG00000014778 MORF4L2 mortality factor 4 like 2  0.008387 0.524559 
ENSOCUG00000021243 EXOSC4 exosome component 4  0.026038 -2.99464 
ENSOCUG00000024309 SMAD7 SMAD family member 7  0.002216 0.707824 
ENSOCUG00000016827 ETV6 ets variant 6  0.032107 -0.57071 
ENSOCUG00000006642 XRCC5b X-ray repair complementing defective repair in Chinese hamster 
cells 5 (double-strand-break rejoining)  0.024364 0.140797 
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ENSOCUG00000014717 Uncharacterized protein  0.013059 2.937234 
ENSOCUG00000010624 POLR3G polymerase (RNA) III (DNA directed) polypeptide G (32kD)  0.016503 0.121737 
ENSOCUG00000017091 MBIP MAP3K12 binding inhibitory protein 1  0.028152 0.787543 
ENSOCUG00000003587 ZMIZ1 zinc finger, MIZ-type containing 1  0.048565 0.274723 
ENSOCUG00000008568 ANKRD28 ankyrin repeat domain 28  0.042355 -0.53151 
ENSOCUG00000012218 MRPS26 mitochondrial ribosomal protein S26  0.01552 -0.14257 
ENSOCUG00000004933 SUPV3L1 SUV3-like helicase  0.024445 -0.1046 
The table shows the rabbits’ genes name involved in the nuclear lumen pathway along with their gene IDs. (-) 
values of log FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza 
compared to untreated controls. P values are significant ≤ 0.04.  
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Table 14   up-regulated and down regulated of LGL transcripts involved in the DNA repair pathway 
 
Gene ID Gene name/description p-value Log FC 
DNA repair 
ENSOCUG00000022356 Uncharacterized protein 0.016451 -0.96062 
ENSOCUT00000006644 XRCC5 X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break re-joining) 0.024364476 0.140797037 
ENSOCUT00000021649 Uncharacterized protein  
0.043449515 
-
0.448723692 
ENSOCUG00000011841 LIG1 ligase I, DNA, ATP-dependent 0.000739 -1.67635 
ENSOCUG00000014274 MNAT1 MNAT CDK-activating kinase assembly factor 1 0.003235 0.0827 
ENSOCUT00000002540 BNIP3  BCL2/adenovirus E1B 19kDa interacting protein 3 0.010643207 -2.36666053 
ENSOCUG00000003624 RFC3 replication factor C (activator 1) 3, 38kDa 0.015444 -0.24525 
ENSOCUG00000002802 FANCD2 Fanconi anemia, complementation group D2 0.042852 -0.59767 
ENSOCUG00000004604 EME1 essential meiotic structure-specific endonuclease 1 0.009054 0.278554 
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ENSOCUG00000014778 MORF4L2 mortality factor 4 like 2 0.008387 0.524559 
ENSOCUT00000010697 BRE Brain And Reproductive Organ-Expressed (TNFRSF1A 
Modulator) 0.040783077 0.323317894 
ENSOCUG00000017091 MBIP MAP3K12 binding inhibitory protein 1 0.028152 0.787543 
ENSOCUT00000005398 CCNE2 Cyclin E2 
0.040346282 
-
0.854855505 
ENSOCUG00000012218 MRPS26 mitochondrial ribosomal protein S26 0.01552 -0.14257 
ENSOCUT00000012453 EIF2AK3  Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 0.001836194 0.588992333 
ENSOCUT00000009875 XIAP  X-Linked Inhibitor Of Apoptosis, E3 Ubiquitin Protein Ligase 
0.023859876 
-
1.292221674 
ENSOCUT00000003039 SLK  STE20-Like Kinase 0.013003841 2.362971241 
ENSOCUT00000011792 RIPK1  Receptor (TNFRSF)-Interacting Serine-Threonine Kinase 1 0.031130748 0.443478374 
ENSOCUT00000014532 PARP4  Poly (ADP-Ribose) Polymerase Family, Member 4 0.047262905 0.218631005 
ENSOCUT00000024642 BAX BCL2-Associated X Protein 0.03360173 1.01942528 
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The table shows the rabbits’ genes name involved in the DNA repair pathway along with their gene IDs. (-) values 
of log FC indicates gene down regulation where positive values indicate gene up-regulation in 5-aza treated to 
untreated controls. P values are significant ≤ 0.04.  
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Table 15   up-regulated and down regulated LGL transcripts involved in cellular death and apoptosis pathway  
 
Gene ID Gene name/ description p-value Log FC 
Cell death and apoptosis 
ENSOCUG00000014274 MNAT1 MNAT CDK-activating kinase assembly factor 1 0.003235 0.0827 
ENSOCUG00000027381 Uncharacterized protein 0.04345 -0.44872 
ENSOCUG00000002541 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 0.010643 -2.36666 
ENSOCUG00000006642 XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 
5 (double-strand-break re-joining) 0.024364 0.140797 
ENSOCUG00000012451 EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 0.001836 0.588992 
ENSOCUG00000009878 XIAP E3 ubiquitin-protein ligase XIAP 0.02386 -1.29222 
ENSOCUG00000011791 RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 0.031131 0.443478 
ENSOCUG00000006423 BAX BCL2-associated X protein 0.033602 1.019425 
ENSOCUG00000014529 PARP4 poly (ADP-ribose) polymerase family, member 4 0.047263 0.218631 
ENSOCUG00000003035 SLK STE20-like kinase 0.013004 2.362971 
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ENSOCUG00000010695 BRE brain and reproductive organ-expressed (TNFRSF1A modulator) 0.040783 0.323318 
ENSOCUG00000015154 MAPK7 mitogen-activated protein kinase 7 0.018904 0.796661 
ENSOCUG00000006975 NR2C2 nuclear receptor subfamily 2, group C, member 2 0.023524 -0.35353 
ENSOCUG00000005276 NF2  neurofibromin 2 (merlin) 0.04231 0.231713 
ENSOCUG00000007979 TBP  TATA box binding protein 0.045047 0.407046 
ENSOCUG00000006610 MAEA macrophage erythroblast attacher 0.02166 -0.85255 
ENSOCUG00000014717 Uncharacterized protein 0.013059 2.937234 
ENSOCUG00000001542 RIPK2 receptor-interacting serine-threonine kinase 2 0.001105 -0.59341 
ENSOCUG00000000172 VAV3  vav 3 guanine nucleotide exchange factor 0.006063 1.138616 
ENSOCUG00000007938 ALDH1A3  aldehyde dehydrogenase 1 family, member A3 0.010062 0.170754 
ENSOCUG00000012028 PIM1 Pim-1 proto-oncogene, serine/threonine kinase 0.019968 0.398831 
ENSOCUG00000004627 APH1B  APH1B gamma secretase subunit 0.020786 0.424591 
ENSOCUG00000015236 Uncharacterized protein 0.021786 -1.71366 
ENSOCUG00000006277 BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2 0.034452 0.307168 
ENSOCUG00000000040 BNIP1 BCL2/adenovirus E1B 19kDa interacting protein 1 0.025577 -3.16923 
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ENSOCUG00000014127 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 0.048762 -1.25577 
ENSOCUG00000002187 TUBB  tubulin, beta class I 0.038957 -0.37109 
ENSOCUG00000006958 TMEM173 transmembrane protein 173 0.039155 0.522144 
ENSOCUG00000028156 Uncharacterized protein 0.020263 -0.21927 
ENSOCUG00000017921 BCAP31  B-cell receptor-associated protein 31 0.043509 -0.3856 
ENSOCUG00000015961 PPP2CA  Serine/threonine-protein phosphatase 2A catalytic subunit alpha 
isoform 0.007485 0.092106 
ENSOCUG00000015961 PPP2CA  Serine/threonine-protein phosphatase 2A catalytic subunit alpha 
isoform 0.007485 0.092106 
ENSOCUG00000015413 PDCD10  programmed cell death 10 0.008327 0.106757 
ENSOCUG00000026354 PGF  placental growth factor 0.032233 0.349872 
The table shows the rabbits’ genes name involved in the cellular death and apoptosis pathway along with their 
gene IDs. (-) values of log FC indicates gene down regulation where positive values indicate gene up-regulation in 
5-aza treated in comparison to untreated controls. P values are significant ≤ 0.04.  
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Table 16  up-regulated and down regulated LGL transcripts involved in the cell cycle pathway 
 
Gene ID Gene name/ description p-value Log FC 
Cell Cycle   
ENSOCUG00000014274 MNAT1 MNAT CDK-activating kinase assembly factor 1 0.003235 0.0827 
ENSOCUG00000006423 BAX  BCL2-associated X protein 0.033602 1.019425 
ENSOCUG00000015154 MAPK7 mitogen-activated protein kinase 7 0.018904 0.796661 
ENSOCUG00000006975 NR2C2 nuclear receptor subfamily 2, group C, member 2 0.023524 -0.35353 
ENSOCUG00000006610 MAEA  macrophage erythroblast attacher 0.02166 -0.85255 
ENSOCUG00000012028 PIM1  Pim-1 proto-oncogene, serine/threonine kinase 0.019968 0.398831 
ENSOCUG00000002187 TUBB  tubulin, beta class I 0.038957 -0.37109 
ENSOCUG00000011841 LIG1  ligase I, DNA, ATP-dependent 0.000739 -1.67635 
ENSOCUG00000005398 CCNE2 cyclin E2 0.040346 -0.85486 
ENSOCUG00000002802 FANCD2 Fanconi anemia, complementation group D2 0.042852 -0.59767 
ENSOCUG00000004921 DCLRE1A DNA cross-link repair 1A 0.009148 0.087371 
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ENSOCUG00000009275 PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme 0.023446 -1.71405 
ENSOCUG00000014124 SENP5 SUMO1/sentrin specific peptidase 5 0.048374 -0.53382 
ENSOCUG00000007827 SASS6 SAS-6 centriolar assembly protein 0.00895 -0.42226 
ENSOCUG00000011298 FAM83D family with sequence similarity 83, member D 0.018536 -1.03649 
ENSOCUG00000009879 STAG2 cohesin subunit SA-2 0.021314 0.364604 
ENSOCUG00000016706 KIF11  kinesin family member 11 0.027452 -0.19417 
ENSOCUG00000006348 PSMB10 proteasome subunit beta 10 
0.028911 
0.5946833
23 
ENSOCUG00000001418 PSMD14 proteasome 26S subuni, non-ATPase 14 0.029403 -0.62192 
ENSOCUG00000001097 CGRRF1 cell growth regulator with ring finger domain 1 0.035752 -1.73356 
ENSOCUG00000000791 RPL24  ribosomal protein L24 0.043664 -1.61249 
ENSOCUG00000003623 ITGB1 integrin, beta 1 0.00548 4.106411 
ENSOCUG00000014903 RGCC  regulator of cell cycle 0.042739 0.620927 
ENSOCUG00000010944 NEDD1  neural precursor cell expressed, developmentally down-
regulated 1 0.033882 -1.16131 
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ENSOCUG00000005880 PDS5A  PDS5 cohesin associated factor A 0.048663 0.879025 
 
The table shows the rabbits’ genes name involved in the cell cycle pathway along with their gene IDs. (-) values of 
log FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza treated compared 
to untreated controls. P values are significant ≤ 0.04.  
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Table 17  up-regulated and down regulated of cattle BT transcripts involved in the mitochondrion integrity pathway 
 
Gene ID Gene name/description p-value Log FC 
Mitochondrion 
ENSBTAG00000006272 nth-like DNA glycosylase 1 0.017064 0.52413 
ENSBTAG00000015294 COX10 heme A:farnesyltransferase cytochrome c oxidase assembly factor 0.016254 -0.62018 
ENSBTAG00000045703 cytochrome c oxidase assembly homolog 15 (yeast) 0.018873 4.340498 
ENSBTAG00000007332 Uncharacterized protein 0.029911 -7.33293 
ENSBTAG00000005791 uroporphyrinogen III synthase 0.036102 -4.84748 
ENSBTAG00000047462 Uncharacterized protein 0.045345 -2.40732 
ENSBTAG00000046690 Uncharacterized protein 0.023888 1.060966 
ENSBTAG00000011931 CD63 antigen 0.028907 -0.32749 
ENSBTAG00000006065 proliferating cell nuclear antigen 0.004827 -2.10674 
ENSBTAG00000015006 mitochondrial ribosomal protein L11 0.009037 -1.45233 
ENSBTAG00000047906 mitochondrial ribosomal protein L36 0.015561 0.068833 
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ENSBTAG00000015567 translocase of inner mitochondrial membrane 44 homolog (yeast) 0.016698 -0.84677 
ENSBTAG00000015833 DEAH (Asp-Glu-Ala-His) box helicase 30 0.016792 -8.03291 
ENSBTAG00000001780 serine--tRNA ligase, mitochondrial precursor 0.019816 -1.32708 
ENSBTAG00000001780 serine--tRNA ligase, mitochondrial precursor 0.029509 -1.15327 
ENSBTAG00000009091 ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 0.036661 1.759817 
ENSBTAG00000001107 calcyclin binding protein 0.040685 0.183786 
ENSBTAG00000006978 hydroxysteroid (17-beta) dehydrogenase 4 0.046434 0.519715 
ENSBTAG00000009839 glutathione S-transferase kappa 1 0.049364 -0.69816 
ENSBTAG00000015098 Rab9 effector protein with kelch motifs 0.008312 7.027562 
ENSBTAG00000004019 premelanosome protein 0.020502 -1.15137 
ENSBTAG00000008135 SRA stem-loop-interacting RNA-binding protein, mitochondrial 0.004899 -3.087 
ENSBTAG00000011760 mitochondrial ribosomal protein L14 0.011364 -2.85854 
ENSBTAG00000002474 MAD1 mitotic arrest deficient-like 1 (yeast) 0.012979 -1.7572 
ENSBTAG00000011809 nudix (nucleoside diphosphate linked moiety X)-type motif 8 0.014434 4.202557 
ENSBTAG00000020898 carbohydrate (chondroitin 4) sulfotransferase 12 0.014673 4.543596 
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ENSBTAG00000018770 hydroxysteroid dehydrogenase like 1 0.015835 2.683234 
ENSBTAG00000014653 spinster homolog 1 (Drosophila) 0.016729 1.300334 
ENSBTAG00000009682 LOC532995 protein; Uncharacterized protein 0.017564 -4.66056 
ENSBTAG00000008730 sideroflexin 4 0.019208 0.333715 
ENSBTAG00000008077 solute carrier family 37 (glucose-6-phosphate transporter), member 4 0.020471 -3.86726 
ENSBTAG00000043959 platelet derived growth factor C 0.020528 -5.22392 
ENSBTAG00000019854 ATP-binding cassette, sub-family E (OABP), member 1 0.021995 -1.79642 
ENSBTAG00000021780 SCO1 cytochrome c oxidase assembly protein 0.02314 -0.33666 
ENSBTAG00000003177 solute carrier family 25 (pyrimidine nucleotide carrier), member 33 0.023753 -0.50344 
ENSBTAG00000001463 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 0.024295 1.709409 
ENSBTAG00000015255 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 0.031701 0.68046 
ENSBTAG00000024781 39S ribosomal protein L17, mitochondrial 0.031911 -0.41802 
ENSBTAG00000008629 mitochondrial fission regulator 1 0.036049 -0.20923 
ENSBTAG00000004240 thymopoietin 0.037698 -4.9725 
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ENSBTAG00000006398 translocase of outer mitochondrial membrane 7 homolog (yeast) 0.037962 -5.25928 
ENSBTAG00000000301 Glycerol kinase; Uncharacterized protein 0.038167 -0.30485 
ENSBTAG00000001962 mitochondrial ribosomal protein S27 0.040067 -0.25581 
ENSBTAG00000021790 apolipoprotein O-like 0.040527 -2.04374 
ENSBTAG00000047836 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 0.041881 2.67723 
ENSBTAG00000008438 ADP-ribosylation factor interacting protein 1 0.042427 2.705246 
ENSBTAG00000012107 solute carrier family 25 (mitochondrial iron transporter), member 28 0.042458 -4.15644 
ENSBTAG00000005903 low density lipoprotein receptor-related protein 5 0.042508 3.191428 
ENSBTAG00000012072 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 0.046031 -2.11016 
ENSBTAG00000030566 GLE1 RNA export mediator 0.046476 -0.51529 
ENSBTAG00000034827 platelet derived growth factor D 0.046738 6.932076 
ENSBTAG00000006966 nurim (nuclear envelope membrane protein) 0.046957 -3.65053 
ENSBTAG00000013282 NECAP endocytosis associated 2 0.048582 -0.20713 
ENSBTAG00000046671 Wolfram syndrome 1 (wolframin) 0.049274 2.497423 
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The table shows cattle gene names involved in the mitochondrion pathway along with their gene IDs. (-) values of 
log FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza treated compared 
to untreated controls. P values are significant ≤ 0.04.  
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 Table 18  up-regulated and down regulated of cattle BT transcripts involved in endosomal pathways 
 
Gene ID Gene name/description p-value Log FC 
endosome 
ENSBTAG00000046690 Uncharacterized protein 0.023888 1.060966 
ENSBTAG00000011931 CD63 antigen 0.028907 -0.32749 
ENSBTAG00000016094 solute carrier family 36 (proton/amino acid symporter), member 1 0.002693 -3.00111 
ENSBTAG00000018202 cytochrome b561 family, member A3 0.013663 -3.80245 
ENSBTAG00000039968 transmembrane protein 55A 0.023713 3.109691 
ENSBTAG00000034689 zinc and ring finger 1, E3 ubiquitin protein ligase 0.036233 1.176685 
ENSBTAG00000003745 WD repeat domain 48 0.037767 0.725065 
ENSBTAG00000015098 Rab9 effector protein with kelch motifs 0.008312 7.027562 
ENSBTAG00000004019 premelanosome protein 0.020502 -1.15137 
ENSBTAG00000046467 protein tyrosine phosphatase type IVA, member 3 0.009776 -2.61277 
ENSBTAG00000018915 WASH complex subunit FAM21 0.01622 3.690243 
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ENSBTAG00000025297 membrane magnesium transporter 1 0.018348 10.41085 
ENSBTAG00000003565 tripartite motif containing 3 0.022235 4.037245 
ENSBTAG00000021639 activity-regulated cytoskeleton-associated protein 0.040311 -0.17954 
 
The table shows cattle’s genes name involved in the endosome pathway along with their gene IDs. (-) values of log 
FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza-treated compared to 
untreated controls. P values are significant ≤ 0.04.  
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Table 19  up-regulated and down regulated of cattle BT gene transcripts involved in the organelle lumen pathway 
 
Gene ID Gene name/description p-value Log FC 
Organelle lumen  
ENSBTAG00000006272 nth-like DNA glycosylase 1 0.017064 0.52413 
ENSBTAG00000008825 polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa 0.038073 -1.69785 
ENSBTAG00000006065 proliferating cell nuclear antigen 0.004827 -2.10674 
ENSBTAG00000015006 mitochondrial ribosomal protein L11 0.009037 -1.45233 
ENSBTAG00000047906 mitochondrial ribosomal protein L36 0.015561 0.068833 
ENSBTAG00000015567 translocase of inner mitochondrial membrane 44 homolog (yeast) 0.016698 -0.84677 
ENSBTAG00000015833 DEAH (Asp-Glu-Ala-His) box helicase 30 0.016792 -8.03291 
ENSBTAG00000001780 serine--tRNA ligase, mitochondrial precursor  0.019816 -1.32708 
ENSBTAG00000001780 serine--tRNA ligase, mitochondrial precursor  0.029509 -1.15327 
ENSBTAG00000009091 ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 0.036661 1.759817 
ENSBTAG00000001107 calcyclin binding protein 0.040685 0.183786 
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ENSBTAG00000006978 hydroxysteroid (17-beta) dehydrogenase 4 0.046434 0.519715 
ENSBTAG00000009839 glutathione S-transferase kappa 1 0.049364 -0.69816 
ENSBTAG00000011360 pre-mRNA-splicing factor SYF1 0.00146 -1.66151 
ENSBTAG00000003849 guanine nucleotide binding protein-like 2 (nucleolar) 0.005061 -3.48445 
ENSBTAG00000016606 polycomb group ring finger 1 0.00592 7.051528 
ENSBTAG00000019707 GATA binding protein 2 0.007854 -0.29559 
ENSBTAG00000007323 cleavage and polyadenylation specific factor 6, 68kDa 0.008762 1.478988 
ENSBTAG00000012777 serum response factor 0.008861 -1.61675 
ENSBTAG00000009562 zinc finger protein 593 0.0127 -1.68797 
ENSBTAG00000016332 inhibitor of growth family, member 3 0.015852 -2.50246 
ENSBTAG00000012575 macrophage erythroblast attacher 0.016016 1.536743 
ENSBTAG00000008190 sulfatase modifying factor 2 0.0175 -0.57121 
ENSBTAG00000007480 cold inducible RNA binding protein 0.018909 8.773147 
ENSBTAG00000038409 methyl-CpG binding domain protein 3 0.01934 -0.93366 
ENSBTAG00000026585 transcription elongation factor B (SIII), polypeptide 3 (110kDa, elongin A) 0.019828 1.808792 
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ENSBTAG00000003697 TAR DNA binding protein 0.021319 -6.7882 
ENSBTAG00000015946 retinoblastoma binding protein 5 0.021543 1.793306 
ENSBTAG00000020490 NACC family member 2, BEN and BTB (POZ) domain containing 0.02163 -4.77528 
ENSBTAG00000005076 synovial apoptosis inhibitor 1, synoviolin 0.025081 1.024949 
ENSBTAG00000021192 glioma tumor suppressor candidate region gene 2 0.025745 0.595285 
ENSBTAG00000006112 SprT-like N-terminal domain 0.027078 1.98873 
ENSBTAG00000010384 cell division cycle 6 0.0276 -1.29413 
ENSBTAG00000021845 striatin, calmodulin binding protein 3 0.028528 -1.55617 
ENSBTAG00000016271 small nuclear ribonucleoprotein polypeptide F 0.029432 -1.43929 
ENSBTAG00000003423 DEAD (Asp-Glu-Ala-Asp) box helicase 24 0.030951 -2.64543 
ENSBTAG00000018498 polyglutamine binding protein 1 0.031957 -5.22647 
ENSBTAG00000017582 checkpoint kinase 1 0.032011 4.752555 
ENSBTAG00000008905 folliculogenesis specific bHLH transcription factor 0.03221 -0.81315 
ENSBTAG00000012699 exosome component 1  0.034345 -1.84211 
ENSBTAG00000008704 fidgetin 0.038805 -1.51006 
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ENSBTAG00000019846 alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase 0.03964 11.41241 
ENSBTAG00000017219 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 0.044658 3.336827 
ENSBTAG00000020355 Kruppel-like factor 4 (gut) 0.045216 -9.77397 
ENSBTAG00000003934 paraspeckle component 1 0.047011 5.469299 
The table shows cattle’s genes name involved in the organelle lumen pathway along with their gene IDs. (-) values 
of log FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza treated 
compared to untreated controls. P values are significant ≤ 0.04.  
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Table 20  up-regulated and down regulated of cattle BT gene transcripts involved in lysosomal pathways 
 
Gene ID Gene name/description p-value Log FC 
Lysosome 
ENSBTAG00000011960 glutamic-oxaloacetic transaminase 1, soluble 0.009702 0.410793 
ENSBTAG00000046690 Uncharacterized protein 0.023888 1.060966 
ENSBTAG00000011931 CD63 antigen 0.028907 -0.32749 
ENSBTAG00000016094 solute carrier family 36 0.002693 -3.00111 
ENSBTAG00000018202 cytochrome b561 family, member A3 0.013663 -3.80245 
ENSBTAG00000039968 transmembrane protein 55A 0.023713 3.109691 
ENSBTAG00000034689 zinc and ring finger 1, E3 ubiquitin protein ligase 0.036233 1.176685 
ENSBTAG00000003745 WD repeat domain 48 0.037767 0.725065 
ENSBTAG00000000484 hyaluronoglucosaminidase 2 0.042501 -0.97983 
The table shows cattle’s genes name involved in the lysosome pathway along with their gene IDs. (-) values of log 
FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza-treated compared to 
untreated controls. P values are significant ≤ 0.04.  
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Table 21  up-regulated and down regulated of cattle BT gene transcripts involved in purine and pyrimidine biosynthesis pathways 
 
Gene ID Gene name/description p-value Log FC 
Purine and pyrimidine biosynthèses 
ENSBTAG00000011960 glutamic-oxaloacetic transaminase 1, soluble 0.009702 0.410793 
ENSBTAG00000006272 nth-like DNA glycosylase 1 0.017064 0.52413 
ENSBTAG00000008825 polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa 0.038073 -1.69785 
ENSBTAG00000015294 COX10 heme A:farnesyltransferase cytochrome c oxidase assembly factor 0.016254 -0.62018 
ENSBTAG00000045703 cytochrome c oxidase assembly homolog 15 (yeast) 0.018873 4.340498 
ENSBTAG00000007332 Uncharacterized protein 0.029911 -7.33293 
ENSBTAG00000005791 uroporphyrinogen III synthase 0.036102 -4.84748 
ENSBTAG00000047462 Uncharacterized protein 0.045345 -2.40732 
ENSBTAG00000015509 nicotinamide phosphoribosyltransferase 0.00014 6.215473 
ENSBTAG00000019274 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase 0.006476 10.49776 
 205 
O
s
a
m
a
 K
u
m
a
ti                                                                 R
e
s
u
lts
 
ENSBTAG00000007758 phosphodiesterase 10A 0.011243 4.872506 
ENSBTAG00000013776 inosine triphosphatase 0.013862 -0.93005 
ENSBTAG00000003025 NME/NM23 nucleoside diphosphate kinase 6 0.032176 5.09935 
ENSBTAG00000016552 NME/NM23 nucleoside diphosphate kinase 3 0.036335 14.84213 
ENSBTAG00000004549 uracil phosphoribosyltransferase (FUR1) homolog 0.037439 -5.2164 
ENSBTAG00000013825 branched chain amino-acid transaminase 1, cytosolic 0.044216 3.56528 
ENSBTAG00000002689 NME/NM23 family member 7 0.048514 -0.52516 
The table shows cattle’s genes name involved in the purine and pyrimidine biosynthesis pathway along with their gene 
IDs. (-) values of log FC indicates gene down regulation where positive values indicate gen up-regulation in 5-aza-
treated compared to untreated controls. P values are significant ≤ 0.04.  
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5.4.5 Differentially-expressed virus genes detected by RNA-
Seq 
The sequence analysis revealed that one virus gene differentially 
expressed (ORF 8, down-regulated in 5-aza group compared to 
controls, figure 34) in the cattle samples whereas two virus genes 
(ORF 21 and ORF 7) were up-regulated in the rabbit samples in the 
presence of 5-azacitidine in comparison to infected control (Figure 
34). Table 22 shows viral DNA load and viral gene transcripts in 
rabbit LGL and cattle BT cells in the presence and absence of 5-
azacitidine as measured by PCR and qPCR.   
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Table 22 summary of viral gene transcripts and viral DNA load in rabbit LGL and 
cattle BT cells in the presence and absence of 5-azacitidine as measured by qPCR 
and PCR approaches. 
 
Cell type/treatment Viral 
DNA 
Transcripts 
Non-treated LGLs 
IYJJ + Undetectable level of all transcripts 
IYDY + Undetectable level of all transcripts 
LFKJ + Low level ORF25, ORF63, ORFA4.5 and 
undetectable level of ORF50, ORF73, ORF 
A.9.5 
LFLK + Low level of all transcripts 
5-aza treated LGLs 
IYJJ + Very low level of ORF25 and ORF A4.5 
IYDY + Undetectable level of all transcripts 
LFKJ + Low level ORF25, ORF A4.5 and 
undetectable level of ORF73, OR50, ORF63, 
ORF A9.5 
LFLK + Low level of all transcripts 
 
infected only BT cells  + High level of ORF50, ORF25, ORF A4.5 and 
low level of ORF73, ORF63 
5-aza treated and 
infected BT cells 
+ Low level of ORF50, ORF25, ORF A4.5 and 
undetectable level of ORF73, ORF63 
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Figure 34 differentially expressed AlHV-1 virus in rabbits' LGLs and BT cells. 
The figure shows the differentially expressed genes (ORF 8) in bovine turbinate 
(BT) cells and ORF21 and ORF 7 in rabbits’ LGLs in the presence of 5-azacitidine 
in comparison to infected control. The figure also shows that ORF 8 gene was 
down regulated (log FC) whereas ORF 7 and ORF 21 were up-regulated. The 
genes were significantly expressed with p value < 0.05.     
 
     
5.4.6 David clustering  
The human orthologue gene ID’s lists for both rabbit and cattle were 
uploaded in David’s software http//david.ncifcrf.gov in order to 
cluster the functionally annotated genes. The results showed that 
there were 93 and 100 clusters in rabbit and cattle species 
respectively (see the sections (8.2 and 8.3) in appendix). These 
were reduced to 15 and 11 clusters for both rabbit and cattle 
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respectively (see sections (8.7 and 8.9) in appendix) based upon 
the enrichment score by which the clusters trimmed. These clusters 
with enrichment score of ≥1 were kept for further analysis. 
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5.4.7 IPA results 
Ingenuity pathway analysis (IPA) was performed on the data 
obtained from RNA sequencing analysis. For this it was necessary to 
generate one to one orthologues between our species (cattle and 
rabbit) and human using BioMart ensemble www.ensemble.org . The 
data obtained is placed in sections 8.6 and 8.7 in the appendix. The 
IPA system was used to investigate the differentially regulated 
pathways in the comparison between the treated (5-aza) and 
untreated cells (cattle or rabbit). The entire data sets were uploaded 
to the IPA software for global analysis. The top five significant 
canonical pathways affected in LGLs in the presence of 5-azacitidine 
in comparison to control LGLs were related to cell death and T cell 
activation (Table 23). The principal networks/pathways recognised 
contained those connected with: cell death and survival; cellular 
growth and proliferation; lymphoid tissue structure and 
development; lipid metabolism and the humoral immune response 
(Table 23). In general, genes within the pathways were down 
regulated in 5aza treated LGLs compared to untreated controls and 
the overall impact of this was possible induction of apoptosis and 
immune response genes. In addition, the top five significant 
canonical pathways affected in BT cells in the presence of 5-
azacitidine in comparison to control BT cells were related to: mRNA 
translation and mitochondrion structure (Table 24). The most 
significant networks/pathways observed are those associated with 
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cell cycle, gene expression, DNA replication and cancer (Table 24). 
The balance of genes in the majority of affected pathways were 
down regulated in 5aza treated in BT cells compared to untreated 
controls and the overall affect was a decrease in transcription and 
translation.  
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Table 23 summary of ingenuity pathway analysis of rabbit LGLs in the presence of 
5-azacitidine 
 
Top Canonical Pathways 
 p-value overlap 
Ceramide Signalling 9.18E-05 8.8 % 7/80 
Induction of Apoptosis by AlHV-1 1.40E-04 10.0 % 6/60 
Death Receptor Signalling 2.21E-04 7.6 % 7/92 
Tec Kinase Signalling 2.51E-04 5.7 % 9/157 
NF-B Activation by Viruses 4.12E-04 8.2 % 6/73 
 
Molecular and cellular functions 
 p-value #Molecules 
Cell Death and Survival 1.32E-02 - 9.08E-
06 
98 
Cellular Function and Maintenance 1.32E-02 - 9.08E-
06 
49 
Cellular Development 1.32E-02 - 1.34E-
05 
66 
Cellular Growth and Proliferation 1.32E-02 - 1.34E-
05 
95 
Lipid Metabolism 1.32E-02 - 3.65E-
05 
31 
 
ID Associated Network Functions Score 
Antimicrobial Response, Cell Morphology, Cellular Assembly 51 
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and Organization 
Cancer, Organismal Injury and Abnormalities, 
Gastrointestinal Disease 
41 
Auditory and Vestibular System Development and Function, 
Cellular Development, Cellular Growth and 
Proliferation 
35 
Lymphoid Tissue Structure and Development, Organ 
Development, DNA Replication, Recombination, and Repair 
33 
Cell Death and Survival, Cancer, Organismal Injury and 
Abnormalities 
30 
IPA uses Fisher’s Exact test to calculate p value 
 
Table 24 summary of ingenuity pathway analysis of bovine turbinate (BT) cells in 
the presence of 5-azacitidine 
 
Top Canonical Pathways   
 p-value Overlap 
Regulation of eIF4 and p70S6K 
Signaling 
2.35E-04 6.8 % 
10/146 
EIF2 Signaling 1.43E-03 5.4 % 
10/184 
mTOR Signaling 1.61E-03 5.3 % 
10/187 
2-oxobutanoate Degradation I 2.89E-03 40.0 % 2/5 
Oxidative Phosphorylation 2.89E-03 6.4 % 7/109 
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Molecular and Cellular Functions   
 p-value #Molecules 
Cellular Assembly and Organization 2.41E-02 - 2.67E-
06 
43 
Gene Expression 1.73E-02 - 1.52E-
04 
62 
RNA Damage and Repair 1.33E-02 - 1.52E-
04 
7 
RNA Post-Transcriptional Modification 1.52E-04 - 1.52E-
04 
6 
DNA Replication, Recombination, and 
Repair 
2.24E-02 - 1.71E-
04 
35 
 
ID Associated Network Functions Score 
Cancer, Organismal Injury and Abnormalities, 
Gastrointestinal Disease 
53 
Cancer, Organismal Injury and Abnormalities, 
Gastrointestinal Disease 
41 
Cell Cycle, DNA Replication, Recombination, and Repair, 
Gene Expression 
36 
Ophthalmic Disease, Organismal Injury and Abnormalities, 
Skeletal and Muscular Disorders 
36 
Cell Cycle, DNA Replication, Recombination, and Repair, 
Developmental Disorder 
34 
IPA uses Fisher’s Exact test to calculate p value 
 
Osama Kumati                                                                  Results 
215 
5.5 Discussion 
In this study the aim was to investigate the pathways affected by 
AlHV-1 in rabbit LGLs and cattle BT cells infected with AlHV-1 in the 
presence or absence of 5-azacitidine. The viral DNA copy number 
was used to identify the presence of AlHV-1 virus in LGLs samples. 
The RNA integrity number (RIN) results showed that all samples 
exhibited high quality RNA. This is important as the degradation of 
RNA can affect the gene expression level (Romero et al., 2014, 
Schroeder et al., 2006). The RNA sequencing analysis revealed that 
the mapping efficiency (the percentage of reads aligned to host 
genome or transcripts) was high (92% to 98%) indicating that high 
percentage of the RNA reads matched to rabbit and cattle 
transcripts (Benjamin et al., 2014, Mortazavi et al., 2008). 
The pathway analysis indicated that cell death and T cell 
accumulation, proliferation and immune response pathways were 
augmented in 5-aza-treated LGLs in comparison to infected only 
control LGL suggesting that LGLs have selected genes involved in T 
cell activation, proliferation and apoptosis that are normally 
suppressed in infected untreated cells. This makes sense as the 
virus requires inhabiting the infected T cell without killing the cell or 
being removed by an activation process. From other published work 
(Swa et al., 2001) it is known that the infected LGLs do not exhibit 
significant apoptosis but do have a heightened activation state with 
respect to T cell cytotoxicity and constitutive activation of the T cell 
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receptor. Thus the RNA-Seq study is recording a net effect based on 
the genes differentially regulated by 5-aza, that may not affect 
other activation genes and pathways. This picture is also in 
agreement with observations made by other authors (Palmeira et 
al., 2013, Parameswaran et al., 2014, Russell et al., 2012) who 
found the similar pathways (in the in vivo study) from rabbit and 
cattle Lymph nodes infected with AlHV-1 and LGLs derived from 
rabbits infected with AlHV-1 virus. In addition, the results are in line 
with analysis of transcription profiles in lymph node tissues from 
OvHV-2 infected cattle (Meier-Trummer et al., 2009). As mentioned 
above the results showed that a number of genes involved in the 
various pathways were either up or down regulated in the presence 
of 5-aza in comparison to infected control, allowing a clue to overall 
function only when the activity of the particular genes is known.  
Among those genes were Bcl-2 family members, which can be either 
anti-apoptotic or pro-apoptotic (Czabotar et al., 2014, Tsujimoto, 
1998). In this study, the overall effect of these changes was a net 
pro-apoptotic state in 5-aza-treated cells, but with no time course 
aspect to the analysis, it is difficult to see if there are any time 
related changes. However, the analysis was done when the LGLs 
were in a steady state of growth in IL-2 with a stable phenotype. 
The dysregulation of this gene family could also be under the effect 
of AlHV-1 ORF A4.5 or ORF A9 which has similarities to the Bcl-2 
family (Hart et al., 2007, Mills et al., 2003). However, their role 
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whether they act as anti-apoptotic or cell death activator is yet 
unknown. The presence of the viral bcl-2 orthologues indicates that 
these are required in the virus life cycle. Importantly, the study only 
identifies changes associated with 5-aza treatment as both the 
control and treated cells were infected. Regarding the objective to 
this study it was hoped that the changes would represent those 
seen as part of a latent state induced by 5-aza. The impact of 5-
azacitidine on the expression of OvHV-2 Ov4.5, the homologue of 
AlHV-1 A4.5, has been recorded where it increased in expression in 
cattle LGLs but not rabbit LGLs (Thonur et al., 2006). It is an 
advantage to the virus to escape the recognition by the immune 
system in order to survive and replicate within cells. Latency is the 
approach by which the virus can avoid the immune evasion by the 
expression of ORF73 LANA protein (Coscoy, 2007). 5-azacitidine is a 
nucleoside analogue which inhibits the methyltransferase enzyme 
and hence altering gene expression (Haaf, 1995, Jones, 1985). It 
was found that the drug can establish latency in LGLs from OvHV-2 
infected rabbits (Thonur et al., 2006) but failed to control latency III 
in primary lymphoma cells infected with recombinant Epstein-Barr 
virus (Anastasiadou et al., 2005). Two genes (XIAP and TNFRSF1B) 
which are known as inhibitors of apoptosis (Morizane et al., 2005, 
Schall et al., 1990) were down regulated in the presence of 5-
azacitidine indicating that the virus may affect these genes in order 
to alter cell survival. It was demonstrated that KSHV ORF73 LANA 
Osama Kumati                                                                  Results 
218 
was involved in tumour necrosis factor regulatory network which 
affects in the survival of latently infected cells (Si and Robertson, 
2006, Uppal et al., 2014).  
LGLs are known to be predominantly productive cycle programmed 
or latently programmed or have a mixture of both productive and 
latent virus cycles (Rosbottom et al., 2002, Thunor et al., 2006). 
The analysis demonstrated that many host genes involved in the 
various pathways; in particular cell death and cell cycle, acting as 
both cell death inhibitors and activators, were either up or down 
regulated in the presence of 5-aza compared to non-treated 
controls. In addition, two viral genes (ORF7 and ORF21), where 
their role in the life cycle and the pathogenesis of MCF is unknown, 
were up-regulated in the presence of 5-aza-treated group in 
comparison to non-treated controls. Moreover, the viral gene 
profiles from the previous chapter indicated that the expression of 
ORF73 and ORF50 supporting latent and productive virus cycle were 
very low (Table 22). Taking these observations together, one could 
extrapolate that it is not obvious that the cells support either 
productive or latent virus cycle or both.    
The pathway analysis in treated BT cells versus infected controls is 
likely to identify productive cycle versus latency cycle changes 
better than in LGLs as the effect of 5-aza on infected BT cells was 
more profound (induction of a latency phenotype with respect to 
lack of CPE and reduction of productive cycle gene transcripts). 
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Overall, genes involved in mitochondrion integrity, mRNA 
translation, regulator of gene expression, cell cycle and DNA 
replication, post transcriptional modification and genes known to be 
associated with neoplasia were down regulated in 5-aza treated 
infected BT cells compared to untreated BT cells. These effects are 
compatible with the fact that the virus replicates in these cells and 
establishes a productive/lytic infection and may reveal the latency 
programme in the transcriptome of the cells treated with 5-aza. The 
results also showed that ORF8 gene was differentially expressed, 
being down regulated in the presence of 5-azacitidine in BT cells 
compared to non-treated control indicating that the virus may affect 
the expression of this gene. ORF8 is a glycoprotein required for viral 
entry to the host cell (Dry et al., 2016) and is also expressed during 
productive infection (Palmeira et al., 2013). This is therefore 
predicted as BT cells support productive virus infection (Dry et al., 
2008, Dry et al., 2016, Parameswaran et al., 2014). However, upon 
treatment with 5-azacitidine, ORF 73 was not highly expressed 
(Table 22) even though BT cells did not show any CPE. The 
explanation of this is that the expression of ORF73 may not, in 
isolation, be diagnostic of the latent state (i.e. an increase in 
expression rather than expression per se). 5-azacitidine is a hypo-
methylation agent (Christman, 2002) which may have not 
completely removed ORF50 gene in BT cells meaning that ORF50 
may have repressed the expression of ORF 73 gene. Recombinant 
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murine Gama herpesvirus (MHV-68) was engineered to overexpress 
RTA, transcriptional and replication activator encoded by ORF50 of 
Gama herpesviruses, was found to inhibit the expression of ORF73 
gene and induce lytic virus cycle (Hair et al., 2007). The approach 
one could think of to address the expression of ORF73 in BT cells 
therefore is to completely remove ORF 50, the productive gene, by 
knockout gene technique. 
The work study revealed that there were differences between the 
gene expression profiles between 5-aza treated and non-treated 
cells and also between rabbit LGLs and cattle BT cells, which reflects 
the different types of cell under study. 
 
  
Chapter 6 
The effect of Cyclosporine-A 
on T cell recruitment, viral 
gene expression and disease 
pathogenesis in infected 
rabbits
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6.1 Abstract 
The mechanism by which MCF viruses (AlHV-1 and OvHV-2) cause 
the disease is not fully understood. The tissue damage seen in the 
affected tissues is attributed to the accumulation of T lymphocytes. 
However, it is not well established whether the damage is due to the 
direct effect of infiltrated T lymphocytes (infected or bystander non-
infected) or due to the effect of small number of infected non T cells 
or both. Cyclosporine A drug, in rabbits infected with OvHV-2 
prevented lymphocyte accumulation but not overt MCF (Buxton et 
al., 1984). This is a key observation and the basis of the aims of 
this thesis. Rabbits were infected with AlHV-1 and treated with 
cyclosporine A. Unfortunately; the rabbits reacted badly to the CsA 
and infection such that they had to be euthanized before full onset 
of MCF. However, these animals showed some pathological changes 
and these data were analysed. In a subsequent trial to examine the 
pathogenesis of MCF in rabbits infected only with AlHV-1, results 
were again inadequate due to the early termination of the 
experiment as the animals reacted unexpectedly to infection.  The 
viral transcript profile analysis revealed that the productive/lytic 
genes were expressed at low level in the infected only group 
indicating the virus may replicate at this stage of the disease.  
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6.2 Introduction 
There has been a controversy for long time over the mechanism by 
which MCF viruses (AlHV-1 and OvHV-2) cause the disease (Buxton 
et al., 1984, Dewals et al., 2011, Palmeira et al., 2013, Schock et 
al., 1998). The core of this debate has been over the issue whether 
the tissue damage is due to dysregulated immune response or direct 
viral impact, and whether the disease is one of viral latency or not 
(Palmeira et al., 2013). Rabbits are a good model for MCF because 
they exhibit clinical signs and pathological changes similar to those 
seen in susceptible species (Anderson et al., 2007, Cunha et al., 
2013). Treating rabbits infected with OvHV-2 with cyclosporine A, 
an immunosuppressive drug, eliminated the lymphocytes infiltrating 
the infected tissues but did not prevent disease development 
(Buxton et al., 1984). There is a scarcity of the virus in the infected 
tissues (Bridgen et al., 1992, Thonur et al., 2006) making analysis 
difficult. The phenotype and cytokine profile of the lymphoblastoid 
cells infiltrating the infected tissues represent unregulated cytotoxic 
cells (Schock et al., 1998, Swa et al., 2001). Nonetheless, growing 
evidence demonstrates that lymphocytes accumulating in MCF-
affected tissues are infected with the virus and the virus establishes 
latency in them (Palmeira et al., 2013, Simon et al., 2003). 
Furthermore, the cells are cytotoxic and secrete cytokines and 
proteins that are responsible for the tissue damage seen (Dewals et 
al., 2008, Dewals et al., 2011, Palmeira et al., 2013). I aim to treat 
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AlHV-1 infected rabbits with CsA to examine the role of T 
lymphocytes in the pathogenesis of AlHV-1 MCF and to study the 
gene expression using known productive/lytic and latent viral 
transcripts in rabbits during MCF disease course. Cyclosporine acts 
by inhibiting calcineurin which is responsible for triggering a 
significant signal transduction pathway of T cell activation. The 
outcome of this action is a reduction in T cell maturation (Matsuda 
and Koyasu, 2000, Mott et al., 2004). We hoped to see whether 
ablation of T cells would alter the course of MCF and whether there 
was an associated change or not in gene transcription profiles. For 
this, q PCR and in situ hybridisation techniques will be used. 
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6.3 Materials and methods 
6.3.1 Animals 
See the materials and methods chapter section (2.6). 
6.3.2 Inoculum  
As described in the materials and methods chapter section (2.6.1). 
6.3.3 Experimental design  
As described in the materials and methods chapter sections (2.6.2) 
and (2.6.3).  
6.3.6 Molecular techniques 
The molecular approaches as described in materials and methods 
chapter. Quantitative R-T PCR was used to measure both viral load 
and gene expression in the infected tissues as described in materials 
and methods sections (2.4.3) and (2.4.4). 
6.3.4 Samples collection 
As described in the materials and methods chapter section (2.6.4). 
6.3.5 Histology 
See the materials and methods chapter section (2.7). 
6.3.7 In situ Hybridization 
The in situ hybridisation method used as described in materials and 
methods sections (2.8.1) to (2.8.5).  
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6.4 Results 
 
6.4.1 Experiment (1) results 
10 rabbits split into two groups of 6 to get CsA and infection and 4 
to get infection only with vehicle IV rather than CsA (See table 25). 
Two rabbits were culled from CsA treated group (IYTU and IYDI) 
without collecting samples from them as they died suddenly (see 
below). Tissue samples were collected from the remaining animals 
in both CsA treated group (4 animals, day 12) and infected only 
group (4 animals, day 17).    
6.4.1.1 Clinical signs 
None of the rabbits injected with cyclosporine A and infected with 
AlHV-1 developed clinical signs until around day 10 of the 
experiment two rabbits died from the CsA treated group (IYTU and 
IYDI) after exhibiting fever, weight loss, and conjunctivitis (Table 
25). They then died suddenly overnight. In the control group 
(infected with the virus along with vehicle), one of the rabbits 
developed a diarrhoea with high temperature that reached 41.2C° 
on day 17 of the experiment. Nearly all of the rabbits in this group 
exhibited high temperature, in-appetence, lethargy and 
conjunctivitis just prior to euthanasia. No other clinical findings were 
recorded on the rabbits up to the seventeenth day of the 
experiment when all rabbits were euthanized. 
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Table 25 shows the design of two rabbit's experiments infected and treated with cyclosporine A as long as pathological changes 
 
Exp # (1) Clinical signs/euthanasia Pathological changes 
4 rabbits infected + CsA  Started on day 10 (2 animals). 
Animals developed fever, 
conjunctivitis, apathy, weight loss. 
Reminder euthanized due to 
severe reaction to CsA on day 12.    
Small numbers white foci on the 
kidney, intestines, liver and spleen. 
Lung haemorrhage in both IYBM and 
IYKA.  
4 rabbits infected only  On day 15 animals developed 
fever, conjunctivitis, apathy and 
weight loss and were euthanized 
on day 17 of the experiment.  
Multiple white foci on the kidney, 
liver, lung, enlarged lymph nodes 
and enlarged spleen. Some micro-
haemorrhage in the intestines and 
lung.  
Exp #(2) Clinical signs/euthanasia Pathological changes 
4 rabbits infected + CsA  Adverse reaction to CsA seen days 
9-10. Fever, apathy, and rapid 
demise. Animals euthanized on 
day 10 
Slight lung haemorrhage, slight 
lymph nodes enlargement and small 
numbers of white foci on the liver 
and kidney. 
4 rabbits infected not 
treated.  
Day 9 animals exhibited fever and 
weight loss. Animals euthanized 
on day 10 of the experiment.   
Enlarged spleen, white foci on the 
liver, haemorrhage in the intestines 
and lung.  
2 rabbits, uninfected 
controls 
No clinical signs seen. Animals 
euthanized on day 10. 
No pathological changes seen.  
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6.4.1.2 Gross appearance of MCF lesions 
In the cyclosporine A treated group there were some small white 
foci on the kidney, liver, intestines and spleen along with 
haemorrhage in the lung of the rabbit IYBM as well as haemorrhagic 
lung and red eyes in the rabbit IYKA (Table 25). In the infected 
control group, the lesions were diverse affecting many body 
systems and more pronounced in three rabbits (LFKJ, LFLK, and 
IYDY) ranging from multiple white foci on the kidneys, liver, and 
lung, enlarged lymph nodes (in particular popliteal lymph nodes) 
and slight enlargement in mesenteric lymph nodes (MLN), 
congested intestines, enlarged and dark spleen, and dark and 
enlarged urinary bladder (Table 25). 
 
6.4.1.3 Viral DNA load measurement 
Viral DNA load was identified in both blood and lymph nodes of 
three animals from each group (Figure 35). In the tissues (Liver, 
kidney, lung, spleen and appendix), the viral load was detected in 
the infected control group confirming infection. The viral copy 
number was below the detection level in the cyclosporine A treated 
group in these tissues (Figure 36). 
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Figure 35  viral DNA load in lymph nodes and blood from rabbits tissues infected 
and treated with cyclosporine and infected only control animals. 
The figure shows viral DNA load in the blood and lymph nodes from 
rabbits infected with AlHV-1. Samples were collected on day 12 and 
17 of the experiment. The viral load was estimated by normalizing 
the viral DNA per 105 rabbit β globin using q PCR. 
 
 
Figure 36  viral DNA load in rabbits’ tissues infected and treated with cyclosporine 
A and infected only controls.  
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The figure demonstrates viral DNA load in rabbit tissues infected 
with AlHV-1 virus. Samples were collected on day 12 and 17 of the 
experiment. The viral load was estimated by normalizing the viral 
DNA copy number to 105 rabbit β globin gene copies using q PCR. 
 
6.4.1.4 Histological analysis of AlHV-1 in rabbits 
The major histological findings in regard to MCF lesions in rabbits in 
both groups (infected control and infected plus cyclosporine A 
treated) are summarised in Table 26. The non-lymphoid tissues in 
the control group (Liver, kidney, and lung) illustrated marked 
lymphocyte infiltration (accumulation of lymphoid cells) especially 
around the blood vessels, which showed evidence of vasculitis. In 
addition, there has been marked hyperplasia in the lymphoid 
follicles in the lymphoid tissues (appendix and spleen). In the 
cyclosporine A treated group there was not any change in either 
lymphoid or non-lymphoid tissues. 
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Table 26  cyclosporine A experiment: AlHV-1 MCF histology on lymphoid and non-lymphoid tissues.  
 
Exp (1) Exp (2) Lymphoid Tissues Non-lymphoid Tissues 
  Hyperplasia/Necrosis1 Lymphoid cell accumulation2 
animal animal Appendix spleen Kidney Liver lung 
Infected only Infected only      
LFKJ JYDR  +/0                     0/0 +/0                0/0 ++                   0 ++                   + ++                    0 
LFLK JYBU          +/0                     0/0 +/0                0/0 ++                   0 +                     + ++                    0 
IYJJ JYFC  +/0                     0/0 +/0                0/0 ++                   0 ++                   + ++                    0 
IYDY JYJE  +/0                     0/0 +/0                0/0 ++                   0 +                     - ++                    0 
                                                                                                       
CsA+infection CsA+infection        
IYKA JYIS -/-                    -/- -/-                   -/- 0                    0 0                      0 0                      0 
IYBM JXXS -/-                      -/- -/-                    -/- 0                    0 0                      0 0                      0 
IYJY JXTS  -/-                    -/- -/-                   -/- 0                    0 0                      0 0                      0 
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IYJX JXJJ -/-                    -/- -/-                  -/- 0                    0 0                     0 0                      0 
IYTU (Culled)       
IYDI (Culled)                                                                                                
                                                                             
Uninfected control Uninfected control      
C1 JXXL 0                       0 0                      0 0                    0 0                       0 0                       0 
C2 JXXR 0                       0 0                      0 0                    0 0                       0 0                       0 
       
       
Lymphoid tissues: + = change present, 0 = change not present (hyperplasia = increased lymphoid cell 
accumulation /proliferation compared to the controls).  
 
2Non- lymphoid tissues: Interstitial and perivascular lymphoid cell accumulations. ++ = marked accumulation, + = moderate 
accumulation, 0 = no accumulation. There was evidence of vasculitis (vascular endothelium thickening) in the infected control 
animal tissues. The rabbits were not marked in the table are those which were thrown away without samples being collected.   
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Kidney: there was perivascular lymphocyte infiltration in the cortex 
in the kidneys of the control group while in the cyclosporine A (CsA) 
treated group there was not any evidence of infiltration around the 
blood vessels (Figure 37). 
Liver: in the infected control group there was an obvious 
perivascular lymphoid accumulation in the periportal area whereas 
there was no infiltration in the cyclosporine A treated group (Figure 
38). 
Lung: no lymphocyte accumulation seen in the lungs from the 
cyclosporine A group, however, there was a clear lymphocyte 
infiltration in the peri-bronchial region as well as disperse infiltration 
throughout the parenchyma (Figure 39).    
 
Figure 37 haematoxylin and eosin stain of rabbits’ kidney 
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The images show the formalin fixed, haematoxylin and eosin stained histological 
sections of rabbits’ kidney (A, D, E, and F). Slides A and D show typical 
histological lesions of MCF after infection with AlHV-1 C500 strain. The most 
obvious appearance in these slides is the infiltration of lymphocytes around the 
blood vessels in the cortex area. Slides (E and F) are from the rabbits infected 
with AlHV-1 C500 strain and treated with cyclosporine A. There is an absence of 
lymphocyte infiltration. (a) Blood vessel, (Li) lymphocyte infiltration, (Ld) No 
evidence of lymphocyte accumulation, (RC) renal corpuscle, (T) uriniferous 
tubules. Pictures represent scale bar of 500 µm.  
 
 
Figure 38  haematoxylin and eosin stain of rabbit's liver 
The images depict the Formalin fixed, haematoxylin and eosin stained histological 
sections of rabbits’ liver (A, B, C, D). There is obvious lymphoid infiltration around 
the blood vessels in the periportal area in the infected tissues only with AlHV-1 
C500 strain virus (slid A and B) whereas no infiltration in the tissues infected with 
the same virus and treated with cyclosporine A drug (slides C and D).  CsA: 
cyclosporine A treated group, LI: lymphoid infiltration, HPV: hepatic portal vein. 
Pictures A and B represent scale bar of 500 µm whereas pictures C and D 
represent 200 µm. 
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Figure 39  haematoxylin and eosin stain of rabbit's lung 
The images depict the Formalin fixed, haematoxylin and eosin stained histological 
sections of rabbits’ lung (A, B, C, D, E, F). There is obvious evidence of 
peribronchial lymphoid infiltration as well as dispersed lymphocyte infiltration 
throughout the parenchyma slides (A, B,C) in the tissues infected only with AlHV-
1 C500 strain virus. No lymphocyte infiltration in the tissues infected with AlHV-1 
C500 strain virus and treated with cyclosporine A drug slides (D, E, F). LI: 
lymphocyte infiltration. Pictures represent scale bar of 200 µm.   
 
Appendix: there was an obvious expansion of the lymphatic 
nodules, absence of the inter-follicular space, haemorrhage in the 
blood vessels, and loss of the tissue architecture in the infected 
control group. No apparent changes in the cyclosporine A treated 
group (Figure 40). 
Spleen: there were no remarkable changes in the tissues from the 
cyclosporine A treated group. However, there was hyperplasia in the 
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white bulb nodules, intensive scattered lymphocyte infiltration, and 
loss of architecture in the infected control group (Figure 41). 
 
 
Figure 40  haematoxylin and eosin stain of rabbit's appendix 
The images show the formalin fixed, haematoxylin and eosin stained histological 
sections of rabbit’s appendix (G, H, I, and J). Slides G, H, and I are from rabbits 
infected with AlHV-1 virus without treatment with CsA. Slides illustrate expansion 
of follicles, relative absence of inter-follicular space, loss of tissue architecture as 
well as congested blood vessels. Slide J is from CsA treated group where the 
appearance is more normal. LN, lymphatic nodule; IS, inter-follicular space; CB, 
congested blood vessel. Pictures represent scale bar of 200 µm. 
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Figure 41  haematoxylin and eosin stain of rabbit's spleen 
The images show the Formalin fixed, haematoxylin and eosin stained histological 
sections of rabbit’s spleen (A, B, C, D). There was apparent hyperplasia in the 
white bulb (black arrow) as well as intensive dispersing of lymphoid cells 
throughout the tissue (arrow head) in the tissue infected only with AlHV-1 C500 
strain virus slide (A and B). No clear and remarkable changes in the cyclosporine 
A treated group (C and D). CsA: cyclosporine A treated group, WB: white bulb, 
RB: red bulb, LI: lymphocyte infiltration. Pictures A and B represent scale bar of 
200 µm whereas pictures C and D represent scale bar of 500 µm. 
 
6.4.1.5 Gene expression 
Gene expression in the infected tissues was measured by 
normalising viral target genes with rabbit SDHA1 reference gene 
using q PCR. The results showed that the gene expression of viral 
target genes was higher in infected controls than cyclosporine A 
treated group. Also, the pattern of expression was similar in nearly 
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all genes tested with highest values in spleen, lung, and kidney. 
ORF A4.5 recorded the highest gene expression in tissues of 
infected animals and in the spleen of the cyclosporine A treated 
group. The expression of ORF25, ORF50, and ORF63 was similar in 
the tissues of infected animals. The expression of ORF73 was lower 
than the other genes whereas ORF A9.5 was the lowest. Figure 42 
shows the gene expression of 6 viral genes putatively responsible 
for productive/lytic and latent virus infection in rabbit tissues.  
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Figure 42  viral transcripts of six AlHV-1 genes in rabbits' tissues 
The figure shows viral gene expression of six AlHV-1 genes (ORF50, ORF25, 
ORF63, ORF73, ORF9.5, and A4.5) in five rabbits’ tissues (liver, kidney, lung, 
spleen, and appendix) from infected only and infected and treated with 
cyclosporine A groups euthanized on day 12 (CsA group) and 17 of the 
experiment. The transcripts were measured using qPCR and normalised with 
rabbit SDHA1 reference gene. CsA 12 day; cyclosporine A treated group 
euthanized on day 12 of the experiment, Ctrl 17 days; infected control group 
euthanized on day 17 of the experiment. 
Osama Kumati                                                                  Results 
239 
 
6.4.1.6 In situ Hybridisation 
No results were obtained from the in situ hybridisation work despite 
the fact that synthesis of RNA probe for ORF65 and ORF A9.5 genes 
was unsuccessful.    
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6.4.2 Experiment (2) results 
The clinical signs associated with MCF in the infected cyclosporine A 
treated group were fever, apathy, and rapid demise. At this time 
two CsA-treated rabbits showed a rapid decline with fever, 
respiratory distress and apathy, and were euthanized for humane 
reasons. In the infected control group number of animals developed 
fever, weight loss, enlarged spleen, white foci on the liver and 
haemorrhage in the intestines and lung. In the negative control 
group there were no clinical signs and pathological changes seen. All 
animals were euthanized on day 10.  
In terms of the histological changes, the only changes were seen in 
the liver from infected group in form of small perivascular 
lymphocyte infiltration in the periportal area whereas there was no 
lymphoid infiltration in infected cyclosporine A treated group 
animals or the uninfected control group (Figure 43) 
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Figure 43 haematoxylin and eosin stain in rabbit's liver (1) 
The figure illustrates formalin fixed, haematoxylin and eosin stained liver (A, B, C, 
D). There is obvious lymphoid infiltration around the blood vessels in the 
periportal area in the infected only group tissues (slides C and D) whereas no 
infiltration was seen in the tissues of the infected and CsA-treated animals (slide 
A) or the uninfected control (slide B).  CsA: cyclosporine A treated group, LI: 
lymphoid infiltration, CV: central vein, CB: congested blood vessel, LD: infiltration 
disappearance. Pictures represent scale bar of 500 µm. 
 
The viral DNA load data revealed that this was under detectable 
level in most animals’ tissues except some liver and kidney samples 
from the CsA+infection group, the viral load was more than 3x106 in 
one of the kidneys (rabbit JXTS). There was no change recorded in 
the uninfected control group (Figure 44). 
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Figure 44  viral DNA load in tissues in infected only and infected and treated with 
cyclosporine A group animals (1) 
 
The figure demonstrates the viral DNA load in infected tissues and from samples 
collected on day 10 of the experiment. Infected control group; rabbits infected 
only with the virus, Cyclosporine A treated group; rabbits infected with the virus 
and treated with cyclosporine A uninfected control group; non-infected and non-
treated rabbits. The viral DNA load was calculated by normalizing the viral DNA 
per 105 rabbit β globin gene copy number using quantitative PCR. 
 
No results were obtained from the gene expression experiment in 
any sample. 
  
Osama Kumati                                                                  Results 
243 
6.5 Discussion 
Two in vivo experiments were carried out in order to investigate the 
role of CsA on MCF induction, and whether it would prevent T cell 
accumulation as shown previously (Buxton et al., 1984). The clinical 
signs and pathological changes observed in both experiments were 
typical for MCF in the control infected groups and consistent with 
other observations (Anderson et al., 2007, Dewals et al., 2008, 
Jacoby et al., 1988). There was a severe reaction to CsA in some 
animals necessitating the euthanasia of the entire group in each 
case. Thus, throughout this series of experiments the CsA-treated 
animal tissues examined represented an early stage of MCF and the 
infection only controls were not time matched to this in experiment 
1.  
Consequently, in terms of the histological findings, typical MCF-
associated changes were seen in the infected only groups in all the 
tissues collected which is in agreement with previous observations 
(Anderson et al., 2007, Buxton et al., 1984, Palmeira et al., 2013). 
In the cyclosporine A treated group, however, the lymphocytes did 
not accumulate around the blood vessels. This is also in agreement 
with results recorded by Buxton et al. (1984) with OvHV-2 infection, 
but this is an early time in infection before control infection only 
animals got MCF and this most likely explains the result. 
Similarly, possibly due to early euthanasia, it was noticed that the 
viral DNA load in the tissues of the control infection group was 
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considerably higher than the cyclosporine A treated group and in 
general although in some of the cyclosporine A animals viral DNA 
load was high in blood and MLN. However, detectable levels of MCF 
viral DNA (AlHV-1 and OvHV-2) can be identified as early as five 
days in the tissues and blood of infected animals (Cunha et al., 
2012, Dewals et al., 2008, Taus et al., 2005). 
All studied viral genes were expressed at low level in both groups 
and were higher in infected control groups than cyclosporine A 
treated group. Again this is due to the early death of the animals 
before MCF fully developed. The gene expression patterns were 
typical of AlHV-1 MCF with ORF73 (encoding latency associated 
nuclear antigen (LANA)) expressed at a lower level than most of the 
others. ORF A9.5 which encodes a secreted glycoprotein that is 
similar to IL-4 (Lankester et al., 2015, Russell et al., 2013) was 
expressed at very low level in the infected group. The role of this 
gene in the virus life cycle is still unknown.  
It was hoped to perform in situ hybridisation to localise viral genes 
to tissues and cells in vivo. Much time was spent developing the 
technique. Although synthesis of RNA probes was achieved, there 
were no convincing results obtained from the in situ analysis of 
infected tissues. Time was not available to troubleshoot the 
technique further. In situ hybridisation is a powerful technique 
which is used to detect cellular location of certain genes 
representing latent or lytic cycle (Jin and Lloyd, 1997, Malarkey and 
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Maronpot, 1996, Nouri-Aria, 2008).  This means that the viral mRNA 
copy numbers may have been below the in situ hybridisation 
threshold (Simon et al., 2003). The approach necessitates the 
presence of around 10-20 mRNA copy numbers in a single cell to 
make the signal detectible (Jin and Lloyd, 1997).  
The second CsA experiment was terminated on the tenth day due to 
an adverse reaction to CsA once again in spite of changing the 
vehicle used to dissolve the drug. Consequently, there were no 
results obtained as MCF did not develop. We surmise that in both 
experiments the CsA may have not been fully dissolved and formed 
micro-precipitates causing vascular obstruction/damage. Buxton et 
al. (1984) injected rabbits with cyclosporine A intramuscularly which 
may delay the drug diffusion, hence its effect on the animals’ 
tissues and the disease course. However, I applied intravenous 
route where the drug absorption time is fast.  
  
Chapter 7 
 
General discussion
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7.1 General discussion  
Although the pathological changes of MCF such as vasculitis, 
lymphocyte infiltration and tissue necrosis are well characterised, 
the pathogenesis of the disease is still not completely understood 
(Parameswaran et al., 2014, Russell et al., 2012). The tissue 
damage seen in MCF-affected tissues, especially epithelium and 
endothelium could be due to the infiltration and activity of cytotoxic 
T cells (either containing the virus or dysregulated non-infected 
cells) or virus infection of epithelium and endothelium or a mixture 
of both.  
The main hypothesis of this project work was that malignant 
catarrhal fever is initiated by aberrant virus gene expression in 
infected T cells, epithelium and endothelium. Whether the disease 
was predominantly one of latency (as has been suggested (Palmeira 
et al., 2013, Dewals et al., 2008)) or productive virus infection still 
remains controversial. The first aim was to determine whether 
epithelium and endothelium can be infected in vitro using q PCR 
and, if so whether a latent or productive viral cycle is established. 
Rabbit epithelial (SRIC) cells, Bovine aortic endothelial (BAE) cells 
and bovine turbinate fibroblast (BT) cells (productive virus control) 
were infected with both low pass (virulent) and high (attenuated) 
AlHV-1. It was clear that both cell-types can be infected with either 
form of AlHV-1 as shown by the presence of viral DNA and the 
ability to transfer infection to uninfected fresh cells where, in BT 
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cells, a productive infection was detected. If these cells represent 
epithelial cells and endothelial cells in vivo then it is possible that 
these cell types can contain virus. Interestingly, a lack of CPE in the 
SIRC and BAE cells indicated a lack of productive viral life cycle, 
raising the possibility that the cells are latently infected. The viral 
gene transcription analysis of these cells did not confirm a latency 
pattern, but levels of transcripts were very low and there was no 
gene transcription pattern typically seen in productively-infected BT 
cells. The ability of virus isolated from the SIRC and BAE cells to 
induce a productive infection in BT cells (as measured by a CPE) 
strongly suggests the virus was latent in the SIRC and BAE cells. It 
is also possible that the low viral transcripts were due to the fact 
that the virus could not enter or penetrate the cells. Consequently, 
the effect in the serial infection may have been the result of transfer 
of virus direct from the supernatant or that was attached to the 
surface of the first cells, and not virus that had “infected” the first 
cells. 
The question remains why ORF73 gene (the LANA equivalent 
latency-associated transcript) was not expressed in epithelium and 
endothelium in the in vitro model if the latent state was established. 
One explanation is that viral DNA load in the cells is present but 
transcript abundance is below detectable level. Another, explanation 
more speculative and less likely is that there might be biological 
factors in the in vivo system not available in the in vitro paradigm to 
Osama Kumati                                                General Discussion 
248 
make the virus express ORF73 gene and hence establish true 
latency. One of these is a lack of immune cells in the in vitro system 
which may be important to establish latency to escape the detection 
by the immune system (Blake, 2010). Finally, an important point 
when studying latency in MCF, is that this will have evolved in the 
host reservoir species (wildebeest for AlHV-1) and not the disease-
susceptible species, where the virus cannot transmit between 
animals (at least that we know of). Consequently, the virus life 
cycles may be altered or corrupted in some way in the MCF 
susceptible species cells, a possibility explored by Thonur et al., in 
studying cycles in LGLs from reservoir (sheep) and MCF susceptible 
animals in OvHV-2 MCF. A study of wildebeest cells infected with 
AlHV-1 was beyond the scope of this project.  
So, what is in BT vs SIRC and BAE that causes the productive virus 
cycle to switch on. The RNA-Seq analysis of infected BT cells and 
LGLs with and without 5-aza did not reveal any obvious answer to 
this, at least from the host transcriptome analyses. There was not 
enough resource to do transcriptome analyses on infected SIRC or 
BAE cells versus infected BT cells to address this directly. 
Large granular lymphocytes (LGLs), with T/natural killer cells 
morphology that are infected with AlHV-1 (Schock et al., 1998, Swa 
et al., 2001), were obtained from the infected rabbits and were 
treated with 5-azacitidine, a drug used to drive latency in gamma 
herpes viruses (Schaefer et al., 1997, Thonur et al., 2006). Bovine 
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turbinate fibroblast (BT) cells were infected with AlHV-1 and infected 
and treated with 5-azacitidine as productive cycle virus controls. 
The notion was to see if 5-aza could inhibit the productive cycle and 
establish a latent state and allow identification of latency-associated 
transcripts for AlHV-1. All infected cells treated or not were shown 
to have viral DNA using q PCR and PCR analysis indicating that the 
cells were infected with the virus. The most noticeable effect was in 
the infected BT cells where 5-aza treatment inhibited a CPE and this 
was associated with a marked reduction in gene transcripts 
associated with the productive viral life cycle (ORF50 and ORF25 
and ORF A4.5 and low level expression of ORF 73 the latency-
associated transcript).  This confirms that 5-aza drives a latency-like 
state in AlHV-1-infected cells as it does with OvHV-2 infected cells 
(Thonur et al., 2006). The results for LGLs were less clear. 5-aza 
treatment caused a dramatic effect on the pan T antigen 
(uncharacterised to date) recognised by a monoclonal antibody, but 
although there was some evidence of changes in viral productive 
and latent gene expression this was at low level, near detection 
limits and not consistent between the LGL lines. It is known that the 
A2 gene of AlHV-1 is a leucine zipper transcriptional regulator that 
has multiple functions on gene regulation in rabbits infected with an 
A2 gene knock-out virus or wild-type /gene reinsertion controls 
(Parameswaran et al., 2014). One of these effects is to alter the T 
cell receptor phenotype, downregulating alpha-beta TCR and 
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augmenting the gamma-delta TCR. It is known that there is a gd T 
cell subset that expresses CD8 (the predominant T cell marker 
detectable on the LGLs), found particularly at mucosal sites (Nelson 
et al., 2010, Wilson et al., 2002, Davis et al., 1996). 
Unfortunately, there is no gd T cell-specific antibody for the rabbit 
to test this theory out. Furthermore, the gd T cells lack the CD3 
molecule that is a pan T cell marker (Owens et al., 2015). 
Although the effect seen in this study is due to 5-aza treatment, it 
may be that this or the associated drive to a latent state may have 
stimulated this phenotypic change in the T cells and that A2 may be 
active in this way during latency. All of this speculation is open to 
further research. In contrast possibly, the impact of 5-azacitidine on 
(uninfected) human T cells especially CD4 and CD8 T cells has been 
documented. It was established that 5-azacitidine treatment of 
human T cells decreased CD8+ T cells whereas CD4+ T cells were 
augmented (Stübig et al., 2014). CD8+ T cells were the prevalent 
cell type after flow cytometry analysis of rabbit LGLs in both 5-
azacitidine and non-treated groups. The results are compatible with 
the observations made by other researchers who found that CD8+ T 
cells were the main cell type in LGLs and infected tissues in vivo 
(Dewals et al., 2008, Dewals et al., 2011). Also, there was a lack of 
CD4+ T cells in both groups.  Anderson et al. (2007) also observed 
the reduction in CD4+ T cells in MCF affected tissues. The target cell 
Osama Kumati                                                General Discussion 
251 
in the T cell lineage for virus infection in MCF is unknown 
(Parameswaran et al., 2014).  
The global transcriptome analysis by RNAseq on the 5-aza-treated 
and control infected LGLs and BT cells did not reveal an answer to 
the above speculation. However, the genes differentially expressed 
in 5-aza-treated versus untreated infected BT cells showed a pattern 
consistent with changes in mRNA translation, mitochondrion 
integrity, regulation of gene expression, cell cycle control, DNA 
replication, post transcriptional modification and in genes associated 
with neoplasia (see gene lists and pathway analyses in chapter 5). 
This is consistent with the fact that these changes are fully active in 
the untreated BT controls indicating productive/lytic virus cycle. 
In LGLs, the effect of 5-aza treatment was less clear on viral gene 
transcripts and the host transcriptome when compared to untreated 
cells. Viral transcript profiles showed that there was low expression 
of ORF50, ORF25, ORF63 and ORF73 in LGLs in two cell lines (LFLK 
and LFKJ) and no evidence of expression in two others. This could 
be because the level of viral transcripts is low to start with, which is 
the most likely explanation, or that a latency state was in these 
cells. A Gardella gel analysis of viral genome configuration was not 
performed due to a lack of time left in the study. This would reveal 
whether the LGLs had closed circular DNA (latent configuration, 
tight band on the gel) or linear DNA (lytic cycle configuration, smear 
on the gel). In the Thonur et al., (2006) analysis of rabbit LGLs 
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infected with OvHV-2, a mixed latent and lytic configuration was 
seen. After 5-azacitidine treatment there was a rise in ORF73 
expression in one cell line (LFLK) compared to the infected control 
but ORF50 was also detected. This is consistent with 5-azacitidine 
driving latency via increased ORF73 expression and was also seen in 
LGL infected with OvHV-2 virus and treated with 5-azacitidine 
(Thonur et al., 2006). It is worth mentioning that ORF73 can be 
‘leaky’ with respect to expression in the different virus life cycles 
such that complete absence of ORF73 in productive infection is not 
usually recorded (Thonur et al., 2006). The expression of ORF50 
confirms that the cells support at least productive infection and its 
transcript may be abundant. There was an increase in ORF A4.5 in 
one cell line due to 5-azacitidine. Thonur et al. (2006) found an 
increase in OvHV-2 Ov4.5 in cattle LGLs but not rabbit LGLs treated 
with 5-aza. The reason for the difference in this study is not known, 
but may be due to some difference between AlHV-1 and OvHv-2. 
The expression of ORF73 may not, in isolation, be diagnostic of the 
latent state (i.e. an increase in expression rather than expression 
per se). 5-azacitidine is a hypo-methylation agent (Christman, 
2002) which may have not completely removed ORF50 gene in BT 
cells meaning that ORF50 may have blocked the expression of ORF 
73 gene. The suppression of ORF73 gene and the induction of lytic 
virus cycle had been observed when ORF50 overexpressed using an 
Osama Kumati                                                General Discussion 
253 
engineered recombinant murine Gama herpesvirus (MHV-68) (Hair 
et al., 2007). 
The pathway analysis showed that cell death and T cell 
accumulation, proliferation and immune response pathways were 
increased in 5-azacitidine treated LGLs compared to infected-only 
control LGL indicating that LGLs have genes associated in 
immunological, cell death and proliferation processes. The pathways 
present in the untreated LGLs are similar to those in lymphoid 
tissues from MCF-affected cattle or rabbits (Palmeira et al., 2013, 
Paramiswaran et al., 2014, Russell et al., 2012). This indicates that 
the LGLs are an accurate representation of the host changes in vivo.  
The result also shows that 5-aza affects the above pathways 
(increased in treated versus untreated LGLs). This may be as a 
consequence of inducing a latent viral state, but there could also be 
some productive cycle activity as well as the results on this were not 
clear. It will be of interest in future work to determine if this is as a 
consequence of forcing the latent state for the virus and that these 
changes are at least in part stimulated by the latent gene 
expression programme or a lack of productive cycle gene 
expression. These pathways do not fit with classical latency, where 
inducing cell death in particular is not a good strategy for the virus. 
But, the viral gene expression may not be typical (i.e. is aberrant) 
in MCF-susceptible species. This all requires further research.  
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Importantly, although the pathway analysis identified several 
pathways affected by 5-aza-treated LGLs compared to untreated 
cells, the contribution of up and down regulated genes within these 
pathways can only really be assessed for a net overall effect if the 
precise functions of the genes are known in the context of the LGLs. 
For the apoptosis (cell death) pathway, this is possible as the 
function of many of the genes is known and conserved in animals. 
For example, there are both cell death inhibitors (BNIP1 and BNIP2) 
and activators (BAX and BNIP3) that were differentially expressed in 
the presence of 5-aza compared to non-treated controls. The overall 
effect is a tendency towards increased cell death in the 5-aza-
treated LGLs compared to control cells.  
In the final set of experiments, it was hoped that the Buxton et al., 
1984 study on the effect of CsA on OvHV-2-infected rabbits could be 
repeated for AlHV-1-infected ones. This is because the CsA 
prevented the accumulation of T cells in the tissues, but did not 
prevent MCF. This key paper was the main reason for the 
hypothesis and objectives of this thesis, namely that if the 
accumulating T cells (that we now know are infected with virus) are 
not present to cause epithelial and endothelial damage /tissue 
damage in MCF, what other possible mechanisms can cause 
disease? That is why we looked at infecting epithelial cells and 
endothelial cells in chapter 1. 
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Unfortunately, the rabbits reacted badly to IV CsA and had to be 
euthanized early in the development of MCF (around 10-12 days 
over two experiments). Changing the formulation for CsA delivery 
did not help (experiment 2). In the Buxton paper, the formulation 
was given intramuscularly, which may have avoided the problems 
experienced in this study. Nonetheless, the pathological changes 
and clinical signs seen in infected only rabbits represented early 
stages of MCF. These observations are compatible with results 
observed by other authors (Anderson et al., 2007, Jacoby et al., 
1988, Liggitt and DeMartini, 1980a, Liggitt and DeMartini, 1980b). 
There was not any accumulation of lymphocytes in the tissues of the 
cyclosporine A treated group in the non-lymphoid tissues. This was 
probably due to the early demise of the animals. However, and 
interestingly, in the control infected animals in experiment two 
(euthanased on day 10 after infection and therefore at a similar 
time to the CsA-treated animals) lymphoid accumulations were 
seen, mainly around blood vessels (e.g figure 43). So some effect 
on lymphocyte accumulation by the CsA treatment is implied. Also 
interestingly, in the CsA-tereated animals but not the infected 
controls, high levels of viral DNA were seen in kidney and liver 
samples in some animals. These could be sites of virus replication at 
this time in the presence of CsA. 
The viral transcript profiles in the experiments revealed that the 
level of gene expression was low but higher in the infected control 
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group than cyclosporine A treated group. This may have been due 
to the early finish of the experiment and also due to the variable 
viral copy number between the two groups as it was higher in the 
infected control than the cyclosporine A group. In addition, the 
results showed that the pattern of expression in the infected only 
animals was similar. Most of the genes especially those supporting 
productive/lytic virus cycles were expressed in the lung and spleen 
of the infected animals as seen in experiment 1 (Figure 42). The 
expression of ORF50, ORF25, ORF63 and ORF A4.5 and the low 
expression of ORF73 gene indicating that the virus may replicate 
and not tend to establish latency at this stage of the disease.  
The other main objective of this series of experiments was to use in 
situ hybridisation to localise putative productive virus cycle or 
latency cycle gene transcripts to particular cells in various tissues. 
This was to determine whether MCF was associated with 
predominantly latent viral gene expression or a productive cycle 
one, comparing animals with and without T cell accumulation (CsA-
treatment). 
Unfortunately, no results were obtained as time ran out to perform 
a comprehensive study. ORF 65 (productive cycle gene) and ORF 
A9.5 (secreted IL-4 orthologue) riboprobes were made and the 
technique developed and validated (with help from Dashty Amin and 
James Stewart in Liverpool). First attempts to detect the transcripts 
in the tissues of the infected animals were unsuccessful. In situ 
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hybridisation is a powerful approach which is utilized to localize 
certain genes signifying latent or lytic cycle along with the detection 
of cellular cytokine mRNA during viral infection (Anderson et al., 
2008, Anderson et al., 2001, Bridgen et al., 1992). It was 
documented that for potential detection of certain transcripts the 
approach requires the existence of approximately 10-20 mRNA copy 
numbers in a single cell to make the signal measureable (Jin and 
Lloyd, 1997). This may explain the inability to detect the transcripts 
in the affected tissues as viral mRNA copy numbers may have been 
below the in situ hybridisation threshold (Simon et al., 2003).   
 
7.1.1 Conclusion and recommendations  
The results of the in vitro epithelial and endothelial cell cultures 
indicate that the cells can be infected and establish a latent state, 
indicating that this is also possible in vivo, which should be looked 
at when studying MCF pathogenesis. The identification of proven 
latency transcripts by using 5-aza treatment on BTs and LGLs was 
unsuccessful, and more viral genes should be measured or other 
means as stimulating latency explored. The effect of 5-aza/ possible 
latency-associated expression the pan T antigen in LGLs is 
interesting and deserves further research. The transcriptome 
analyses in the infected and treated BTs and LGLs revealed several 
changes that may help future work to focus in on latency and 
productive infections in vivo. Moreover, the use of Gardella gel 
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analysis would have been useful in analysing the DNA configuration 
and hence the virus life cycle. The development of the in situ 
hybridisation work using productive virus cycle and latency gene 
riboprobes should proceed and the technique is partially developed 
here. 
The conclusion from this study using q PCR is that MCF in rabbits 
involves virus expressing both productive and putative latency 
transcripts. This raises some doubts that MCF is a disease of 
latency. Gene expression may be ‘aberrant’ but more work is 
required. 
Two papers are in preparation from this work. The first is on the in 
vitro analyses of more BT samples and LGLs with 5-aza, and also 
the use of phosphonoacetic acid as a treatment to induce latency. 
This has worked more efficiently on BT cells and LGLs than 5-aza 
treatment and was used by Abbie Jones, a student in D Haig lab. 
The second will be on the in vitro infection of endothelial and 
epithelial cells after some further analyses and increased sensitivity 
and extended range gene transcription analyses by q PCR. A work to 
address the role of ORF A9, a second bcl-2-like gene in AlHV-1 
(along with A4.5) in the pathogenesis of MCF is ongoing by a 
graduate student. 
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7.1.2 Project summary 
The research work was carried out to investigate the virus life cycle 
and the pathogenesis of malignant catarrhal fever (MCF). Rabbits, 
which are good model for MCF, were infected with alcelphine 
herpesvirus 1 (AlHV-1) and treated with cyclosporine A to suppress 
the accumulation of lymphocytes in the infected tissues. Large 
granular lymphocytes (LGLs) with the morphology of T/natural killer 
cells derived from the infected only rabbits were treated with 5-
azacitidine in order to drive the latency programme in them. RNA-
Seq was performed on the cells RNA (as copy DNA) samples to 
identify virus latency transcripts and the host transcriptome in 
latently-infected cells. Epithelial (SIRC) and endothelial (BAE) cells 
were infected with the virus in vitro to identify whether the cells can 
be infected and if so what kind of infection can be established 
(latent or productive/lytic). The results obtained can be summarised 
as following: 
 
 The in vitro epithelium and endothelium cell culture showed 
that the cells can be latently infected with the virus and this 
may be possible in vivo. 
 The identification of latency transcripts on LGLs and BT cells 
using 5-azacitidine was unsuccessful. 
 The flow cytometry analysis of LGLs showed that CD8+ T cells 
was the predominant cell subset in both 5-aza treated and 
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non-treated LGLs and the percentage of Pan-T cells were 
higher 5-aza treated LGLs. 
 The pathway analysis of LGLs and BT cells showed that there 
were variations between rabbit LGLs and cattle BT cells.  LGLs 
have pathways supporting T cell proliferation and 
accumulation and immune responsiveness in 5-aza-treated 
groups compared to untreated ones, BT cells contain 
pathways that aid gene expression and mRNA translation in 
treated groups compared to untreated.   
 The viral genes profile from the infected rabbits euthanized at 
early stage of the disease showed a mixture of both latent and 
productive virus cycle.    
 Unfortunately, no results obtained from the in situ 
hybridisation work. 
 
  
 
Appendices
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8.1 SOLUTIONS  
Use distilled water to make up solutions, then autoclave solution. 
When using distilled water within the protocol, use autoclaved 
distilled water. 
 
8.1.1 DEPC water 
(ddH2O, diethylepyrocarbonate-treated) 
1 ml DEPC (Fluka, 32490) add 1000 ml ddH2O 
Dissolve overnight on magnetic stirrer. Autoclave at 0.4 atm, 
120°C, 20 min. Care: This solution is regarded as carcinogenic! 
 
8.1.2 ddH2O 
Autoclave ddH2O without DEPC (like all other solutions) at 0.4 atm, 
120°C, 20 min. 
 
8.1.3 TrisHCl 
(MW 121.14): 1 M, pH 8.0 
12.11g Tris(hydroxymethyl)aminomethane (Fluka, 93352) in 100 ml 
ddH2O  
Adjust pH with concentrated HCl. 
 
8.1.4 CaCl2 
(MW 147.02) for proteinase K: 0.1 M 
1.47 g CaCl2 (Merck, 102382) in 100 ml ddH2O 
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8.1.5 MgCl2-hexahydrate 
(MW 203.3) for PBS: 5mM MgCl2 
1 M: 20.33 g MgCl2-hexahydrate (Merck, 105833) in 100 ml ddH2O 
 
8.1.6 NaCl 
(MW 58,44; Merck, 1.06400.5000) 
For hybridisation salts: 5 M = 29.22 g/100 ml ddH2O 
For RNAse treatment: 3 M = 87.66 g/500 ml ddH2O 
 
8.1.7 0.2 M HCl (Sterilize prior to use; not 2 N HCl) 
50 ml 2 N HCl (Merck, 1.09970. Titrisol®) 
450 ml ddH2O 
 
8.1.8 PIPES 
(Piperazin-N,N’bis(2-ethanesulfate-acid)), pH 7,0 (MW 346.3; 
Sigma, P3768) 
For hybridisation salts: 0.5 M = 1.7315 g/10 ml ddH2O (sterile 
preparation!) 
 
8.1.9 10x PBS 
(Phosphate buffered saline), 1x PBS: 
Dilute some 10 x PBS 1:10 to 1x PBS (in ddH2O without DEPC) and 
adjust the pH to 7.4 with 1M HCl or 1M NaCl. 
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8.1.10 Buffer 1, pH 7,5 
Tris (MW 121,14)  12.11 g Tris (final concentration 100 mM) 
NaCl (MW 58,44)  8.77 g NaCl (final concentration 100 mM) 
add 1000 ml ddH2O (without DEPC). 
Adjust pH with concentrated HCl. 
 
8.1.11 Buffer 3, pH 9.5 
Prepare fresh! To 150ml ddH2O without DEPC add; 
Tris (MW 121,14)  2.422 g (3.633g) Tris (final concentration 
100 mM) 
NaCl (MW 58,44)  1.168 g (1.752g) NaCl (final concentration 
100 mM) 
Adjust pH to 9.5, then add 
MgCl2 + 6H20 (MW 203,3) 2.034 g (3.051g) MgCl2 (final 
concentration 50 mM) 
Make volume to 200 ml (300ml) with ddH2O (without DEPC). 
 
8.1.12 Buffer 4, pH 8.0 
Tris (MW 121,14)  1.21 g  Tris (final concentration 10 mM) 
EDTA (MW 372,3)   0.37 g  EDTA (final 
concentration 1 mM; Serva, 11280.01) 
add 1000 ml ddH2O (without DEPC). Adjust pH with 2 N HCl. 
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8.1.13 1x PBS + 5 mM MgCl2 
10x PBS   10 ml 
1 M MgCl2  0.5 ml 
add 100 ml ddH2O (without DEPC) 
 
8.1.14 2x SSC + 5 mM EDTA-Na2 
20x SSC     50 ml 
0.5 M EDTA-Na2     5 ml 
add 500 ml ddH2O (without DEPC) 
 
8.1.15 0.2% Glycine in 1x PBS 
1 g glycine 
500 ml 1x PBS (adjust pH before!) 
 
8.1.16 4% paraformaldehyde (PFA) 
For 250 ml: 
Dissolve 10 g paraformaldehyde in approx. 200 ml 1x PBS at 
approx. 60°C (on magnetic stirrer; do not increase the temperature 
above 70°C, as the solution will precipitate!); adjust pH to 7.35 – 
7.4. Fill with 1x PBS to 250 ml. Solution can be stored for up to one 
month. N.B.: poisonous fumes so do this in hood. Takes about 2 
hours. 
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Do not autoclave the prehybridisation mix, hybridisation mix 
or their components, but produce them under sterile, that is 
to say RNAse-free, conditions!! (You may autoclave: 20x SSC, 
Triton X-100, 5 M NaOH) 
 
8.1.17 50x Denhardt`s solution 
100x Denhardt` s solution 100 ml 
ddH2O (without DEPC) 100 ml 
Store at –20°C. 
 
8.1.18 20x hybridisation salts 
EDTA  pH 8.0 0.5 M  10 ml (final concentration 0.1 M) 
PIPES pH 7.0  0.5 M  10 ml (final concentration 0.1 M) 
NaCl,       5.0 M  30 ml  
Produce the salt solutions with ddH2O (without DEPC). 
 
8.1.19 Prehybridisation mix (PHB-Mix) 
20x SSC    150 ml 
100% formamide, deion.  225 ml 
50x Denhardts solution    50 ml 
ddH2O with DEPC     70 ml 
store at –20°C. 
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8.1.20 50x TAE Electrophoresis Buffer 
Tris free base 242 g 
Disodium EDTA 18.61 g 
Glacial Acetic Acid 57.1 ml 
DDI H2O to 1 l 
Add the Tris free base and EDTA to approximately 700 ml DDI H2O 
and stir until the Tris and EDTA are dissolved. Add the acetic acid 
and adjust the volume to 1 liter. 
 
8.1.21 1x TAE Electrophoresis Buffer 
The 1x TAE solution is 40mM Tris, 20mM Acetate and 1mM EDTA 
and typically has a pH around 8.6 
(do not adjust). 
Or add 480 ml DDI H2O to 20 ml 50x TAE solution. 
Hybridisation mix (HB-Mix): 
100% formamide, deion.   16 ml 
20x hybridisation salts     8 ml 
50x Denhardts solution  3.2 ml 
Heparin         400 μl (Heparin (20,000 U),  diluted in 1 ml ddH2O) 
10% Triton X-100   320 μl 
27.84 ml = 40 aliquots a 696 μl; store at –20°C. 
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8.1.22 ssDNA 
Dissolve ssDNA (Deoxyribonucleic acid (DNA) Sodium Salt Type XIV 
from Salmon sperm; Sigma, D6898, 250 mg) in buffer 4, pH 8.0 to 
a final concentration of 10 mg/ml. 
 
8.1.23 Proteinase K solution: 
Is supplied by company (diluted in 10 mM TrisHCl, pH 7.5 (15.6 
mg/ml); Roche Diagnostics, 1413783). 
 
8.1.24 Dextransulfate solution 
250mg dextransulfate + 400µl ddH2O with DEPC; pipette into 
Eppendorf tube, mix well and dissolve by placing eppendorf in 
boiling waterbath; takes time! 
 
8.1.25 RNA stock solution 
10 mg RNA (Sigma, R 7250) 
1 ml ddH2O (DEPC-treated) 
Need 1.3ml per run (for steps V and VI); keep on ice 
 
8.1.26 Dye solution 
Nitrobluetetrazoliumchloride (NBT): 
Sigma, Order No. N 6639 
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1 g NBT add 13.3 ml 70% dimethylformamide (DMF: = 30 ml Aqua 
ddH2O + 70 ml DMF) = Stock solution with 75 mg/ml final 
concentration 
5-bromo-4-chloro-3-indolylephosphate (X-phosphate, BCIP) 
Sigma, Order.No. B6777 
500 mg X-Phosphate add 10 ml 100% dimethylformamide (syock 
solution) 
The solutions are prepared in their original container. N.B.: toxic. 
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8.6 Rabbit to human with gene description 
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8.8 Cattle to human with gene description 
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8.10 Scripts 
8.10.1 EdgeR 
#source("http://bioconductor.org/biocLite.R") 
#biocLite("edgeR") 
library(edgeR) 
library(limma) 
library(gtools) 
 
##################################################################
######################################## 
## SET THE WORKING DIRECTORY  
 
setwd('/home/svztg/Desktop/David_haig_Rabbit_vs_Cattle/RABBIT/Edge
R_DE') 
 
 
directory <- getwd() 
filenames <- list.files(directory, pattern="*.counts") 
 
for (file in filenames)  
   
  { 
   
  x <- read.delim(file,row.names="GENE") 
  group <- factor(c(2,2,1,1)) 
   
  all_results_table = paste(file,"_all_Results_edgeR.xls") 
  FDR.lt0.05_table = paste(file,"_FDR_p0.05_edgeR.xls") 
  PValue.lt0.05_table = paste(file,"_PValue_p0.05_edgeR.xls") 
  mds.plot.name = paste(file,".MDS.plot.pdf") 
  smear.plot.name = paste(file,".smear.plot.pdf") 
  volcano.plot.name = paste(file,".volcano.plot.pdf") 
   
  
##################################################################
######################################## 
   
  y <- DGEList(counts=x,group=group) 
  z <- DGEList(counts=x,group=group) 
  ## Since the smallest group size is TWO, we keep genes that 
achieve at least one count per million (cpm) in at least TWO 
samples:\n"; 
  keep <- rowSums(cpm(y)>1) >= 1 
  y <- y[keep,] 
  # Re-compute the library sizes 
  y$samples$lib.size <- colSums(y$counts) 
  z$samples$lib.size <- colSums(z$counts) 
  # Compute effective library sizes using TMM normalization:\n"; 
  y <- calcNormFactors(y) 
  z <- calcNormFactors(z) 
  y$samples 
  #  Output plot as a pdf 
  pdf(mds.plot.name) 
  plotMDS(y) 
  dev.off() 
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  y <- estimateCommonDisp(y) 
  z <- estimateCommonDisp(z) 
  y <- estimateTagwiseDisp(y) 
  z <- estimateTagwiseDisp(z) 
  #plotBCV(y) 
  et <- exactTest(y) 
  etz <- exactTest(z) 
  top <- topTags(et) 
   
  pdf(smear.plot.name) 
  plotSmear(y, de.tags=top, main="Differential expression using 
the common dispersion")  
  dev.off() 
   
  ## Check the individual cpm values for the top genes: 
  cpm(y)[rownames(top), ] 
  ## The total number of DE genes at 5% FDR is given by: 
  summary(de <- decideTestsDGE(et)) 
  ## Plot the log-fold-changes, highlighting the DE genes: 
  detags <- rownames(y)[as.logical(de)] 
   
  ## Get LogFC values 
  LogFCvalues <- etz$table$logFC  
  ## Get the Genenames 
  RownamesforLogFC <- rownames(etz) 
   
  ## Convert LogFC to FC 
  FC <- logratio2foldchange(LogFCvalues, base=2)  
  ## Convert FC list to dataframe with Genenames 
  FClist <-  data.frame( RownamesforLogFC, FC ) 
   
   
  # volcano plot 
  pdf(volcano.plot.name) 
  plot(et$table$logFC, -log10(et$table$PValue), pch=19, cex=0.2, 
main  ="Volcano Plot", xlab = "LogFC", ylab = "-log10 pvalue") 
  dev.off() 
   
  ## Generate an EdgeR results table 
  EdgeRResults <- topTags( et , n = nrow( et$table ) )$table 
  ## Generate an counts table 
  gene.counts <- z$counts 
  ## Merge tables 
  most.results <- merge(gene.counts, EdgeRResults, by=0, all=TRUE) 
  combined.results <- merge(most.results, FClist,  by=1, all=TRUE) 
   
  ## Identify if a gene is up or down regulated 
  #combined.results.UP.G2 <- subset(combined.results, logFC > 0) 
  # combined.results.DOWN.G2 <- subset(combined.results, logFC <= 
0) 
  # combined.results.UP.G2[, "G2vsG1"] <- "UP" 
  #combined.results.DOWN.G2[, "G2vsG1"] <- "DOWN" 
   
  ## Add Up or Down to combined results 
  #combined.results <- 
rbind(combined.results.UP.G2,combined.results.DOWN.G2) 
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  ## Filter combined.results to identify significant genes 
  significant.results0.05FDR <- subset(combined.results, FDR <= 
0.05)  
  significant.results0.05 <- subset(combined.results, PValue <= 
0.05)  
  ## Write tables    
  write.table(combined.results, 
file=all_results_table,row.names=FALSE,col.names=TRUE,quote=FALSE) 
  write.table(significant.results0.05, file= 
PValue.lt0.05_table,row.names=FALSE,col.names=TRUE,quote=FALSE) 
  write.table(significant.results0.05FDR, 
file=FDR.lt0.05_table,row.names=FALSE,col.names=TRUE,quote=FALSE) 
 
  } 
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8.10.2 Ballgown 
## ----loadmethods, echo=FALSE, message=FALSE, warning=FALSE------
--------- 
## source("http://bioconductor.org/biocLite.R") 
## biocLite("ballgown") 
 
library(edgeR) 
library(limma) 
library(ballgown) 
library(gtools) 
 
## ----Variables--------------------------------------------------
--------- 
 
group = factor(c(1,1,2,2))  
data_directory 
='/home/svztg/Desktop/David_haig_Rabbit_vs_Cattle/COW/assemblies' 
 
## ----makebg, message=FALSE--------------------------------------
------ 
 
setwd(data_directory) 
directory <- getwd() 
bg = ballgown(dataDir=data_directory, samplePattern='assembly', 
meas='all') 
 
## ----getexpr----------------------------------------------------
--------- 
 
gene_expression = texpr(bg, 'FPKM') 
transcript_values = texpr(bg, 'all') 
transcript_names = transcriptNames(bg) 
 
## ----pData------------------------------------------------------
--------- 
 
pData(bg) = data.frame(id=sampleNames(bg), group) 
phenotype_results = pData(bg) 
 
## ----getStats---------------------------------------------------
---------                        
 
stats_results = stattest(bg, feature='transcript', 
gexpr=gene_expression, getFC=TRUE, meas='FPKM', covariate='group') 
stats_results <- merge(transcript_names, stats_results, by=0, 
all=TRUE) 
stats_results = subset(stats_results, 
select=c("x","fc","pval","qval")) 
colnames(stats_results)[1] <- "t_name" 
colnames(stats_results)[2] <- "Ratio" 
Log_FC <- log2(stats_results$Ratio) 
FC <- logratio2foldchange(Log_FC, base=2) 
stats_results <- cbind(stats_results, Log_FC, FC) 
stats_results = subset(stats_results, 
select=c("t_name","Ratio","FC","Log_FC","pval","qval")) 
stats_results <- merge(stats_results, transcript_values) 
colnames(stats_results)[1] <- "Transcript_Name" 
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stats_results <- stats_results[ order(stats_results$pval) ,] 
 
## ----writeTable-------------------------------------------------
-------------- 
 
#transcript_table = paste("transcript_table", sep="" ) 
#write.table(transcript_values, 
file=transcript_table,row.names=FALSE,col.names=TRUE,quote=FALSE,s
ep="\t") 
 
phenotype_results_table = paste("phenotype_results_table", sep = 
"" ) 
write.table(phenotype_results, 
file=phenotype_results_table,row.names=FALSE,col.names=TRUE,quote=
FALSE,sep="\t") 
 
stats_results_table = paste("stats_results_table", sep="" ) 
write.table(stats_results, 
file=stats_results_table,row.names=FALSE,col.names=TRUE,quote=FALS
E,sep="\t") 
 
 
## ----sessioninfo, results='markup'------------------------------
--------- 
#sessionInfo() 
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8.10.3 Hisat  
#!/usr/bin/bash 
 
#HISAT and StringTie wrapper script v0.0.1  
#Tom Giles  
#09.12.14 
#thomas.giles@nottingham.ac.uk 
 
############################################################## 
# FUNCTIONS: 
############################################################## 
 
help_readme() {  
 
# Help Section 
 
 echo " 
 
HISAT and StringTie wrapper script v1.0.1 by Tom Giles (21.10.15) 
(thomas.giles@nottingham.ac.uk) `basename $0` 
 
This pipeline aligns reads to a genome sequence using Hisat v2 
(Kim D, Langmead B and Salzberg SL. HISAT: a fast spliced aligner 
with low memory requirements. Nature Methods 2015). Technical 
replicates from different lanes are merged using samtools (Heng 
Li, Et Al, The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 2009) and then assembled to identify transcipt 
level expression using stringtie (Pertea M, Et Al. StringTie 
enables improved reconstruction of a transcriptome from RNA-seq 
reads Nature Biotechnology 2015). 
 
Usage: 
 
Hisat_Wrapper.sh <genome_directory> <read_directory>  
 
The genome_directory should contain the following 2 files: 
 
 # GENOME_SEQUENCE = genome_name.fa 
 # GENOME_ANNOTATIONS = genome_name.gtf 
 
if you wish to use the SNP aware indexer the genome folder should 
also contain:  
 
 # GENOME_SNPS = genome_name.vcf 
 
The read_directory should contain trimmed.gz reads in pairs: 
 
You will be prompted to enter the number of CPUS's to use, the 
amount of RAM and the unique read suffixes 
 
The number of cores and amount of RAM should be specified as whole 
numbers (eg 20 = 20gb) 
 
The read suffixes should be unique: 
 
 # *_R1_001.fq.gz 
 # *_R2_001.fq.gz 
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for optimum compatibility we recomend that the reads are formated 
as follows: 
 
 # SAMPLE_REPLICATE_LANE_READSUFFIX 
 
If the reads are not formated in this manner it is likely that the 
script will crash whilst merging of the sorted bamfiles. 
 
This script assumes that the reads were generated across multiple 
lane (eg: L001, L002).  
 
If the reads were not generated across multiple lanes then the 
script will crash whilst merging of the sorted bamfiles. In this 
instance you may need to re-write the Merge_bam_files function or 
rename your reads so that the technical replicates are defined 
after the second underscore in the readname.   
 
Dependencies (The folowing tools must be installed at $/PATH): 
    
  # HISAT (tested with version 2.0.0-beta) 
  # samtools (tested with version 0.1.19) 
 # HTSeq_count (tested with version 0.6.1) 
  # StringTie (tested with version 1.0.4) 
 
If not set, the CPU and RAM settings determined automatically 
based on the avalible system resources   
 
  
 " 
 
  exit 0 
 
} 
 
#------------------------------------------------------------# 
 
Extract_Splice_sites(){ 
 
# Extract Splice sites from GFF 
 
  START=$(date +%s) 
 
  if [ -f $SPLICE_SITES ];  
 
 then 
 echo "Splice site file $SPLICE_SITES exists"  
 else  
 echo "Extracting splice sites from $GENOME_GTF"  
 python $HISAT2_DIRECTORY/extract_splice_sites.py $GENOME_GTF 
> $SPLICE_SITES 
 
  fi; 
  wait 
 
  END=$(date +%s) 
  TIME_SPLICE_SITES=$((END-START)) 
Osama Kumati                                                          Appendices 
327 
  echo "Time to extract Splice sites from GFF: $TIME_SPLICE_SITES 
seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Extract_Exons(){ 
 
# Extract Exons from GFF 
 
  START=$(date +%s) 
 
  if [ -f $EXONS ];  
 
 then 
 echo "Exon file $EXONS exists"  
 else  
 echo "Extracting exons sites from $GENOME_GTF"  
 python $HISAT2_DIRECTORY/extract_exons.py $GENOME_GTF > 
$EXONS 
  
  fi; 
  wait 
 
  END=$(date +%s) 
  TIME_EXONS=$((END-START)) 
  echo "Time to extract Exons from GFF: $TIME_EXONS  seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Extract_SNPs(){ 
 
# Extract Exons from VCF 
 
  START=$(date +%s) 
 
  if [ -f $SNPS ];  
 
  then 
 echo "Exon file $SNPS exists"  
 else  
 echo "Extracting SNPs from $GENOME_VCF"  
 
  cat $GENOME_VCF | awk -F $'\t' 'BEGIN {OFS = FS}{ 
                if (index($8, "deletion")) { print 
$3,"deletion"$1,$2,length($5);}   
                else if (index($8, "SNV")) { print 
$3,"single"$1,$2,$5;}  
                else if (index($8,"insertion")) { print 
$3,"insertion"$1,$2,$5;}  
        }' | tr '[,]' '[\t]' | awk -F $'\t' 'BEGIN {OFS = FS}{ 
                if ($6=="") { print $1,$2,$3,$4,"$5;} 
                else { for (i=4; i<=NF; i++) print 
$1,$2,$3,$4,"$i;  
 }' >  $SNPS 
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  fi; 
  wait 
 
  END=$(date +%s) 
  TIME_EXONS=$((END-START)) 
  echo "Time to extract SNPs from GFF: $TIME_SNPs  seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Index_reference_genome_no_SNPs(){ 
 
# Build the reference genome without the SNP aware indexer 
 
  START=$(date +%s) 
 
  if [ -f $INDEX_NAME.1.ht2 ] ; 
 
 then 
 echo "GENOME_SEQUENCE $INDEX_NAME Exists. If you need to re-
index the genome please remove current version in 
$GENOME_DIRECTORY" 
 else  
 echo "Indexing $GENOME_SEQUENCE with splice site aware 
algorithm"; 
 hisat2-build --verbose -p $NPROC --ss $SPLICE_SITES --exon 
$EXONS  $GENOME_SEQUENCE $INDEX_NAME  
  
  
  fi; 
  wait 
 
  END=$(date +%s) 
  TIME_INDEXING=$((END-START)) 
  echo "Time to index the reference sequence: $TIME_INDEXING 
seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Index_reference_genome_with_SNPs(){ 
 
# Build the reference genome with the SNP aware indexer 
 
  START=$(date +%s) 
 
  if [ -f $INDEX_NAME.1.ht2 ] ; 
 
 then 
 echo "GENOME_SEQUENCE $INDEX_NAME Exists. If you need to re-
index please remove current version" 
 else  
 echo "Indexing $GENOME_SEQUENCE with splice site aware 
algorithm"; 
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 hisat2-build --verbose -p $NPROC --snp $SNP --ss 
$SPLICE_SITES --exon $EXONS  $GENOME_SEQUENCE $INDEX_NAME  
  
  
  fi; 
  wait 
 
  END=$(date +%s) 
  TIME_INDEXING=$((END-START)) 
  echo "Time to index the reference sequence: $TIME_INDEXING 
seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Run_alignment(){ 
 
#Run hisat on all read pairs 
 
  START=$(date +%s) 
 
  for fq_pair_1 in $WORKING_DIRECTORY/*$READ1_SUFFIX ;  
 
 do  
 
 filename=${fq_pair_1%$READ1_SUFFIX} 
 fq_pair_2=${filename}$READ2_SUFFIX 
 
 samfile=$filename.$SAMFILE 
 mapping_statistics=$filename.$MAPPING_STATISTICS 
 novel_splice_sites=$filename.$NOVEL_SPLICE_SITES 
 unaligned_singletons=$filename.$UNMAPPED_SINGLETONS 
 unaligned_pairs=$filename.$UNMAPPED_PAIRS 
 
 if [ -f $samfile ] ;  
  then 
  echo "$samfile Exists" 
  else 
  echo "now aligning $fq_pair_1 and $fq_pair_2" 
  hisat2 -x $INDEX_NAME -p $NPROC --known-splicesite-
infile $SPLICE_SITES --novel-splicesite-outfile 
$novel_splice_sites -1 $fq_pair_1 -2 $fq_pair_2 -S $samfile --met-
file $mapping_statistics --un-gz $unaligned_singletons --un-conc-
gz $unaligned_pairs; 
 fi 
  done; 
  wait 
 
  END=$(date +%s) 
  TIME_ALLGINING=$((END-START)) 
  echo "Time to run hisat: $TIME_ALLGINING seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Convert_SAM_to_BAM(){ 
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#Convert all .sam files to sorted .bam files in batches of NPROC 
 
  START=$(date +%s) 
 
  for samfile in $WORKING_DIRECTORY/*.$SAMFILE;  
 
 do 
 
 bamfile="${samfile%.sam}.alignment" 
 
 if [ -f $bamfile.bam ];  
  then 
  echo "$bamfile.bam Exists" 
  else 
  echo "Now sorting $samfile." 
  samtools view -bS $samfile | samtools sort  - $bamfile 
& 
  PROC=$((PROC+6))  
     
     if [ "$PROC" -ge "$NPROC" ];  
   then 
          wait 
   PROC=0 
  fi 
 fi 
  done; 
  wait 
 
  END=$(date +%s) 
  TIME_SORTING=$((END-START)) 
  echo "Time to convert .sam files to sorted .bam files: 
$TIME_SORTING seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Merge_bam_files(){ 
 
#merge the sorted .bam files 
 
  START=$(date +%s) 
 
  grouped_sample_ID=$(find "$WORKING_DIRECTORY" -name 
"*.alignment.bam" -exec echo "{}" \;) 
  echo "$grouped_sample_ID" > 
$WORKING_DIRECTORY/list_of_alignments.tmp 
  sample_IDs=$(cat $WORKING_DIRECTORY/list_of_alignments.tmp | rev 
| cut -d"/" -f1 | rev | cut -d"_" -f1-2 | sort | uniq) 
 
  for sample in $sample_IDs; 
 do 
 list=$(find  "$WORKING_DIRECTORY" -name 
"$sample*alignment.bam"); 
 
 echo "merging sorted bam files" 
 echo " $list" 
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 samtools merge 
$WORKING_DIRECTORY/"$sample".merged_alignment.bam $list 
  done; 
 
  wait 
 
  END=$(date +%s) 
  TIME_MERGING=$((END-START)) 
  echo "Time to merge .bam files: $TIME_MERGING seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Generate_assembly(){ 
 
#Run stringtie on sorted .bam files 
 
  START=$(date +%s) 
 
  for bamfile in $WORKING_DIRECTORY/*merged_alignment.bam;  
 
 do 
 results_summary="${bamfile%.merged_alignment.bam}_assembly/r
esults_summary.txt" 
 results_folder="${bamfile%.merged_alignment.bam}_assembly" 
 
 if [ -f $results_summary ]; 
 then 
  echo "$results_summary Exists" 
  else 
  echo "Now running StringTie on $bamfile." 
  mkdir $results_folder 
  stringtie $bamfile -G $GENOME_GTF -p $NPROC -b 
$results_folder > $results_summary 
 fi 
  done; 
  wait 
 
  END=$(date +%s) 
  TIME_ASSEMBLING=$((END-START)) 
  echo "Time to run StringTie: $TIME_ASSEMBLING seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Generate_counts(){ 
 
#Run HTSeq on sorted .bam files 
 
  START=$(date +%s) 
 
  for bamfile in $WORKING_DIRECTORY/*merged_alignment.bam;  
 
 do 
 results_counts="${bamfile%.bam}.counts" 
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 if [ -f $results_counts ]; 
 then 
  echo "$results_summary Exists" 
  else 
  echo "Now running HTSeq on $bamfile." 
  samtools view $bamfile | htseq-count - $GENOME_GTF > 
$results_counts  & 
   
  PROC=$((PROC+2))  
     
     if [ "$PROC" -ge "$NPROC" ];  
   then 
          wait 
   PROC=0 
  fi 
 fi 
  done; 
  wait 
 
  END=$(date +%s) 
  TIME_COUNTING=$((END-START)) 
  echo "Time to count alignments with HTSeq counts: $TIME_COUNTING 
seconds" 
 
} 
 
#------------------------------------------------------------# 
 
Generate_statistics(){ 
 
#Calculate total runtime, the number of reads and Mapping 
Statistics 
 
  START=$(date +%s) 
 
  echo "Generating statistics" 
 
  for fq_pair_1 in $WORKING_DIRECTORY/*$READ1_SUFFIX;  
  
 do 
 
 filename=${fq_pair_1%$READ1_SUFFIX} 
 fq_pair_2=${filename}$READ2_SUFFIX 
 samfile=$filename.$SAMFILE 
 bamfile=$filename.alignment.$BAMFILE 
 sample_name=${filename##*/} 
 
  
        number_of_R1_input_reads=$(zcat "$fq_pair_1" | echo $((`wc 
-l`/4))) 
 number_of_R2_input_reads=$(zcat "$fq_pair_2" | echo $((`wc -
l`/4))) 
 flagstat=$(samtools flagstat $bamfile) 
 
 echo "Filename = $sample_name 
number of reads = $number_of_R1_input_reads + 
$number_of_R2_input_read 
Samtools flagstats =  
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$flagstat 
        
      " 
  done > "$WORKING_DIRECTORY/Run_statistics.tsv" 
 
  END=$(date +%s) 
  TIME_GENERATE_STATISTICS=$((END-START)) 
 
} 
 
#------------------------------------------------------------# 
 
Move_files(){ 
 
#Make new directories and move files accordingly 
 
 if [ ! -d "$WORKING_DIRECTORY/reads" ]; then  
 mkdir $WORKING_DIRECTORY/reads 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/reads/trimmed" ]; then  
 mkdir $WORKING_DIRECTORY/reads/trimmed 
 mv $WORKING_DIRECTORY/*$READ1_SUFFIX 
$WORKING_DIRECTORY/reads/trimmed 
 mv $WORKING_DIRECTORY/*$READ2_SUFFIX 
$WORKING_DIRECTORY/reads/trimmed 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/reads/unmapped_singletons" ]; then  
 mkdir $WORKING_DIRECTORY/reads/unmapped_singletons 
 mv $WORKING_DIRECTORY/*$UNMAPPED_SINGLETONS 
$WORKING_DIRECTORY/reads/unmapped_singletons 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/reads/unmapped_pairs" ]; then  
  mkdir $WORKING_DIRECTORY/reads/unmapped_pairs  
   mv $WORKING_DIRECTORY/*.unmapped.pairs.fq.*.gz 
$WORKING_DIRECTORY/reads/unmapped_pairs 
 fi;  
 
 if [ ! -d "$WORKING_DIRECTORY/alignments" ]; then  
  mkdir $WORKING_DIRECTORY/alignments 
 fi;  
 
 if [ ! -d "$WORKING_DIRECTORY/alignments/merged_alignment" ]; 
then  
 mkdir $WORKING_DIRECTORY/alignments/merged_alignment  
 mv $WORKING_DIRECTORY/*.merged_alignment.bam 
$WORKING_DIRECTORY/alignments/merged_alignment 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/alignments/samfiles" ]; then  
  mkdir $WORKING_DIRECTORY/alignments/samfiles 
 mv $WORKING_DIRECTORY/*$SAMFILE 
$WORKING_DIRECTORY/alignments/samfiles 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/alignments/sorted_bamfiles" ]; then  
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  mkdir $WORKING_DIRECTORY/alignments/sorted_bamfiles 
 mv $WORKING_DIRECTORY/*$BAMFILE 
$WORKING_DIRECTORY/alignments/sorted_bamfiles 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/alignments/statistics" ]; then  
  mkdir $WORKING_DIRECTORY/alignments/statistics 
 mv $WORKING_DIRECTORY/*$MAPPING_STATISTICS 
$WORKING_DIRECTORY/alignments/statistics 
 fi; 
 
 if [ ! -d "$WORKING_DIRECTORY/alignments/novel_splice_sites" ]; 
then  
  mkdir $WORKING_DIRECTORY/alignments/novel_splice_sites 
 mv $WORKING_DIRECTORY/*$NOVEL_SPLICE_SITES 
$WORKING_DIRECTORY/alignments/novel_splice_sites 
 fi;  
 
 if [ ! -d "$WORKING_DIRECTORY/assemblies" ]; then  
  mkdir $WORKING_DIRECTORY/assemblies 
 mv $WORKING_DIRECTORY/*assembly 
$WORKING_DIRECTORY/assemblies 
 fi;  
if [ ! -d "$WORKING_DIRECTORY/counts" ]; then  
  mkdir $WORKING_DIRECTORY/counts 
 mv $WORKING_DIRECTORY/*counts $WORKING_DIRECTORY/counts 
 fi;  
 
} 
 
############################################################## 
# Either run the pipeline or exit based on input variables 
############################################################## 
 
 
GENOME_DIRECTORY=$1; 
WORKING_DIRECTORY=$2; 
 
if [ "$1" = -h ];  
 then  
 
 help_readme  
 
elif [ "$1" = --help ];  
 then 
 
 help_readme  
 
elif [  -d "$1" ] && [ -d "$2" ];  
 then 
 
 gtf=$(ls $GENOME_DIRECTORY/*.gtf | wc -l) 
 fa=$(ls $GENOME_DIRECTORY/*.fa | wc -l) 
 vcf=$(ls $GENOME_DIRECTORY/*.vcf | wc -l) 
 
 if [ "$gtf" = "1" ] && [ "$fa" = "1" ]; 
  then 
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  echo "Run Started" 
  echo "HISAT and StringTie wrapper script v1.0.1 by Tom 
Giles (21.10.15) (thomas.giles@nottingham.ac.uk)" 
  echo "for more information on how to run this script 
please use -h or --help" 
  echo "" 
  echo "Genome folder = $1" 
  echo "Read folder = $2" 
 
  #-----------------------------------------------------
-------# 
 
  # Set global variables 
 
  echo -n "Enter the number of CPU cores to use > " 
  read number_of_cores 
  echo -n "Enter the amount of RAM (in GB) to use > " 
  read amount_of_ram 
  echo -n "Enter the unique read_1 suffix > " 
  read READ1_SUFFIX 
  echo -n "Enter the unique read_2 suffix > " 
  read READ2_SUFFIX 
 
  #-----------------------------------------------------
-------# 
 
  # Define the status of the system 
 
  NPROC=$(grep -c ^processor /proc/cpuinfo)    
 
  if [ "$number_of_cores" -lt "$NPROC" ]; 
   then  
 
   NPROC=$number_of_cores 
   else  
   echo "$number_of_cores is greater than the 
avalible number of cores. \n Using $NPROC cores" 
  fi 
 
  KB_RAM=$(head -1 /proc/meminfo | awk '{ print $2 }'); 
  GB_RAM=$(echo "scale=2; $KB_RAM /1048576" | bc); 
  GB_RAM_ROUNDED=$(echo ${GB_RAM%%.*}); 
  RAM=$((GB_RAM_ROUNDED-2)); 
 
 
  if [ "$amount_of_ram" -lt "$RAM" ]; 
   then  
 
   RAM=$amount_of_ram 
   else  
   echo "$amount_of_ram is greater than the 
avalible amount of RAM. \n Using $RAM GB of RAM" 
  fi 
   
  echo "Using $RAM GB of RAM and $NPROC cores" 
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 #~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~# 
 
  # Automatically define the additional core variables 
 
  GENOME_SEQUENCE=$(find $GENOME_DIRECTORY -type f -name 
*.fa) 
  GENOME_GTF=$(find $GENOME_DIRECTORY -type f -name 
*.gtf) 
 
  INDEX_NAME="${GENOME_SEQUENCE%.fa}" 
  SPLICE_SITES="${GENOME_GTF%.gtf}.splice_sites" 
  EXONS="${GENOME_GTF%.gtf}.exons" 
  HISAT2_DIRECTORY=$(which hisat2 | sed 
's,/*[^/]\+/*$,,') 
  SAMFILE="sam" 
  BAMFILE="bam" 
  MAPPING_STATISTICS="mapping_statistics.txt" 
  NOVEL_SPLICE_SITES="novel_splice_sites.tsv" 
  UNMAPPED_SINGLETONS="unmapped.singletons.fq.gz" 
  UNMAPPED_PAIRS="unmapped.pairs.fq.gz" 
 
  if [ "$vcf" = "1" ]; 
   then  
 
   $GENOME_VCF=$(find $GENOME_DIRECTORY -type f -
name *.vcf)  
   $SNPS="${GENOME_VCF%.vcf}.snps" 
   echo "SNP file present - will attempt to 
generate a SNP sensitive genome index" 
   else 
   echo "SNP file not present - will not attempt to 
generate a SNP sensitive genome index" 
  fi 
 
 
 #~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~# 
   
  # call functions 
 
  Extract_Splice_sites; 
  Extract_Exons; 
 
  if [ "$vcf" = "1" ]; 
   then  
 
   Extract_SNPs; 
  fi 
 
  if [ "$vcf" = "1" ]; 
   then  
 
   Index_reference_genome_with_SNPs; 
   else 
 
   Index_reference_genome_no_SNPs; 
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  fi 
  Run_alignment; 
  Convert_SAM_to_BAM; 
  Merge_bam_files; 
  Generate_counts; 
  Generate_assembly; 
  Generate_statistics; 
  Move_files; 
 
 
 #~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~# 
 
  # Collect Statistics 
 
  echo "Run Finished" 
  rm $WORKING_DIRECTORY/*.tmp 
 
  Run_date=$(date); 
 
  TIME_SPLICE_SITES=$(echo $TIME_SPLICE_SITES | awk 
'{print int($1/60)"m:"int($1%60)}"s"') 
  TIME_EXONS=$(echo $TIME_EXONS | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_INDEXING=$(echo $TIME_INDEXING | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_ALLGINING=$(echo $TIME_ALLGINING | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_SORTING=$(echo $TIME_SORTING | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_MERGING=$(echo $TIME_MERGING | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_COUNTS=$(echo $TIME_COUNTS | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_ASSEMBLING=$(echo $TIME_ASSEMBLING | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
  TIME_GENERATE_STATISTICS=$(echo 
$TIME_GENERATE_STATISTICS | awk '{print 
int($1/60)"m:"int($1%60)}"s"') 
 
  echo "" 
  echo "PERFORMANCE STATISTICS:" 
  echo "Number of CPUs = $NPROC | Amount of Ram used = 
$RAM" 
  
  if [ "$TIME_SPLICE_SITES" != "0m:0s" ];  
  then  
   echo "Time to extract splice sites from GFF: 
$TIME_SPLICE_SITES"  
  else  
   echo "splice sites file existed";  
  fi 
  if [ "$TIME_EXONS" != "0m:0s" ]; then echo "Time to 
extract exons from GFF: $TIME_EXONS";  
  else  
   echo "Exon file already existed";  
  fi 
  if [ "$TIME_INDEXING" != "0m:0s" ]; then  
Osama Kumati                                                          Appendices 
338 
   echo "Time to index the reference sequence: 
$TIME_INDEXING";  
  else  
   echo "Genome was already indexed"  
  fi 
  if [ "$TIME_ALLGINING" != "0m:0s" ];  
  then  
   echo "Time to run HISAT: $TIME_ALLGINING";  
  fi 
  if [ "$TIME_SORTING" != "0m:0s" ];  
  then   
   echo "Time to convert .sam files to sorted .bam 
files: $TIME_SORTING";  
  fi 
  if [ "$TIME_MERGING" != "0m:0s" ];  
  then   
   echo "Time to merge .bam files: $TIME_MERGING";  
  fi 
  if [ "$TIME_COUNTS" != "0m:0s" ];  
  then   
   echo "Time to count alignments with HTSeq 
counts: $TIME_COUNTS";  
  fi 
  if [ "$TIME_ASSEMBLING" != "0m:0s" ];  
  then  
   echo "Time to run StringTie: $TIME_ASSEMBLING";  
  fi 
  if [ "$TIME_GENERATE_STATISTICS" != "0m:0s" ];  
  then  
   echo "Time to generate statistics: 
$TIME_GENERATE_STATISTICS";  
  fi 
  exit 0 
 
 else  
  help_readme  
 
 fi 
else  
 
help_readme  
 
fi 
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